Prof. Dr. MUHİT ÖZCAN

Yayın Ağı

Makaleler 356

1. Comparing two different doses of inotuzumab ozogamicin treatment in adult patients with acute lymphoblastic leukemia: a plain language summary of publication.

Özcan M., Cassaday R. D., Zarzycka E., Vandendries E., Zhang F., Chen Y., et al.

Therapeutic advances in medical oncology , cilt.17, 2025 (SCI-Expanded)

2. Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory/relapsed large B-cell lymphoma: primary results of the phase 3 SUNMO trial.

Budde L. E., Zhang H., Kim W., Maruyama D., Rego E. M., Norasetthada L., et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology , 2025 (SCI-Expanded)

3. COMMENT ON FACTORS AFFECTING HAPLOIDENTICAL TRANSPLANT OUTCOMES WITH POSTTRANSPLANT CYCLOPHOSPHAMIDE PLUS ATG.

Sahin U., Ozcan M.

Transplantation and cellular therapy , sa.1, 2025 (SCI-Expanded)

4. Real-Life Retrospective Turkiye Data of the De-Escalation of ABVD to AVD in Hodgkin Lymphoma: On Behalf of the TSH Turkish Lymphoma Study Group.

Isleyen E., Alhan N., Terzi Demirsoy E., Geduk A., Avci D. N., Yeral M., et al.

Journal of clinical medicine , cilt.14, sa.19, 2025 (SCI-Expanded, Scopus)

5. Poor Response to Chemotherapy in a Newly Diagnosed Metastatic Intraabdominal Follicular Dendritic Cell Sarcoma: A Call for Alternative Treatment Strategies

Koyun D., Yuksel S., Kuzu I., Özcan M.

TURK ONKOLOJI DERGISI , cilt.40, sa.3, ss.252-256, 2025 (ESCI)

6. Foliküler Lenfomalarda Mikroçevrenin Organizasyonunda TGFβ/Smad Yolağının Rolü ve Prognozla İlişkisi

Köm Ş., Civriz Bozdağ S., Özcan M., Kuzu I.

Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları , cilt.9, sa.2, ss.41-52, 2025 (Hakemli Dergi)

7. Real-World Efficacy and Safety of the Combination of Rituximab, Lenalidomide, and Ibrutinib in Patients with Relapsed and/or Refractory Non-Hodgkin Lymphoma

KOYUN D., Şahin U., Gökmen A., ÖZCAN M.

Indian Journal of Hematology and Blood Transfusion , cilt.41, sa.3, ss.511-518, 2025 (SCI-Expanded)

8. Immune Checkpoint Molecule Expression, 9p24.1 Gene Alterations, and Tumor Microenvironment of Primary Central Nervous System Lymphomas and Their Clinical Relevance.

Akbulut D., Yuksel S., Kircali E., Aktas B. Y., Demirkol Canli S., Doganay Erdogan B., et al.

Applied immunohistochemistry & molecular morphology : AIMM , 2025 (SCI-Expanded)

9. What Does Radiologic Assessment Contribute to Asthma: A Subanalysis of the Turkish Adult Asthma Registry

KIZILIRMAK D., Uzun O., GÖKMEN D., AYDIN Ö., BAŞYİĞİT İ., DURSUN A. B., et al.

Bratislava Medical Journal , cilt.126, sa.6, ss.1008-1022, 2025 (SCI-Expanded)

10. MOLECULAR MECHANISMS INVOLVED IN THE PATHOGENESIS OF POST TREATMENT PERSISTENT ERYTHROCYTOSIS IN PATIENTS WITH HODGKIN LYMPHOMA

Koyun D., Yüksel S., Civriz Bozdağ S., Tuncalı T., Kuzu I., Özcan M.

HEMATOLOGICAL ONCOLOGY , cilt.43, sa.S3, ss.206, 2025 (SCI-Expanded)

11. Primary Gastric Extranodal NK/T Cell Lymphoma with T Cell Phenotype: A Very Rare EBV-Related Locally Involved Aggressive T Cell Lymphoma Case and the Therapeutic Effects of COVID-19 Infection.

Koyun D., Yüksel S., Özcan M., Kuzu I., Civriz Bozdağ S.

Turkish journal of haematology : official journal of Turkish Society of Haematology , 2025 (SCI-Expanded)

12. A predictive metabolomic model for FLT3 and NPM1 mutations in Acute Myeloid Leukemia patients.

Gerekci Yeşi Lyurt S., Koyun D., Toprak S. K., Özcan M., Özen C.

Journal of pharmaceutical and biomedical analysis , cilt.260, ss.116789, 2025 (SCI-Expanded, Scopus)

13. A Real World Study: Efficacy and Safety of Pegylated Interferon Alpha-2a in Patients with Myeloproliferative Neoplasm

Koyun D., Seval G. C., Civriz Bozdağ S., Koçak Toprak S., Topçuoğlu P., Arslan Ö., et al.

Ankara Üniversitesi Tıp Fakültesi Mecmuası , cilt.78, sa.1, ss.60-68, 2025 (Hakemli Dergi)

14. Efficacy and safety of currently approved and lower starting doses of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukemia: a phase IV study.

Özcan M., Cassaday R. D., Zarzycka E., Vandendries E., Zhang F., Chen Y., et al.

Haematologica , 2025 (SCI-Expanded)

15. Asthma patients with obesity have a unique phenotype: a subanalysis of the Turkish adult asthma registry

ÇELEBİ SÖZENER Z., OĞUZÜLGEN İ. K., Ozalp Ates F. S., Baccioglu A., ARGUN BARIŞ S., EDİGER D., et al.

Journal of Asthma , cilt.62, sa.7, ss.1183-1194, 2025 (SCI-Expanded)

16. Acute myeloid leukemia: a brief historical perspective of AML treatment

Urlu S. M., ÖZCAN M.

Hematology (United Kingdom) , cilt.30, sa.1, 2025 (SCI-Expanded)

17. Hodgkin Lenfomalı Hastalarda Tedavi Sonrası Geç Dönemde Yüksek Hematokrit Değerleri: Lenfoma ile Eritrositoz Arasında İlişki mi var?

KOYUN D., ATEŞAĞAOĞLU B., YÜKSEL S., SEVAL G. C., BOZDAĞ S. C., TOPRAK S. K., et al.

Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları , cilt.8, sa.3, ss.86-91, 2024 (TRDizin)

18. Relaps Nodüler Lenfosit Predominant Hodgkin Lenfomada Kurtarma Tedavisi Sonrası Otolog Kök Hücre Nakli Sonuçları

URLU S. M., ŞAHİN U., GÖKMEN A., ARSLAN Ö., ÖZCAN M.

Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları , cilt.8, sa.3, ss.92-97, 2024 (Hakemli Dergi)

19. The effects of plerixafor on the hemostatic system in patients undergoing stem cell mobilization

Koç Ö., Doğan Ö., Şahin U., Kircali E., Koyun D., Arat M., et al.

Hematology/oncology and stem cell therapy , cilt.17, sa.4, ss.211-218, 2024 (Scopus)

20. Anaplastic Multiple Myeloma: An Aggressive Myeloma Variant with A Poor Response to Autologous Stem Cell Transplantation

Koyun D., Doğan İ. Ö., Kuzu I., Toprak S. K., Özcan M., Demirer T.

Ankara Üniversitesi Tıp Fakültesi Mecmuası , cilt.77, sa.4, ss.416-418, 2024 (Hakemli Dergi)

21. CHRONOS-4: phase 3 study of copanlisib plus rituximab-based immunochemotherapy in relapsed indolent B-cell lymphoma

Zinzani P. L., Wang H., Feng J., Kim T. M., Tao R., Zhang H., et al.

Blood Advances , cilt.8, sa.18, ss.4866-4876, 2024 (SCI-Expanded)

22. Zilovertamab Vedotin (ZV) Alone or in Combination With Nemtabrutinib in Relapsed or Refractory (R/R) Aggressive and Indolent B-Cell Malignancies (waveLINE-006): An Open-Label, Phase 2 Basket Study

Paskiewicz-Kozik E., Glimelius I., Moreira C., Garrido M., Ernst D., Jurczak W., et al.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , 2024 (SCI-Expanded)

23. Phase 3 BELLWAVE-010: Nemtabrutinib Plus Venetoclax Versus Venetoclax Plus Rituximab (VR) in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Lavie D., ÖZCAN M., Chaudhry A., Zhou X., Paydar I., Farooqui M. Z. H., et al.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , 2024 (SCI-Expanded)

24. Precision in classification: impact of WHO and ICC 2022 criteria on myeloid neoplasms

Cagdas E. K., Koyun D., Toprak S. K., Ozcan M., Kuzu I.

VIRCHOWS ARCHIV , 2024 (SCI-Expanded)

25. Akut Lenfoblastik Lösemide Allojenik Hematopoietik Kök Hücre Nakli Sonrası Sitomegalovirüs Reaktivasyonunun Etkileri: Retrospektif Bir Analiz

KALACI E., EROĞLU D. Ş., SEVAL G. C., ÖZCAN M., TOPÇUOĞLU P., TOPRAK S. K., et al.

Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları , cilt.8, sa.2, ss.65-72, 2024 (TRDizin)

26. The effects of substituting cladribine for fludarabine on outcomes of a reduced intensity conditioning regimen

Sahin U., Urlu S. M., Gokmen A., Arslan O., Ozcan M.

JOURNAL OF CLINICAL ONCOLOGY , sa.16, 2024 (SCI-Expanded)

27. BELLWAVE-010: A phase 3 study of nemtabrutinib plus venetoclax versus venetoclax plus rituximab (VR) in previously treated patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

Ozcan M., Lavie D., Chaudhry A., Zhou X., Paydar I., Farooqui M. Z. H., et al.

JOURNAL OF CLINICAL ONCOLOGY , sa.16, 2024 (SCI-Expanded)

28. Lenfoplazmasitik Lenfomada Yeni Nesil Dizileme Yöntemiyle Mutasyon İncelemesinin Tanı ve Tedavi Planında Yeri

KOYUN D., YÜKSEL S., Cengiz Seval G., CİVRİZ BOZDAĞ S., Toprak S. K., Topcuoglu P., et al.

Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları , cilt.8, sa.1, ss.39-45, 2024 (TRDizin)

29. A new scoring system to predict survival in elderly advanced stage Hodgkin lymphoma patients

MEHTAP Ö., TOPTAŞ T., Dal M. S., Karadag F. K., Atas U., ÖZSAN G. H., et al.

Leukemia and Lymphoma , cilt.65, sa.14, ss.2190-2198, 2024 (SCI-Expanded)

30. Prognostic Significance of Combined Inflammatory Index (CII) in Nodular Lymphocyte Predominant Hodgkin Lymphoma

PAYDAS S., CAKAR M. K., BARISTA I., SEYDAOGLU G., PEHLIVAN M., DOGAN M., et al.

Eurasian Journal of Medical Investigation , cilt.7, sa.3, ss.235-245, 2023 (Hakemli Dergi)

31. Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study

Pabst T., Papayannidis C., DEMİRKAN F., Doronin V., Fogliatto L. M., Guttke C., et al.

The Lancet Haematology , cilt.10, sa.11, 2023 (SCI-Expanded)

32. Dose-Escalation, Dose-Confirmation, and CohortExpansion Study of Nemtabrutinib in Patients With Hematologic Malignancies: Multicohort, Open label, Phase 2BELLWAVE-003Study

Jurczak W., Perini G. F., Owen C., ÖZCAN M., Gonzalez Barca E., Wrobel T., et al.

AMERICAN JOURNAL OF HEMATOLOGY , 2023 (SCI-Expanded)

33. Zilovertamab Vedotin Alone or in Combination With Nemtabrutinib in Aggressive and Indolent B-Cell Malignancies: Phase 2waveLINE-006Study

Zinzani P. L., Mayer J., Benjamini O., Berkovits A., Glimelius I., Stevens D., et al.

AMERICAN JOURNAL OF HEMATOLOGY , 2023 (SCI-Expanded)

34. Glofitamab in relapsed/refractory diffuse large B-cell lymphoma: Real-world data

Atesoglu E. B., Gulbas Z., Uzay A., ÖZCAN M., ÖZKALEMKAŞ F., Dal M. S., et al.

HEMATOLOGICAL ONCOLOGY , cilt.41, sa.4, ss.663-673, 2023 (SCI-Expanded, Scopus)

35. Allojeneik Hematopoetik Kök Hücre Nakli Sonrası Aseptik Nekroz Gelişen Olgularda Vitamin D Reseptör Gen Polimorfizmi

Soydan E., Sahin U., Ceylaner S., gökmen a., Dogan H., Kurdal Okcu M., et al.

Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları , cilt.7, sa.2, ss.51-56, 2023 (Hakemli Dergi)

36. KEYFORM-008: Coformulated favezelimab and pembrolizumab (MK4280A) versus chemotherapy in relapsed/refractory classical Hodgkin lymphoma.

Lavie D., Timmerman J., Sanz R. G., Kim W. S., Kim T. M., Avigdor A., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.41, sa.16, 2023 (SCI-Expanded, Scopus)

37. Association of FLT3 and NPM1 mutations in patients with acute myeloid leukemia with metabolomic patterns determined by mass spectrometry

Toprak S. K., Yesilyurt S. G., Koyun D., Ozcan M., Ozen C.

JOURNAL OF CLINICAL ONCOLOGY , cilt.41, sa.16, 2023 (SCI-Expanded, Scopus)

38. Efficacy and safety of pembrolizumab every six weeks in relapsed/refractory classical Hodgkin lymphoma or primary mediastinal B-cell lymphoma: The phase 2 KEYNOTE-B68 trial.

McDonald A. B., Verburgh E., Gotti M., Pinto A., Zaucha J., Ivanov V., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.41, sa.16, 2023 (SCI-Expanded)

39. waveLINE-006: A phase 2 study of the safety and efficacy of zilovertamab vedotin as monotherapy or in combination in patients (pts) with aggressive and indolent B-cell malignancies.

Zinzani P. L., Mayer J., Benjamini O., Berkovits A., Glimelius I., Stevens D. A., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.41, sa.16, 2023 (SCI-Expanded, Scopus)

40. waveLINE-007: Phase 2 study of zilovertamab vedotin (ZV) in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab (R-CHP) in previously untreated diffuse large B-cell lymphoma (DLBCL).

Lavie D., Ozcan M., Paszkiewicz-Kozik E., Barca E. G., Kim T. M., Puccini B., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.41, sa.16, 2023 (SCI-Expanded)

41. Zilovertamab vedotin (MK 2140) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Early results from the phase 2 waveLINE-004 study.

Ozcan M., Lee S. T., Mensah F., Modi D., Fossa A., Kim W. S., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.41, sa.16, 2023 (SCI-Expanded, Scopus)

42. BELLWAVE-003: A phase 2 dose escalation, confirmation, and cohort expansion study of nemtabrutinib in hematologic malignancies.

Perini G. F., Owen C., Ozcan M., Jurczak W., Barca E. G., Wrobel T., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.41, sa.16, 2023 (SCI-Expanded)

43. Kazanılmış Faktör VIII ve IX İnhibitörü Olan Hastalarda İmmünosüpresif Tedavi Etkinlik ve Güvenilirliğinin Değerlendirilmesi

KOYUN D., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., ÖZCAN M., TOPÇUOĞLU P.

Ankara Üniversitesi Tıp Fakültesi Mecmuası , cilt.76, ss.24-29, 2023 (Hakemli Dergi)

44. Allogeneic Hematopoietic Stem Cell Transplantation for Primary Myelofibrosis: A 20-year Experience in a Single Center

CENGİZ SEVAL G., Civriz Bozdag S., TOPRAK S. K., Kurt Yuksel M., TOPÇUOĞLU P., ARSLAN Ö., et al.

Balkan medical journal , cilt.40, sa.3, ss.197-204, 2023 (SCI-Expanded, Scopus)

45. Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma: Final Analysis of KEYNOTE-170.

Zinzani P. L. L., Thieblemont C., Melnichenko V., Bouabdallah K., Walewski J., Majlis A., et al.

Blood , 2023 (SCI-Expanded)

46. Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma

Nastoupil L. J., Hess G., Pavlovsky M. A., Danielewicz I., Freeman J., García-Sancho A. M., et al.

Blood Advances , cilt.7, sa.22, ss.7141-7150, 2023 (SCI-Expanded)

47. Eltrombopag for the Treatment of Poor Graft Function Following Haematopoietic Cell Transplantation: Real-Life Data

Kırcalı E., Cengiz Seval G., Öztürk C., Yılmaz H., Koyun D., Civriz Bozdağ S., et al.

BALKAN MEDICAL JOURNAL , cilt.40, sa.1, ss.51-56, 2023 (SCI-Expanded, Scopus)

48. Outcomes of Autologous Stem Cell Transplantation as a Consolidative Strategy for the Treatment of Primary and Isolated Secondary Central Nervous System Diffuse Large B Cell Lymphomas

Sahin U., Gokmen A., Soydan E., Urlu S. M., Merter M., Gokgoz Z., et al.

Clinical Lymphoma, Myeloma and Leukemia , cilt.23, 2023 (SCI-Expanded, Scopus)

49. Gemcitabine, Cisplatin, and Dexamethasone as a Salvage and Mobilization Chemotherapy Before Autologous Stem Cell Transplantation is Effective and Safe Outpatient Regimen in Relapsed and Refractory Hodgkin Lymphoma Patients

Gokmen A., Sahin U., Soydan E., Gokgoz Z., Okcu M. K., Ozan U., et al.

Clinical Lymphoma, Myeloma and Leukemia , cilt.22, sa.10, 2022 (SCI-Expanded)

50. Pretransplant Consolidation Therapies Improve the Outcome of Myeloablative Allogeneic Transplantation in Adults with Ph-negative Acute Lymphoblastic Leukemia

Ozdemir Z. N., Kircali E., Şahin U., Seval G., Bozdağ S. C., Toprak S. K., et al.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , cilt.22, sa.8, ss.596-600, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

51. Alpha-1-Antitrypsin Experience for Steroid-Resistant Acute Graft-Versus-Host Disease

KOYUN D., CENGİZ SEVAL G., Kircali E., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., et al.

INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION , cilt.38, sa.3, ss.601-605, 2022 (SCI-Expanded, Scopus)

52. Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.

Wang M. L., Jurczak W., Jerkeman M., Trotman J., Zinzani P. L., Belada D., et al.

The New England journal of medicine , cilt.386, ss.2482-2494, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

53. The efficacy and safety of second allogeneic hematopoietic stem cell transplantation.

Toprak S. K., Korcalo E., Seval G. C., Bozdag S. C., Yuksel M. K., Topcuoglu P., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.40, sa.16, 2022 (SCI-Expanded, Scopus)

54. Allogeneic hematopoietic stem cell transplantation for heavily pretreated patients with mycosis fungoides and Sezary syndrome

CENGİZ SEVAL G., Sahin U., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., AKAY B. N., et al.

Dermatologic Therapy , cilt.35, sa.5, 2022 (SCI-Expanded, Scopus)

55. P28: RESPONSE AND VACCINATION STATUS OR LACK OF IMMUNOPARESIS ARE ASSOCIATED WITH BETTER OUTCOME FOLLOWING COVID-19 INFECTION AMONG PATIENTS DIAGNOSED WITH MULTIPLE MYELOMA: A SINGLE CENTER EXPERIENCE ON 110 PATIENTS

Seval G. C., Kircali E., Koyun D., Karakaya B., Yilmaz H., Yavuz G., et al.

HemaSphere , cilt.6, ss.26, 2022 (Scopus)

56. Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia with Venetoclax and Azacitidine

Pratz K. W., Jonas B. A., Pullarkat V., Recher C., Schuh A. C., Thirman M. J., et al.

Journal of Clinical Oncology , cilt.40, sa.8, ss.855-865, 2022 (SCI-Expanded, Scopus)

57. Low Dose TBI in Addition to Low Dose Melphalan and Fludarabine As a Reduced-Intensity Conditioning Regimen for Allogeneic Stem Cell Transplantation in Patients with High Risk Hematologic Malignancies

Gokmen A., Şahin U., Soydan E., Okcu M. K., Arslan O., Özcan M.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION , cilt.28, sa.3, ss.245, 2022 (Hakemli Dergi)

58. Polatuzumab vedotin plus bendamustine and rituximab in relapsed/ refractory DLBCL: Survival update and new extension cohort data

Sehn L. H., Hertzberg M., Opat S., Herrera A. F., Assouline S., Flowers C. R., et al.

Blood Advances , cilt.6, sa.2, ss.533-543, 2022 (SCI-Expanded, Scopus)

59. Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma

Zinzani P. L., Ramchandren R., Santoro A., Paszkiewicz-Kozik E., Gasiorowski R., Johnson N. A., et al.

Blood Advances , cilt.6, sa.2, ss.590-599, 2022 (SCI-Expanded, Scopus)

60. Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies

Civriz Bozdağ S., Cengiz Seval G., Yönal Hindilerden İ., Hindilerden F., Andıç N., Baydar M., et al.

TURKISH JOURNAL OF HEMATOLOGY , cilt.39, sa.1, ss.43-54, 2022 (SCI-Expanded, Scopus, TRDizin)

61. The Effects of Exercise Prescription on Aerobic Performance and Quality of Life During the Course of Lymphoma Chemotherapy: Results of a Prospective Controlled Study

Sahin U., Dundar I., Çelebi M. M., Merter M., Oktay E. I., Zergeroğlu A. M., et al.

Clinical Lymphoma, Myeloma and Leukemia , cilt.22, 2022 (SCI-Expanded, Scopus)

62. Relevance of Additional Immunohistochemical Markers in the Differential Diagnosis of Small B-Cell Lymphomas: A Case-Control Study Küçük B-Hücreli Lenfomalarda Ek İmmünohistokimyasal Belirteçlerin Ayırıcı Tanıdaki Yeri: Bir Olgu-Kontrol Çalışması

Kıvrak H., Yüksel S., Ateş C., Merter M., Kaygusuz G., Özcan M., et al.

Turkish Journal of Hematology , cilt.39, sa.3, ss.178-187, 2022 (SCI-Expanded, Scopus, TRDizin)

63. Duration of Objective Responses for Patients with Indolent Non-Hodgkin Lymphoma Discontinuing Treatment before Progression: Analysis from the Phase III Chronos-3 Trial Comparing Copanlisib Plus Rituximab with Placebo Plus Rituximab

Matasar M. J., Capra M., Özcan M., Lv F., Li W., Yañez E., et al.

BLOOD , cilt.138, sa.Supplement 1, ss.3538, 2021 (SCI-Expanded) Sürdürülebilir Kalkınma

64. The Efficacy and Safety of Low-Dose Inotuzumab Ozogamicin in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia: Interim Results of a Phase 4 Study

Özcan M., Cassaday R. D., Singh P., Zarzycka E., Zhang X., Nègre E., et al.

BLOOD , cilt.138, sa.Supplement 1, ss.1208-1210, 2021 (SCI-Expanded, Scopus)

65. Final Analysis of Keynote-170: Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL)

Zinzani P. L. L., Thieblemont C., Melnichenko V., Bouabdallah K., Waleswski J., Majlis A., et al.

BLOOD , cilt.138, sa.Supplement 1, ss.306, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

66. The Outcome of Autologous Hematopoietic Cell Transplantation in Elderly Patients with Aggressive Non-Hodgkin Lymphoma

Ilhan O., Cengiz Seval G., Civriz Bozdag S., Toprak S. K., Kurt Yuksel M., Topcuoglu P., et al.

BLOOD , cilt.138, 2021 (SCI-Expanded)

67. The Influence of ATG on the Outcomes of Patients With AML at the Time of Unrelated Donor Transplantation

CENGİZ SEVAL G., KIRCALI E., CİVRİZ BOZDAĞ S., TOPÇUOĞLU P., YÜKSEL M., DALVA K., et al.

Ankara Üniversitesi Tıp Fakültesi Mecmuası , cilt.74, sa.3, ss.337-342, 2021 (TRDizin)

68. CHRONOS-3: Randomized Phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma (iNHL).

Matasar M. J., Capra M., ÖZCAN M., Lv F., Li W., Yanez E., et al.

CANCER RESEARCH , cilt.81, sa.13, 2021 (SCI-Expanded)

69. Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial

Matasar M. J., Capra M., ÖZCAN M., Lv F., Li W., Yanez E., et al.

LANCET ONCOLOGY , cilt.22, sa.5, ss.678-689, 2021 (SCI-Expanded, Scopus)

70. Measurable residual disease response in acute myeloid leukemia treated with venetoclax and azacitidine.

Pratz K., Jonas B. A., Pullarkat V., Recher C., Schuh A. C., Thirman M. J., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.39, sa.15_suppl, ss.7018, 2021 (SCI-Expanded, Scopus)

71. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study

Kuruvilla J., Ramchandren R., Santoro A., Paszkiewicz-Kozik E., Gasiorowski R., Johnson N. A., et al.

The Lancet Oncology , cilt.22, sa.4, ss.512-524, 2021 (SCI-Expanded) Sürdürülebilir Kalkınma

72. ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma

Nowakowski G. S., Chiappella A., Gascoyne R. D., Scott D. W., Zhang Q., Jurczak W., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.39, sa.12, ss.1317-1340, 2021 (SCI-Expanded, Scopus)

73. Comparative Analysis and Validation of CIBMTR Early Relapse Risk Score with ISS and R-ISS: Single Center Experience from Ankara University

Seval G. C., Bozdag S. C., Toprak S. K., Yuksel M. K., Topcuoglu P., Arslan O., et al.

Transplantation and Cellular Therapy , cilt.27, sa.3, ss.401, 2021 (Scopus)

74. Impact of Peritransplant Metronidazole Use on Acute Graft Versus Host Disease in Allogeneic Hematopoietic Transplant Patients

Kircali E., Seval G. C., Bozdag S. C., Yuksel M. K., Topcuoglu P., Arslan O., et al.

Transplantation and Cellular Therapy , cilt.27, sa.3, ss.271, 2021 (Scopus)

75. Immune Checkpoint Molecule (PD-1, PD-L1, PD-L2) Expression, 9p24.1 Gene Locus Alterations and Tumor Microenvironment Status of Primary Central Nervous System Lymphoma and Their Clinical Relevance: A Quantitative Analysis

Akbulut D., Yüksel S., Kircali E., Aktaş B. Y., Kaygusuz G., Saglam A., et al.

MODERN PATHOLOGY , cilt.34, sa.SUPPL 2, ss.796-797, 2021 (SCI-Expanded)

76. Immune Checkpoint Molecule (PD-1, PD-L1, PD-L2) Expression, 9p24.1 Gene Locus Alterations and Tumor Microenvironment Status of Primary Central Nervous System Lymphoma and Their Clinical Relevance: A Quantitative Analysis

Akbulut D., YÜKSEL S., Kircali E., AKTAŞ B. Y., KAYGUSUZ G., Saglam A., et al.

LABORATORY INVESTIGATION , cilt.101, sa.SUPPL 1, ss.796-797, 2021 (SCI-Expanded)

77. Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma

Panayiotidis P., Follows G. A., Mollica L., Nagler A., ÖZCAN M., Santoro A., et al.

Blood Advances , cilt.5, sa.3, ss.823-828, 2021 (SCI-Expanded, Scopus)

78. REPLY FROM THE AUTHORS

Bozdag S. C., Seval G. C., Hindilerden I. Y., Hindilerden F., Andic N., Baydar M., et al.

TURKISH JOURNAL OF HEMATOLOGY , cilt.38, sa.4, ss.332, 2021 (SCI-Expanded, Scopus, TRDizin)

79. Allojeneik kök hücre naklinde Primer ve sekonder graft yetmezliği

ATİLLA E., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., ARSLAN Ö., et al.

Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları , cilt.5, 2021 (TRDizin)

80. Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation

Hodkinson B. P., Schaffer M., Brody J. D., Jurczak W., Carpio C., Ben-Yehuda D., et al.

TRANSLATIONAL ONCOLOGY , cilt.14, sa.1, 2021 (SCI-Expanded, Scopus)

81. Highlighting the Prognostic Importance of Measurable Residual Disease Among Acute Myeloid Leukemia Risk Factors

Ozdemir Z. N., Sahin U., DALVA K., BALTACI M. A., Uslu A., Ozturk C., et al.

TURKISH JOURNAL OF HEMATOLOGY , cilt.38, sa.2, ss.111-118, 2021 (SCI-Expanded, Scopus, TRDizin)

82. The Efficacy of Therapeutic Thrombocytapheresis in Patients with Thrombocytosis

NARLI ÖZDEMİR Z., ŞAHİN U., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., TOPÇUOĞLU P., et al.

Ankara Üniversitesi Tıp Fakültesi Mecmuası , cilt.74, 2021 (TRDizin)

83. Melphalan pharmacokinetics and transplant related toxicity during autologous stem cell transplantation

Sahin U., Soydan E., Gokmen A., ÖZCAN M., ARSLAN Ö.

BONE MARROW TRANSPLANTATION , cilt.56, sa.1, ss.7-8, 2021 (SCI-Expanded, Scopus)

84. Blastic Plasmacytoid Dendritic Cell Neoplasm: Single Center Experience on a Rare Hematological Malignancy

Ozdemir Z. N., CENGİZ SEVAL G., Sahin U., Uslu A., Gunduz M., CİVRİZ BOZDAĞ S., et al.

INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION , cilt.37, sa.1, ss.67-75, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

85. Treatment of Thrombocytopenia after Allogeneic Stem Cell Transplantation with Eltrombopag

Kircali E., CENGİZ SEVAL G., KOYUN D., Ozturk C., Uslu A., CİVRİZ BOZDAĞ S., et al.

BONE MARROW TRANSPLANTATION , cilt.55, sa.SUPPL 1, ss.410-411, 2020 (SCI-Expanded, Scopus)

86. The Influence of anti-thymocyte Globulin(ATG) on the Outcomes of Patients with AML W/wo Measurable Residual Disease(MRD) at the time of Unrelated Donor Transplantation

CENGİZ SEVAL G., Kircali E., BALTACI M. A., CİVRİZ BOZDAĞ S., Yuksel M. K., TOPÇUOĞLU P., et al.

BONE MARROW TRANSPLANTATION , cilt.55, sa.SUPPL 1, ss.204, 2020 (SCI-Expanded, Scopus)

87. Flamsa-based High-dose Sequential Conditioning Regimen followed by Allogeneic Hematopoietic Stem Cell Transplantation(ALLO-HSCT): Is It Effective in Patients with Primary Refractory or Relapsed Acute Leukemia?

CENGİZ SEVAL G., Kircali E., CİVRİZ BOZDAĞ S., TOPRAK S. K., Yuksel M. K., ARSLAN Ö., et al.

BONE MARROW TRANSPLANTATION , cilt.55, sa.SUPPL 1, ss.305-306, 2020 (SCI-Expanded, Scopus)

88. Role of Chimerism and flow-cytometric Monitoring of Measurable Residual Disease(MRD) after Allogeneic Hematopoietic Stem Cell Transplantation(Allo-HSCT) in Predicting Relapse in Acute Myeloid Leukemia(AML)

CENGİZ SEVAL G., Ulas E. B., TOPRAK S. K., CİVRİZ BOZDAĞ S., Yuksel M. K., TOPÇUOĞLU P., et al.

BONE MARROW TRANSPLANTATION , cilt.55, sa.SUPPL 1, ss.192-193, 2020 (SCI-Expanded, Scopus)

89. Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study and Preliminary Results of a Single-Arm Extension

Sehn L. H., Hertzberg M., Opat S., Herrera A. F., Assouline S. E., Flowers C., et al.

BLOOD , cilt.136, sa.Supplement 1, ss.17-19, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

90. Pembrolizumab Monotherapy in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): 3-Year Follow-up of the Keynote-170 Study

Zinzani P. L., Melnichenko V., Bouabdallah K., Walewski J., Majlis A., Fogliatto L., et al.

BLOOD , cilt.136, sa.Supplement 1, ss.42-43, 2020 (SCI-Expanded)

91. Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience

Bekoz H., Ozbalak M., Karadurmus N., Paydas S., Turker A., Toptas T., et al.

Annals of Hematology , cilt.99, sa.11, ss.2565-2576, 2020 (SCI-Expanded, Scopus)

92. Comparison of Two Alkylating Agents Among Refractory Multiple Myeloma: Published and Our Retrospective Bendamustine Combination Experience with Melflufen As Single Agent

Kircali E., Cengiz G., Çolak S., Gunduz M., Ataca Atilla P., Atilla E., et al.

BLOOD , cilt.136, sa.Supplement 1, ss.13-14, 2020 (SCI-Expanded)

93. Thyroid dysfunctions in adult patients after allogeneic hematopoietic stem cell transplantation

Atilla P. A., AKKUŞ E., Atilla E., Gökmen İnan N., CİVRİZ BOZDAĞ S., Yuksel M. K., et al.

CLINICAL TRANSPLANTATION , cilt.34, sa.10, 2020 (SCI-Expanded, Scopus)

94. Mikozis Fungoides ve Sezary SendromuTanılı Hastaların Tedavisinde AllojeneikHematopoietik Kök Hücre NakliSonuçları: 7 Yıllık Tek Merkez Deneyimi

SEVAL G. C., ATİLLA E., ATİLLA P., BOZDAĞ S. C., YÜKSEL M., TOÇUOĞLU P., et al.

Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları , cilt.4, sa.2, ss.23-27, 2020 (Hakemli Dergi)

95. AML-063: A Randomized, Double-Blind, Placebo-Controlled Study of Venetoclax with Azacitidine Versus Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia Ineligible for Intensive Therapy-Viale-A

Dinardo C. D., Jonas B. A., Pullarkat V., Thirman M. J., Garcia J. S., Wei A. H., et al.

CLINICAL LYMPHOMA, MYELOMA AND LEUKEMIA , cilt.20, ss.179, 2020 (SCI-Expanded)

96. A Randomized, Double-Blind, Placebo-Controlled Study of Venetoclax with Azacitidine Versus Azacitidine in Treatment-Naive Patients with Acute Myeloid Leukemia Ineligible for Intensive Therapy-Viale-A

DiNardo C. D., Jonas B. A., Pullarkat V., Thirman M. J., Garcia J. S., Wei A. H., et al.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , cilt.20, 2020 (SCI-Expanded, Scopus)

97. Allogeneic Stem Cell Transplantation in Myelodysplastic Syndrome

ATACA ATİLLA P., ATİLLA E., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., et al.

Journal of Ankara University Faculty of Medicine , cilt.73, sa.2, ss.113-117, 2020 (TRDizin)

98. Myelodisplastik Sendromda Allojeneik Kök Hücre Nakli

ATACA ATİLLA P., ATİLLA E., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., et al.

Ankara Üniversitesi Tıp Fakültesi Mecmuası , cilt.73, sa.2, ss.113-117, 2020 (TRDizin)

99. Evaluation of Patients With Myelodysplastic Syndromeby Ogata Scoring in Flow Cytometry: Pilot Study

ATİLLA E., Kırcalı E., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., TOPRAK S. K., AKAN H., et al.

LLM Dergi , cilt.4, sa.3, ss.45-49, 2020 (TRDizin)

100. Miyelodisplastik Sendrom HastalarınınAkan Hücre Ölçer ile Yapılan OgataSkorlaması Yoluyla Değerlendirilmesi:Pilot Çalışma

ATİLLA E., Kırcalı E., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., TOPRAK S. K., AKAN H., et al.

LLM Dergi , cilt.4, sa.3, ss.45-49, 2020 (TRDizin)

101. Safety and Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Mycosis Fungoides and Sezary Syndrome: A 7-year Tertiary Center Analysis

SEVAL G. C., ATİLLA E., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., et al.

Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları , cilt.4, sa.2, ss.23-27, 2020 (TRDizin)

102. Safety and Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Mycosis Fungoides and Sezary Syndrome: A 7-year Tertiary Center Analysis

CENGİZ SEVAL G., ATİLLA E., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., et al.

Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları , cilt.4, sa.2, ss.23-27, 2020 (TRDizin)

103. A real-world single-center retrospective study on efficacy and safety of pegylated interferon alpha-2a in patients with myeloproliferative neoplasm.

Özcan M., Koyun D., Cengiz Seval G., Uslu A., Kırcalı E., Ozturk C., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.38, sa.15_suppl, ss.19536, 2020 (SCI-Expanded)

104. Our Treatment Approach to Hairy Cell Leukemia

ATACA ATİLLA P., ATİLLA E., KIRCALI E., TOPÇUOĞLU P., DEMİRER T., ARSLAN Ö., et al.

Ankara Üniversitesi Tıp Fakültesi Mecmuası , cilt.73, sa.1, ss.5-8, 2020 (TRDizin)

105. A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma

Hajek R., Pour L., ÖZCAN M., Sanchez J. M., Sanz R. G., Anagnostopoulos A., et al.

EUROPEAN JOURNAL OF HAEMATOLOGY , cilt.104, sa.5, ss.435-442, 2020 (SCI-Expanded, Scopus)

106. Safety and outcome of allogeneic stem cell transplantation in mycosis fungoides and Sezary syndrome: A seven-year tertiary center analysis.

Toprak S. K., Cengiz Seval G., Atilla E., Civriz Bozdag S., Kurt Yuksel M., Topcuoglu P., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.38, sa.15_suppl, ss.20038, 2020 (SCI-Expanded)

107. Allogeneic hematopoietic stem cell transplantation for primary myelofibrosis: A single-center experience.

Demirer T., Cengiz Seval G., Civriz Bozdag S., Toprak S. K., Kurt Yuksel M., Topcuoglu P., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.38, sa.15_suppl, ss.19522, 2020 (SCI-Expanded)

108. Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study.

Dreyling M., Santoro A., Mollica L., Leppae S., Follows G., Lenz G., et al.

American journal of hematology , cilt.95, sa.4, ss.362-371, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

109. Tüylü Hücreli Lösemide Tedavi Yaklaşımımız

ATACA ATİLLA P., ATİLLA E., Kırcalı E., TOPÇUOĞLU P., DEMİRER T., ARSLAN Ö., et al.

Ankara Üniversitesi Tıp Fakültesi Mecmuası , cilt.73, sa.1, ss.5-8, 2020 (Hakemli Dergi)

110. Effect of Cyclophosphamide on Hemorrhagic Cystitis Following Haploidentical Related Compared to Matched Related/Unrelated Donor Hematopoietic Stem Cell Transplantation: A 7-Year Tertiary Center Analysis

Seval G. C., Ozturk N., Bozdag S. C., Yuksel M. K., Topcuoglu P., Arslan O., et al.

Transplantation and Cellular Therapy , cilt.26, sa.3, ss.109-110, 2020 (SCI-Expanded)

111. The Outcomes of Splenectomy and Drug Therapy in Patients with Splenic Marginal Zone Lymphoma

CENGİZ SEVAL G., ÖZCAN M., TOPÇUOĞLU P., ARSLAN Ö., GÜRMAN G., KUZU I.

LLM Dergi , cilt.4, sa.1, ss.10-13, 2020 (Hakemli Dergi)

112. Large Granular Lymphocytosis and Its Impact on Long Term Clinical Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: 14-Year Follow-up Data

Seval G. C., Uslu A., Kircali E., Bozdag S. C., Toprak S. K., Yuksel M. K., et al.

Transplantation and Cellular Therapy , cilt.26, sa.3, ss.305-306, 2020 (SCI-Expanded)

113. Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience

Ozbalak M., SALİHOĞLU A., Soysal T., Karadogan I., PAYDAŞ S., Ozdemir E., et al.

ANNALS OF HEMATOLOGY , cilt.99, sa.2, ss.301-307, 2020 (SCI-Expanded, Scopus)

114. MİKOZİS FUNGOİDES VE SEZARY SENDROMU TANILI HASTALARIN TEDAVİSİNDE HEMATOPOİETİK KÖK HÜCRE NAKLİ SONUÇLARI:7 YILLIK MERKEZ DENEYİMİ

CENGİZ SEVAL G., ATİLLA E., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., et al.

Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları , cilt.4, sa.2, ss.23-27, 2020 (Hakemli Dergi)

115. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Sehn L. H., Herrera A. F., Flowers C. R., Kamdar M. K., McMillan A., Hertzberg M., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.38, sa.2, ss.155-176, 2020 (SCI-Expanded, Scopus)

116. Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma

Armand P., Rodig S., Melnichenko V., Thieblemont C., Bouabdallah K., Tumyan G., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.37, sa.34, ss.3291-3301, 2019 (SCI-Expanded, Scopus)

117. Impact of Hepatitis B Core Antibody Seropositivity on the Liver Function Tests After Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma

Cengiz Seval G., Karaman Z., Civriz Bozdağ S., Yüksel M., Topçuoğlu P., Arslan Ö., et al.

Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları , cilt.3, sa.3, ss.55-59, 2019 (Hakemli Dergi)

118. IS AGE AN IMPORTANT FACTOR FOR AUTOLOGOUS PERIPHERAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ELDERLY PATIENTS WITH NON-HODGKIN LYMPHOMA?

Ilhan O., Seval G., Uslu A., Bozdag S., Toprak S., Yuksel M., et al.

JOURNAL OF GERIATRIC ONCOLOGY , cilt.10, sa.6, ss.46-47, 2019 (SCI-Expanded)

119. Negative Impact of High LDH at Diagnosis on OS, But Not PFS, Can Be Overcome by Autologous Stem Cell Transplantation

CENGİZ SEVAL G., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , cilt.19, sa.10, 2019 (SCI-Expanded, Scopus)

120. Splenic marginal zone lymphoma: Clinical characteristics and prognostic factors in a series of 52 patients

Cengiz Seval G., Topcuoglu P., Arslan O., Gurman G., Demirer T., Kuzu I., et al.

ANNALS OF ONCOLOGY , cilt.30, ss.441, 2019 (SCI-Expanded)

121. İmatinib Tedavisi Alan Hastalarda T Lenfosit Aktivasyonunun Akım Sitometrik Analizi

GÖREN ŞAHİN D., DALVA K., meriç s., GÜRMAN G., ÖZCAN M., ARSLAN Ö., et al.

Osmangazi Tıp Dergisi , 2019 (Hakemli Dergi)

122. Neutropenic fever and stem cell mobilization

TOPÇUOĞLU P., ÖZCAN M.

JOURNAL OF CLINICAL APHERESIS , cilt.34, sa.4, ss.517-518, 2019 (SCI-Expanded, Scopus)

123. Evaluation of Consultation Results for Histopathological Diagnosis in Hematological Malignancies

CANSIZ ERSÖZ C., KAYGUSUZ G., ÖZCAN M., KUZU I.

LLM Dergi , ss.31-37, 2019 (Hakemli Dergi)

124. AGE IS NOT IMPORTANT IN FIT ELDERLY PATIENTS WITH AGGRESSIVE LYMPHOMA

Ilhan O., Uslu A., Cengiz Seval G., Tap E., Basarir U., Civriz Bozdag S., et al.

HEMATOLOGICAL ONCOLOGY , cilt.37, ss.418, 2019 (SCI-Expanded)

125. Pretransplant hemoglobin and serum creatinine levels correlate with progression free survival in myeloma patients undergoing autologous stem cell transplantation.

Demirer T., Cengiz Seval G., Toprak S. K., Civriz Bozdag S., Yuksel M. K., Topcuoglu P., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.37, sa.15_suppl, ss.19532, 2019 (SCI-Expanded)

126. Can autologous stem cell transplantation abrogate the poor prognosis associated with high LDH in myeloma patients?

Ilhan O., Cengiz Seval G., Toprak S. K., Civriz Bozdag S., Yuksel M. K., Topcuoglu P., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.37, sa.15_suppl, ss.19524, 2019 (SCI-Expanded)

127. Impact of ABO Mismatch on Outcomes of Allogeneic Hematopoietic Stem Cell Recipients: 30 Years of Experience with 1016 Patients

Atilla E., Topcuoglu P., Akkus E., Atilla P. A., Bozdag S. C., Yuksel M. K., et al.

Transplantation and Cellular Therapy , cilt.25, sa.3, ss.322, 2019 (SCI-Expanded)

128. Influence of Conditioning Regimens with Total Body Irradiation (TBI) on Graft Versus Host Disease and Graft Versus Leukemia Effect Following Donor Lymphocyte Infusions (DLI)

Seval G. C., Atilla E., Ulas B., Bozdag S. C., Toprak S. K., Yuksel M. K., et al.

Transplantation and Cellular Therapy , cilt.25, sa.3, ss.176-177, 2019 (SCI-Expanded)

129. Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

O'Connor O. A., ÖZCAN M., Jacobsen E. D., Roncero J. M., Trotman J., Demeter J., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.37, sa.8, ss.613-624, 2019 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

130. Does Level of Vitamin D Prior to Allogeneic Stem Cell Transplantation Affect the Transplant Outcomes?

Soydan E., Gokmen A., Gökgöz Z., Şen Ş., Özkumur K. O., Okcu M. K., et al.

Transplantation and Cellular Therapy , cilt.25, sa.3, ss.110, 2019 (SCI-Expanded)

131. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study

Younes A., Brody J., Carpio C., Lopez-Guillermo A., Ben-Yehuda D., Ferhanoglu B., et al.

LANCET HAEMATOLOGY , cilt.6, sa.2, 2019 (SCI-Expanded, Scopus)

132. Severe Bone Marrow Hypoplasia with Black Cumin (Nigella sativa) Ingestion in a Patient with T-ALL in First Complete Remission

Ozdemir Z. N., Ozturk C., KUZU I., ÖZCAN M.

TURKISH JOURNAL OF HEMATOLOGY , cilt.36, sa.3, ss.215-217, 2019 (SCI-Expanded)

133. Akut Lösemide Allojeneik Nakil Öncesi Serum Ferritin Düzeyinin Nakil Sonuçlarına Etkisi

ŞAHİN U., HASAN E., GÜNDÜZ M., MERTER M., NARLI ÖZDEMİR Z., CİVRİZ BOZDAĞ S., et al.

Lösemi Lenfoma Miyelom Hastaları ve Araştırma Eğitimi Birliği Dergisi , cilt.3, sa.1, ss.1-3, 2019 (Hakemli Dergi)

134. A Multi-Center Study on the Efficacy of Eltrombopag in Management of Refractory Chronic Immune Thrombocytopenia: A Real-Life Experience

Cekdemir D., Guvenc S., Ozdemirkiran F., Eser A., Topts T., ÖZKOCAMAN V., et al.

TURKISH JOURNAL OF HEMATOLOGY , cilt.36, sa.4, ss.230-237, 2019 (SCI-Expanded, Scopus, TRDizin)

135. The Impact of Pre-transplant Serum Ferritin on Outcomes of Allogeneic Transplantation for Acute Leukemia

ŞAHİN U., ERDAL H., GÜNDÜZ M., MERTER M., NARLI ÖZDEMİR Z., CİVRİZ BOZDAĞ S., et al.

Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları , cilt.3, sa.1, ss.9-13, 2019 (Hakemli Dergi)

136. Comparision of Outcomes According to HLA Disparity in Acute Leukemia Patients: A Single Center Institution Experience

Topcuoglu P., Cengiz Seval G., Civriz Bozdag S., Toprak S. K., Kurt Yuksel M., Dalva K., et al.

BLOOD , cilt.132, sa.Supplement 1, ss.5776, 2018 (SCI-Expanded)

137. Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy

Walewski J., Hellmann A., Siritanaratkul N., ÖZSAN G. H., ÖZCAN M., Chuncharunee S., et al.

BRITISH JOURNAL OF HAEMATOLOGY , cilt.183, sa.3, ss.400-410, 2018 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

138. Clinical Reflection of Immunophenotyping in Paroxysmal Nocturnal Hemoglobinuria: Experience af a Single Center

ŞAHİN U., MERTER M., NARLI ÖZDEMİR Z., DALVA K., CİVRİZ BOZDAĞ S., YÜKSEL M., et al.

Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları , cilt.2, sa.4, ss.93-97, 2018 (Hakemli Dergi)

139. Comparing Conditioning Regimens for Autologous Stem Cell Transplantation in Lymphoma Patients

CENGİZ SEVAL G., Sahin D. G., Soydan E. A., Ozcelik T., Gokmen A., Gokgoz Z., et al.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , cilt.18, 2018 (SCI-Expanded)

140. Primer Mediastinal Büyük BHücreli Lenfoma HastalarımızınTedavi Sonuçlarının Geriye DönükDeğerlendirilmesi

ATİLLA E., ATACA ATİLLA P., Cengiz Seval G., TOPRAK S. K., İLHAN O., ARSLAN Ö., et al.

Türkiye’de Lösemi Lenfoma Miyelom Araştırmaları , cilt.2, sa.3, ss.60-64, 2018 (TRDizin)

141. Randomized phase 2 trial of polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed/refractory (r/r) FL and DLBCL.

Sehn L. H., Kamdar M., Herrera A. F., McMillan A., Flowers C., Kim W. S., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.36, sa.15, 2018 (SCI-Expanded, Scopus)

142. Gemcitabine, dexamethasone, and cisplatin (GDP) as an effective therapy as salvage and mobilization regimen in patients with relapsed or refractory Hodgkin lymphoma.

Gokmen A., Soydan E., Gokgoz Z., Kurdal M., Tek I., Ilhan O., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.36, sa.15, 2018 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

143. Retrospective analysis of 115 unselected patients with mantle cell lymphoma: Single center experience.

CENGİZ SEVAL G., Bulat B., Ozel F., Tasci O., KUZU I., CİVRİZ BOZDAĞ S., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.36, sa.15, 2018 (SCI-Expanded)

144. Kronik Lenfositik Lösemi’de Allojeneik Kök Hücre Nakli Deneyimi

ATİLLA E., PEKCAN G., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., et al.

Ankara Üniversitesi Tıp Fakültesi Mecmuası , cilt.71, sa.1, ss.43-46, 2018 (TRDizin)

145. Allogeneic Stem Cell Transplantation Experience in Chronic Lymphocytic Leukemia

ATİLLA E., Pekca G., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., et al.

Ankara Üniversitesi Tıp Fakültesi Mecmuası , cilt.71, sa.1, ss.43-46, 2018 (TRDizin)

146. Retrospective Analysis Leam Conditioning for Autologous Stem Cell Transplantation

Soydan E., Gokmen A., Gökgöz Z., Ilhan O., Arslan O., Ozcan M.

Transplantation and Cellular Therapy , cilt.24, sa.3, ss.144, 2018 (SCI-Expanded)

147. Age is Not an Important Factor for Autologous Peripheral Hematopoietic Stem Cell Mobilization and Collection in Patients with Multiple Myeloma

Ilhan O., Seval G. C., Toprak S. K., Bozdag S. C., Yuksel M. K., Topcuoglu P., et al.

Transplantation and Cellular Therapy , cilt.24, sa.3, ss.142, 2018 (SCI-Expanded)

148. Treatment with methotrexate, rituximab, and cytosine arabinoside followed by autologous stem cell transplantation in primary central nervous system lymphoma: A single-center experience.

Atilla P. A., Atilla E., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., TOPÇUOĞLU P., et al.

Hematology/oncology and stem cell therapy , cilt.11, sa.1, ss.13-17, 2018 (Scopus)

149. KRONİK LENFOSİTİK LÖSEMİ’DE TANI ANINDA HİPOGAMMAGLOBULİNEMİ SAĞKALIM VE ENFEKSİYON RİSKİ ÜZERİNDE ETKİLİ MİDİR?

ATİLLA E., Özel F., ATACA ATİLLA P., TOPÇUOĞLU P., AKAN H., BEKSAÇ M., et al.

Kırıkkale Üniversitesi Tıp Fakültesi Dergisi , cilt.20, sa.3, ss.294-299, 2018 (Hakemli Dergi)

150. Is cytomegalovirus a risk factor for haemorrhagic cystitis in allogeneic haematopoietic stem cell transplantation recipients?

Atilla E., Yalciner M., Ailla P. A., Ates C., CİVRİZ BOZDAĞ S., YÜKSEL M., et al.

ANTIVIRAL THERAPY , cilt.23, sa.8, ss.647-653, 2018 (SCI-Expanded, Scopus)

151. Upper respiratory viral infections in patients with haematological malignancies after allogeneic haematopoietic stem cell transplantation: a retrospective study

Atilla E., ŞAHİN EROĞLU D., Atilla P. A., Dolapci I., TEKELİ F. A., CİVRİZ BOZDAĞ S., et al.

ANTIVIRAL THERAPY , cilt.23, sa.6, ss.523-527, 2018 (SCI-Expanded, Scopus)

152. Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma

Dreyling M., Santoro A., Mollica L., Leppa S., Follows G. A., Lenz G., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.35, sa.35, ss.3898-3909, 2017 (SCI-Expanded, Scopus)

153. Safety and Efficacy of the Combination of Ibrutinib and Nivolumab in Patients with Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

Younes A., Brody J., Carpio C., Lopez-Guillermo A., Ben-Yehuda D., Ferhanoglu A. B., et al.

BLOOD , cilt.130, sa.Suppl_1, ss.833, 2017 (SCI-Expanded)

154. Allogeneic hematopoietic stem cell transplantation for refractory mycosis fungoides (MF) and Sezary syndrome (SS)

Atilla E., Atilla P. A., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., TOPÇUOĞLU P., et al.

INTERNATIONAL JOURNAL OF HEMATOLOGY , cilt.106, sa.3, ss.426-430, 2017 (SCI-Expanded, Scopus)

155. Subsequent malignancies after allogeneic hematopoietic stem cell transplantation

Gunduz M., Ozen M., Sahin U., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., et al.

CLINICAL TRANSPLANTATION , cilt.31, sa.7, 2017 (SCI-Expanded, Scopus)

156. Primary Pulmonary Extranodal Marginal Zone Lymphoma: An Atypical Radiological Pattern

AKIN KABALAK P., ÖZ M., KANKAYA D., ÇİLEDAĞ A., ATASOY K. Ç., ÖZCAN M., et al.

Respiratory Case Reports , 2017 (Hakemli Dergi)

157. Proper diagnosis of antithrombin III deficiency

Ozdemir Z. N., ÖZCAN M.

ANATOLIAN JOURNAL OF CARDIOLOGY , cilt.17, sa.4, 2017 (SCI-Expanded, Scopus, TRDizin)

158. Management and Outcome of Central Nervous System (CNS) Involvement in Acute Lymphoblastic Leukemia (ALL)

Atilla E., Atilla P. A., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION , cilt.23, sa.3, 2017 (SCI-Expanded)

159. Allogeneic Stem-Cell Transplantation for Chronic Lymphocytic Leukemia

Atilla E., Atilla P. A., Pekcan G., İLHAN O., GÜRMAN G., ÖZCAN M., et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION , cilt.23, sa.3, 2017 (SCI-Expanded)

160. Catheter Thrombosis in Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) Recipients

GÜRMAN G., Atilla E., Atilla P. A., CİVRİZ BOZDAĞ S., Yuksel M. K., TOPRAK S. K., et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION , cilt.23, sa.3, 2017 (SCI-Expanded)

161. The End of a Long Debate: Methylenetetrahydrofolate Reductase Gene Polymorphisms do not Increase Thrombosis Risk

Sahin U., ÖZCAN M.

EURASIAN JOURNAL OF MEDICINE , cilt.49, sa.1, ss.76-77, 2017 (ESCI, Scopus, TRDizin)

162. Allogeneic Transplantation in Chronic Myeloid Leukemia and the Effect of Tyrosine Kinase Inhibitors on Survival: A Quasi-Experimental Study

Ozen M., Ustun C., Ozturk B., TOPÇUOĞLU P., Arat M., Gunduz M., et al.

TURKISH JOURNAL OF HEMATOLOGY , cilt.34, sa.1, ss.16-26, 2017 (SCI-Expanded, Scopus, TRDizin)

163. Yoğun Kemoterapi Almış RefrakterHematolojik HastalıklardaHaploidentik Kök Hücre NaklininSağkalıma Etkisİ

YÜKSEL M., DALVA K., ŞAHİN U., KURDALOKCU M., KÖKSAL Ö., GÖKMEN A., et al.

LLM DERGİ , 2017 (Hakemli Dergi)

164. Therapeutic Plasma Exchange for Thrombotic Microangiopathy

Ilhan O., Atilla E., Ataca Atilla P., Civriz Bozdag S., Kurt Yuksel M., Toprak S. K., et al.

BLOOD , cilt.128, sa.22, ss.4939, 2016 (SCI-Expanded)

165. A rare complication after allogeneic stem cell transplantation: post-transplant erythrocytosis

Atilla E., TOPÇUOĞLU P., Ataca P., Pekcan G., CİVRİZ BOZDAĞ S., YÜKSEL M., et al.

CLINICAL TRANSPLANTATION , cilt.30, sa.6, ss.669-672, 2016 (SCI-Expanded, Scopus)

166. The Role of Azacitidine in the Treatment of Elderly Patients with Acute Myeloid Leukemia: Results of a Retrospective Multicenter Study

TOMBAK A., Ucar M. A., AKDENİZ A., TİFTİK E. N., Sahin D. G., Akay O. M., et al.

TURKISH JOURNAL OF HEMATOLOGY , cilt.33, sa.4, ss.273-280, 2016 (SCI-Expanded, Scopus, TRDizin)

167. A Quasi-Experimental Study Analyzing the Effectiveness of Portable High-Efficiency Particulate Absorption Filters in Preventing Infections in Hematology Patients during Construction

Ozen M., Yilmaz G., Coskun B., TOPÇUOĞLU P., Ozturk B., Gunduz M., et al.

TURKISH JOURNAL OF HEMATOLOGY , cilt.33, sa.1, ss.41-47, 2016 (SCI-Expanded, Scopus, TRDizin)

168. Fertility After Allogeneic Hematopoietic Stem Cell Transplantation: A 23-Year Review From A Tertiary Hospital

Atilla P. A., Atilla E., Ediboglu E., CİVRİZ BOZDAĞ S., To-Prak S. K., ARSLAN Ö., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.26, sa.3, ss.145-152, 2016 (SCI-Expanded)

169. First Multicenter, Randomized Phase 3 Study in Patients (Pts) with Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator's Choice (Lumiere trial; NCT01482962)

O'connor O. A., Özcan M., Jacobsen E. D., Roncero Vidal J. M., Trotman J., Demeter J., et al.

BLOOD , cilt.126, sa.23, ss.341, 2015 (SCI-Expanded)

170. Extracorporeal Photopheresis for the Treatment of Mycosis Fungoides

Atilla E., Ataca P., Civriz Bozdag S., Toprak S. K., Yuksel M. K., Akay B. N., et al.

BLOOD , cilt.126, sa.23, ss.5062, 2015 (SCI-Expanded)

171. Seroprevalence for Toxoplasma Gondii in Allogeneic Hematopoietic Stem Cell Transplantation Recipients

Atilla E., Ataca P., Balli S., Isikoglu B., Topcuoglu P., Ozcan M., et al.

BLOOD , cilt.126, sa.23, ss.5459, 2015 (SCI-Expanded)

172. Upper and Lower Respiratory Tract Infections By Respiratory Viruses in Adult Recipients of Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)

Atilla E., Ataca P., Sahin D., Topcuoglu P., Dolapci I., Tekeli A., et al.

BLOOD , cilt.126, sa.23, ss.5479, 2015 (SCI-Expanded)

173. Positive Impact of Chronic Graft-Versus Host Disease on Survival in 928 Allogeneic Hematopoietic Stem Cell Transplant Recipients

Gurman G., Ataca P., Atilla E., Civriz Bozdag S., Toprak S. K., Yuksel M. K., et al.

BLOOD , cilt.126, sa.23, ss.1952, 2015 (SCI-Expanded)

174. Is Initial CD3+ T Cell Dose in Donor Lymphocyte Infusion for Relapsed Hematological Malignancies a Prognostic Determinant?

Atilla E., Ataca P., Toprak S. K., Yuksel M. K., Topcuoglu P., Arslan O., et al.

BLOOD , cilt.126, sa.23, ss.5483, 2015 (SCI-Expanded)

175. Comparison of Two Different Doses of Corticosteroid Premedication for Antithymocyte Globulin in Allogeneic Hematopoietic Stem Cell Transplantation

Merter M., Atilla E., Sahin U., Civriz Bozdag S., Kurt Yuksel M., Topcuoglu P., et al.

BLOOD , cilt.126, sa.23, ss.5456, 2015 (SCI-Expanded)

176. Follow-up of del(5)q MDS patients with or without other chromosomal abnormalities

Turedi O., Ataca P., TUNCALI T., Atilla E., Vicdan A., Durmaz C. D., et al.

CHROMOSOME RESEARCH , cilt.23, 2015 (SCI-Expanded)

177. Treatment of Acute Myeloid Leukemia in Adolescent and Young Adult Patients

CENGİZ SEVAL G., ÖZCAN M.

JOURNAL OF CLINICAL MEDICINE , cilt.4, sa.3, ss.441-459, 2015 (SCI-Expanded, Scopus)

178. Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey

Salihoglu A., ELVERDİ T., Karadogan I., Paydas S., Ozdemir E., Erdem G., et al.

ANNALS OF HEMATOLOGY , cilt.94, sa.3, ss.415-420, 2015 (SCI-Expanded, Scopus)

179. Ruxolitinib Treatment in a Patient with Primary Myelofibrosis Resistant to Conventional Therapies and Splenectomy: A Case Report

Ayh M., ÖZCAN M., CENGİZ SEVAL G.

TURKISH JOURNAL OF HEMATOLOGY , cilt.32, sa.2, ss.180-183, 2015 (SCI-Expanded, Scopus, TRDizin)

180. Successful Desensitization of a Patient with Rituximab Hypersensitivity

Ataca P., Atilla E., Kendir R., BAVBEK S., ÖZCAN M.

CASE REPORTS IN IMMUNOLOGY , cilt.2015, 2015 (ESCI)

181. Antilymphocyte/Thymocyte Globulin for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease: 20-Year Experience at a Single Center

Ozen M., CİVRİZ BOZDAĞ S., Cakmak G., TOPÇUOĞLU P., Eroglu A. H., Glunduz M., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.25, sa.4, ss.236-244, 2015 (SCI-Expanded, Scopus, TRDizin)

182. Clinical Reflection of Immunophenotyping in Paroxysmal Nocturnal Hemoglobinuria: Experience of a Single Center

Sahin U., Merter M., Ataca P., Atilla E., Atesagaoglu B., Pekcan G., et al.

BLOOD , cilt.124, sa.21, ss.5150, 2014 (SCI-Expanded)

183. Favorable Treatment Alternative for Primary Central Nervous System Lymphoma: Combined Chemotherapy Regimen Consisting of High-Dose Methotrexate, Rituximab and Cytosine-Arabinoside

Ataca P., Toprak S. K., Atilla E., Topcuoglu P., Kurt Yuksel M., Kaygusuz G., et al.

BLOOD , cilt.124, sa.21, ss.5462, 2014 (SCI-Expanded)

184. Haploidentical Stem Cell Transplantation (SCT) Using Flamsa Regimen As Salvage Chemotherapy

Yuksel M. K., Gokmen A., Ozcan M., Arslan O., Ilhan O., Ozbek D., et al.

BLOOD , cilt.124, sa.21, ss.5925, 2014 (SCI-Expanded)

185. Do FMS-like Tyrosine Kinase 3 and Nucleophospmin 1 Gene Mutations Really Effect Survival in Acute Myeloid Leukemia ?

Gunduz M., Ataca P., Ozen M., Atilla E., Bozdag S. C., Toprak S. K., et al.

BLOOD , cilt.124, sa.21, ss.5328, 2014 (SCI-Expanded)

186. Treatment Approaches in Acute Leukemia Patients Relapsing Following Allogeneic Hematopoietic Stem Cell Transplantation

Topcuoglu P., Gunduz M., Ozen M., Civriz Bozdag S., Kocak Toprak S., Arslan O., et al.

BLOOD , cilt.124, sa.21, ss.5891, 2014 (SCI-Expanded)

187. Fertility in Our Allogeneic Hematopoietic Stem Cell Transplant Patients

Topcuoglu P., Ataca P., Bozdag S. C., Toprak S. K., Arslan O., Ozcan M., et al.

BLOOD , cilt.124, sa.21, ss.5887, 2014 (SCI-Expanded)

188. Is R-CODOX-M/IVAC Inferior to Other Regimens in Burkitt’s Lymphoma: A Single Center Experience

Atilla E., Sahin U., Ataca P., Uslu A., Kircali E., Atesagaoglu B., et al.

BLOOD , cilt.124, sa.21, ss.5448, 2014 (SCI-Expanded)

189. The Effect of Nilotinib in Chronic Myeloid Leukemia Treatment Dose on Spermatogenesis and Folliculogenesis in a Healthy Mouse Model

Seval G., Ozkavukcu S., Seval M., Ayli M., Ozcan M.

BLOOD , cilt.124, sa.21, ss.1799, 2014 (SCI-Expanded)

190. Is the Chronic Myeloproliferative Disease Prognosis Really Different in Geriatric Patients?

Ilhan O., Ataca P., Atilla E., Toprak S. K., Kaygusuz G., Kuzu I., et al.

BLOOD , cilt.124, sa.21, ss.5555, 2014 (SCI-Expanded)

191. The Efficacy of Tyrosine Kinase Inhibitors with Steroid As First Line Induction Therapy in Ph+ Acute Lymphoblastic Leukemia

Gurman G., Merter M., Ataca P., Ozen M., Atesagaoglu B., Gunduz M., et al.

BLOOD , cilt.124, sa.21, ss.5281, 2014 (SCI-Expanded)

192. The Treatment of Acquired Hemophilia with Combination Therapy of Immunosuppressives and Immunoadsorption

Bilgin A. U., ÖZCAN M., Ayyildiz E., İLHAN O.

TURKISH JOURNAL OF HEMATOLOGY , cilt.31, sa.2, ss.194-196, 2014 (SCI-Expanded, Scopus, TRDizin)

193. Efficacy of FEIBA for acute bleeding and surgical haemostasis in haemophilia A patients with inhibitors: A multicentre registry in Turkey

Kavakli K., ZÜLFİKAR H., ZÜLFİKAR O. B., ZÜLFİKAR O. B., Aydogan G., Aydogan G., et al.

Haemophilia , cilt.18, sa.3, ss.383-391, 2012 (SCI-Expanded)

194. Case-matched comparison with standard versus reduced intensity conditioning regimen in chronic myeloid leukemia patients

TOPÇUOĞLU P., Arat M., ÖZCAN M., ARSLAN Ö., İLHAN O., BEKSAÇ M., et al.

ANNALS OF HEMATOLOGY , cilt.91, sa.4, ss.577-586, 2012 (SCI-Expanded, Scopus)

195. How Does Influenza A (H1N1) Infection Proceed in Allogeneic Stem Cell Transplantation Recipients?

CİVRİZ BOZDAĞ S., Bozkurt G., Topcuoglu P., AZAP A., Ozcan M., Konuk N., et al.

TURKISH JOURNAL OF HEMATOLOGY , cilt.29, sa.1, ss.63-66, 2012 (SCI-Expanded)

196. First and Second High Dose Treatment Supported by Autologous Hematopoetic Cell Transplantation Rescue in Multiple Myeloma

Bozdag S. C., Topcuoglu P., Beksac M., Ilhan O., Ozcan M., Gurman G., et al.

BLOOD , cilt.118, sa.21, ss.4528, 2011 (SCI-Expanded)

197. Immunophenotyping Features in Acute Myeloid Leukemia (AML) with NPM1+ and/or FLT3+

Topcuoglu P., Dalva K., Bozdag S. C., Arslan O., Ozcan M., Ilhan O., et al.

BLOOD , cilt.118, sa.21, ss.4908, 2011 (SCI-Expanded)

198. Aplastic anemia and clopidogrel/Nonfatal aplastic anemia associated with clopidogrel

CİVRİZ BOZDAĞ S., ÖZCAN M.

ANADOLU KARDIYOLOJI DERGISI-THE ANATOLIAN JOURNAL OF CARDIOLOGY , cilt.11, sa.3, ss.276, 2011 (SCI-Expanded)

199. The Efficacy of Vorinostat in Combination With Interferon Alpha and Extracorporeal Photopheresis in Late Stage Mycosis Fungoides and Sezary Syndrome

ŞANLI H., AKAY B. N., Anadolu R., ÖZCAN M., Saral S., Akyol A.

JOURNAL OF DRUGS IN DERMATOLOGY , cilt.10, sa.4, ss.403-408, 2011 (SCI-Expanded, Scopus)

200. Short and long term effects of granulocyte colony-stimulating factor during induction therapy in acute myeloid leukemia patients younger than 65: Results of a randomized multicenter phase III trial

BEKSAÇ M., ALİ R., Ozcelik T., ÖZCAN M., Ozcebe O., Bayik M., et al.

LEUKEMIA RESEARCH , cilt.35, sa.3, ss.340-345, 2011 (SCI-Expanded, Scopus)

201. The effect of CD34 count and clonogenic potential of hematopoietic stem cells on engraftment

Sari T., YÜKSEL M., TOPÇUOĞLU P., Tol M., Ayyildiz E., ÖZCAN M., et al.

TRANSFUSION AND APHERESIS SCIENCE , cilt.43, sa.3, ss.315-320, 2010 (SCI-Expanded, Scopus)

202. Development of Hodgkin's lymphoma under bexarotene treatment for Sézary syndrome and review of the literature.

ŞANLI H., AKAY B. N., Ozcan M.

Journal of drugs in dermatology : JDD , cilt.9, sa.8, ss.1014-6, 2010 (SCI-Expanded)

203. Development of Hodgkin's Lymphoma Under Bexarotene Treatment for Sezary Syndrome and Review of the Literature

Sanli H., AKAY B. N., ÖZCAN M.

JOURNAL OF DRUGS IN DERMATOLOGY , cilt.9, sa.8, ss.1014-1016, 2010 (SCI-Expanded, Scopus)

204. ALLOGENEIC HEMATOPOETIC CELL TRANSPLANTATION IN PATIENTS POSITIVE FOR HEPATITIS B SURFACE ANTIGEN

Topcuoglu P., Soydan E., Idilman R., Arslan O., Ozcan M., Ilhan O., et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION , cilt.16, sa.2, 2010 (SCI-Expanded)

205. Presence Of Abnormal Plasma Cells In Peripheral Stem Cell Harvest Products Predict Early Relapse Following Autologous Stem Cell Transplantation In Patients With Multiple Myeloma

Bakanay S., Dalva K., Koksoy B., Civriz S., Ayyildiz E., Arat M., et al.

Transplantation and Cellular Therapy , cilt.16, sa.2, ss.239, 2010 (SCI-Expanded)

206. Mobilization of PBSCs with chemotherapy and recombinant human G-CSF: a randomized evaluation of early vs late administration of recombinant human G-CSF

Ozcelik T., Topcuoglu P., BEKSAÇ M., Ozcan M., Arat M., Biyikli Z., et al.

BONE MARROW TRANSPLANTATION , cilt.44, sa.12, ss.779-783, 2009 (SCI-Expanded, Scopus)

207. Simultaneous occurrence of Kaposi's sarcoma and nodular lymphocyte predominant subtype of Hodgkin's lymphoma in the same lymph node

Kankaya D., Kaygusuz G., KUZU I., SAVAŞ B., Bakanay S. M., ÖZCAN M.

TURKISH JOURNAL OF HEMATOLOGY , sa.4, ss.201-203, 2009 (SCI-Expanded, Scopus, TRDizin)

208. 2nd international congress on leukemia, lymphoma and myeloma

Arat M., Özsan G. H., Yenerel M. N., Cetin M., ÖZCAN M.

Expert Review of Hematology , cilt.2, sa.5, ss.509-512, 2009 (SCI-Expanded)

209. Diagnostic Utility of Flow Cytometry in Myelodysplastic Syndrome: A Retrospective Validation From a Single Centre.

Topcuoglu P., Dalva K., Bakanay S. M., Bozdag S. C., Arslan O., Ozcan M., et al.

BLOOD , cilt.114, sa.22, ss.4846, 2009 (SCI-Expanded)

210. Follow-up of ADAMTS13 enzyme and its relationship with clinical events after allogeneic hematopoietic stem cell transplantation

CİVRİZ BOZDAĞ S., Gunaltay S., DALVA K., ÖZCAN M.

BLOOD COAGULATION & FIBRINOLYSIS , cilt.20, sa.3, ss.165-169, 2009 (SCI-Expanded, Scopus)

211. Flow Cytometric Analysis of T Cell Functions in CML Patients Under Imatinib Therapy

Sahin D. G., Dalva K., Meric S., Gurman G., Ozcan M., Arslan O., et al.

BLOOD , cilt.112, sa.11, ss.2633, 2008 (SCI-Expanded)

212. Clonal evolution of monosomy 7 in acquired severe aplastic anemia: Two cases treated with allogeneic hematopoietic stem cell transplantation

Bakanay Ş. M., TOPÇUOĞLU P., Bilgin A. U., Yararbaş K., Karaüzüm S. B., ÖZCAN M., et al.

Turkish Journal of Hematology , cilt.25, sa.2, ss.94-97, 2008 (SCI-Expanded)

213. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloblastic leukemia (AML): A single center experience

İLHAN O., TOPÇUOĞLU P., Arat M., Soydan E. A., YÜKSEL M., ARSLAN Ö., et al.

Turkish Journal of Hematology , cilt.25, sa.2, ss.87-93, 2008 (SCI-Expanded)

214. T-helper-1 (Th1) and Th2 cytokines after allogeneic hematopoietic stem cell transplantation (allo-HSCT)

TOPÇUOĞLU P., Bakanay Ş. M., DALVA K., Arat M., BEKSAÇ M., ÖZCAN M.

Turkish Journal of Hematology , cilt.25, sa.1, ss.24-35, 2008 (SCI-Expanded)

215. A case report of the Modified Malmo Protocol: An alternative therapeutic approach to refractory chronic idiopathic thrombocytopenic purpura

Yazman D., Konuk N., ÖZCAN M., Arat M., Soydan E., ARSLAN Ö., et al.

THERAPEUTIC APHERESIS AND DIALYSIS , cilt.12, sa.3, ss.255-258, 2008 (SCI-Expanded)

216. The relevance of T cells and follicular dendritic reticulum cells on predicting the clinical behaviour of follicular lymphomas

Ozgun A., Kankaya D., Altas S., Kaygusuz G., Bakanay S. M., Ozcan M., et al.

VIRCHOWS ARCHIV , sa.2, ss.446, 2007 (SCI-Expanded)

217. How to calculate the quantity of CD34+ cells infused? A single center cohort study based on actual, ideal or adjusted ideal body weight

Topcuoglu P., Soydan E. A., Ekiz F., Ayyildiz E., Dalva K., Ozcan M., et al.

TRANSFUSION AND APHERESIS SCIENCE , cilt.36, sa.3, ss.275-280, 2007 (SCI-Expanded, Scopus)

218. The autologous hematopoietic stem cell transplantation in adult patients with lymphoma: Turkish Bone Marrow Transplantation Registry results

Arpaci F., Ataergin S., GÜRMAN G., Çaǧirgan S., Arat M., Özet A., et al.

Turkish Journal of Cancer , cilt.37, sa.2, ss.45-53, 2007 (Scopus)

219. 277: Allogeneic hematopoietic cell transplantation in imatinib era

Ugur Bilgin A., Soydan E., Topcuoglu P., Arslan O., Ozcan M., Gurman G., et al.

Transplantation and Cellular Therapy , cilt.13, sa.2, ss.100-101, 2007 (SCI-Expanded)

220. Serum transforming growth factor beta 1 levels in multiple myeloma patients

Coşkun H. Ş., Ilham O., ÖZCAN M., Ayaz S., DALVA K., Üstün C., et al.

Turkish Journal of Hematology , cilt.23, sa.1, ss.47-52, 2006 (SCI-Expanded)

221. Granuloma annulare on herpes zoster scars in a Hodgkin's disease patient following autologous peripheral stem cell transplantation.

Sanli H., Kocyigit P., Arica E., Kurtyuksel M., Heper A., Ozcan M.

Journal of the European Academy of Dermatology and Venereology : JEADV , cilt.20, sa.3, ss.314-7, 2006 (SCI-Expanded, Scopus)

222. The Impact of Methylenetetrahydrofolate Reductase C677T Gene Polymorphism on Engraftment after Allogeneic Hematopoetic Cell Transplantation.

Soydan E. A., Topcuoglu P., Ozcan M., Arslan O., Gurman G., Beksac M., et al.

BLOOD , cilt.106, sa.11, ss.5318, 2005 (SCI-Expanded)

223. Expression of IFITM1 in chronic myeloid leukemia patients

AKYERLİ BOYLU C., BEKSAÇ M., Holko M., Frevel M., Dalva K., ÖZBEK U., et al.

LEUKEMIA RESEARCH , cilt.29, sa.3, ss.283-286, 2005 (SCI-Expanded, Scopus)

224. Thrombophilic gene mutations in cirrhotic patients with portal vein thrombosis.

Erkan O., Bozdayi A., DİŞİBEYAZ S., Oguz D., Ozcan M., Bahar K., et al.

European journal of gastroenterology & hepatology , cilt.17, sa.3, ss.339-43, 2005 (SCI-Expanded, Scopus)

225. The Comparison of Myeloablative Versus Reduced Intensity Conditioning Regimen in ABO Mismatched Allogeneic Hematopoietic Cell Transplantation.

Topcuoglu P., Arat M., Bolukbasi T., Soydan E., Ozer Y., Ozcan M., et al.

BLOOD , cilt.104, sa.11, ss.5146, 2004 (SCI-Expanded)

226. Allogeneic Hemapoietic Progenitor Cell Collection Using Four Different Cell Separators: A Retrospective Comparative Analysis.

Arat M., Arslan O., Soydan E. A., Ayyildiz E., Dalva K., Tol M., et al.

BLOOD , cilt.104, sa.11, ss.5009, 2004 (SCI-Expanded)

227. Both Higher Level of (bcr,abl) Transcripts and High Hasford Risk Score Are Associated with Cytogenetic Response but Absence of Molecular Remission during First Line Use of Imatinib Mesilate(IM): A Finding Not Observed Following Use among Interferon Failures.

Toprak S. K., Dalva K., Mizrak D., Arat M., Ozcan M., Gurman G., et al.

BLOOD , cilt.104, sa.11, ss.4671, 2004 (SCI-Expanded)

228. High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation in patients with lymphoma - A retrospective evaluation

Demirer T., Ayli M., Fen T., Ozcan M., Arat M., Buyukberber S., et al.

Bone Marrow Transplantation , cilt.34, sa.9, ss.781-786, 2004 (SCI-Expanded, Scopus)

229. Acute hepatic failure in a case of acute lymphoblastic leukemia

Cesur S., TOPÇUOĞLU P., Aşik O., Birengel S., ÖZCAN M.

Turkish Journal of Medical Sciences , cilt.34, sa.4, ss.275-279, 2004 (Scopus)

230. Extracorporeal photoimmunotherapy for the treatment of steroid refractory progressive chronic graft-versus-host disease.

Ilhan O., Arat M., Arslan O., Ayyildiz E., Sanli H., BEKSAÇ M., et al.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis , cilt.30, sa.3, ss.185-7, 2004 (SCI-Expanded, Scopus)

231. Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies

Idilman R., Arat M., Soydan E., TÖRÜNER M., Soykan I., Akbulut H., et al.

JOURNAL OF VIRAL HEPATITIS , cilt.11, sa.2, ss.141-147, 2004 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

232. The impact of granulocyte colony stimulating factor at content of donor lymphocytes collected for cellular immunotherapy

Arat M., Arslan O., GÜRMAN G., Dalva K., Ozcan M., Ugur A., et al.

TRANSFUSION AND APHERESIS SCIENCE , cilt.30, sa.1, ss.9-15, 2004 (SCI-Expanded, Scopus)

233. Administration of granulocyte-colony-stimulating factor for allogeneic hematopoietic cell collection may induce the tissue factor-dependent pathway in healthy donors

Topcuoglu P., Arat M., Dalva K., Ozcan M.

BONE MARROW TRANSPLANTATION , cilt.33, sa.2, ss.171-176, 2004 (SCI-Expanded, Scopus)

234. Hepatitis B virus vaccination of recipients and donors of allogeneic peripheral blood stem cell transplantation.

Idilman R., Ustun C., Karayaicin S., Aktemel A., Turkyilmaz A., Ozcan M., et al.

Clinical transplantation , cilt.17, sa.5, ss.438-43, 2003 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

235. Elevated whole-blood tissue factor procoagulant activity as a marker of restenosis after percutaneous transluminal coronary angioplasty and stent implantation.

TUTAR D. E., Ozcan M., Kilickap M., GÜLEÇ H. S., Aras O., Pamir G., et al.

Circulation , cilt.108, sa.13, ss.1581-4, 2003 (SCI-Expanded, Scopus)

236. Role of pretransplant interferon-alpha(IFN) treatment in the outcome of stem cell transplantation (SCT) from related donors in chronic myelogenous leukemia (CML): results from three Turkish transplant centers

BEKSAÇ M., Celebi H., Sargin D., Yalcin A., Topcuoglu P., Kalayoglu-Besisik S., et al.

BONE MARROW TRANSPLANTATION , cilt.31, sa.10, ss.897-904, 2003 (SCI-Expanded, Scopus)

237. Effects of replacement fluids on coagulation system used for therapeutic plasma exchange.

Tek I., Arslan O., Arat M., Ozcan M., Akdag B., Ilhan O.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis , cilt.28, sa.1, ss.3-7, 2003 (SCI-Expanded, Scopus)

238. The detection of flow cytometric G-CSF receptor expression and it's effect on therapy in acute myeloid leukemia

Kutlay S., BEKSAÇ M., Dalva K., Ilhan O., Koc H., Akan H., et al.

LEUKEMIA & LYMPHOMA , cilt.44, sa.5, ss.791-795, 2003 (SCI-Expanded)

239. The role of ABO incompatibility in allogeneic peripheral blood stem cell transplantation

ARSLAN Ö., Coşkun H. Ş., Arat M., Soydan E., ÖZCAN M., GÜRMAN G., et al.

Turkish Journal of Haematology , cilt.19, sa.3, ss.401-409, 2002 (SCI-Expanded)

240. Monitoring of peripheral blood CD34+cell counts on the first day of apheresis is highly predictive for efficient CD34+cell yield

Demirer T., Ilhan O., Ayli M., Arat M., Dagli M., Ozcan M., et al.

THERAPEUTIC APHERESIS , cilt.6, sa.5, ss.384-389, 2002 (SCI-Expanded)

241. The Role of ABO Incompatibility in Allogeneic Peripheral Blood Stem Cell Transplant.

Arslan Ö., Coşkun H. Ş., Arat M., Soydan E., Özcan M., Gürman G., et al.

Turkish journal of haematology : official journal of Turkish Society of Haematology , cilt.19, sa.3, ss.401-9, 2002 (Scopus)

242. A randomized trial of assessment of efficacy of leukapheresis volumes, 8 liters vs 12 liters

Demirer T., Dagli M., Ilhan O., Ayli M., Haznedar R., Fen T., et al.

BONE MARROW TRANSPLANTATION , cilt.29, sa.11, ss.893-897, 2002 (SCI-Expanded, Scopus)

243. The profile of erythrocyte antigens after allogeneic hematopoietic stem cell transplantation

Yildirim I., Arsian O., Ozer Y., Arat M., Soydan E., Topcuoglu P., et al.

BONE MARROW TRANSPLANTATION , cilt.29, 2002 (SCI-Expanded)

244. The role of busulfan at post transplant pulmonary complications in allogeneic hematopoietic cell transplantation

Soydan E., Arat M., Ozdemir Kumbasar O., Ozcan M., Arslan O., GÜRMAN G., et al.

BONE MARROW TRANSPLANTATION , cilt.29, 2002 (SCI-Expanded)

245. Is there a correlation between peripheral blood CD34+cells and peripheral blood erythrocyte precursors in healthy G-CSF stimulated donors and the effect of G-CSF and apheresis on complete blood count

Tavat C., Arslan O., Arat M., Ilhan O., Ozcan M., Topcuoglu P., et al.

BONE MARROW TRANSPLANTATION , cilt.29, 2002 (SCI-Expanded)

246. A retrospective comparison of oral versus intravenous administration of Busulfan: Preliminary results show similar toxicity but less relapse

Arat M., Topcuoglu P., Soydan E., GÜRMAN G., Ozcan M., Arslan O., et al.

BONE MARROW TRANSPLANTATION , cilt.29, 2002 (SCI-Expanded)

247. Does donor recipient ABO-incompatibility have any effect on the course and outcome of allogeneic hematopoietic cell transplantation?

Arslan O., Arat M., Soydan E., COŞKUN H. Ş., Topcuoglu P., Ozcan M., et al.

BONE MARROW TRANSPLANTATION , cilt.29, 2002 (SCI-Expanded)

248. Thromboembolic complications after allogeneic hematopoietic cell transplantation: the lbni Sina experience

Yazman D., Topcuoglu P., Arat M., Soydan E., Kurt M., Ozcan M.

BONE MARROW TRANSPLANTATION , cilt.29, 2002 (SCI-Expanded)

249. Presence of tissue factor (TF) antigen expressing cells within allogeneic peripheral blood progenitor cell (PBPC) harvest

Ozcan M., Topcuoglu P., Arat M., Dalva K., Soydan E., Arslan O., et al.

BONE MARROW TRANSPLANTATION , cilt.29, 2002 (SCI-Expanded)

250. Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colony-stimulating factor (rhG-CSF): a randomized evaluation of different doses of rhG-CSF

Demirer T., Ayli M., Ozcan M., Gunel N., Haznedar R., Dagli M., et al.

BRITISH JOURNAL OF HAEMATOLOGY , cilt.116, sa.2, ss.468-474, 2002 (SCI-Expanded, Scopus)

251. In vivo use of all-trans retinoic acid prior to induction chemotherapy improves complete remission rate and increases rhodamine 123 uptake in patients with de novo acute myeloid leukemia

Ustun C., BEKSAÇ M., Dalva K., Koc H., Konuk N., Ilhan O., et al.

MEDICAL ONCOLOGY , cilt.19, sa.1, ss.59-67, 2002 (SCI-Expanded, Scopus)

252. An unusual presentation of plasma cell dyscrasias: cardiac tamponade due to myelomatous infiltration.

Arat M., Ulusoy V., Demirer T., Uysal A., Ozcan M., Dincer S., et al.

Leukemia & lymphoma , cilt.43, sa.1, ss.145-8, 2002 (SCI-Expanded)

253. An atypical Juvenile Chronic Myelocytic Leukemia patient with skin rashes, vasculitis and arthritis

Cesur S., Çiftçi A., Kurt H., ÖZCAN M.

Cancer Research, Therapy and Control , cilt.11, sa.3-4, ss.219-221, 2002 (SCI-Expanded)

254. Nephrotic syndrome after allogeneic peripheral blood stem cell transplantation.

Akar H., KEVEN K., Celebi H., Orhan D., Nergizoglu G., Erbay B., et al.

Journal of nephrology , cilt.15, sa.1, ss.79-82, 2002 (SCI-Expanded, Scopus)

255. A case of familial Mediterranean fever with amyloidosis as the first manifestation

Kutlay S., Yilmaz E., Koytak E., Tulunay O., KEVEN K., Ozcan M., et al.

AMERICAN JOURNAL OF KIDNEY DISEASES , cilt.38, sa.6, 2001 (SCI-Expanded, Scopus)

256. Allogeneic hematopoietic stem cell transplantation using IV Busulfan.

Arat M., BEKSAÇ M., GÜRMAN G., Ozcan M., Arslan O., Soydan E., et al.

BLOOD , cilt.98, sa.11, 2001 (SCI-Expanded)

257. Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte-colony stimulating factor (rh-GSCF): A randomized evaluation of different doses of rh-G-CSF.

Demirer T., Ayli M., Arat M., Ozcan M., Gunel N., Haznedar R., et al.

BLOOD , cilt.98, sa.11, 2001 (SCI-Expanded)

258. A randomized trial of assessment of efficacy of leukapheresis volumes, 8 L versus 10L.

Demirer T., Ayli M., Arat M., Gunel N., Ozcan M., Haznedar R., et al.

BLOOD , cilt.98, sa.11, 2001 (SCI-Expanded)

259. Repopulation of liver endothelial cells, but not hepatocytes, by allogeneic hematopoietic cell transplants.

Idilman R., Tukun A., Erdem E., Arat M., TÖRÜNER M., Soykan I., et al.

BLOOD , cilt.98, sa.11, 2001 (SCI-Expanded)

260. Thrombophilic gene mutations in cirrhosis with portal vein thrombosis

Erkan O., Bozdayi A., Bozbas A., Disibeyaz S., Ozcan M., Bozkaya H., et al.

JOURNAL OF HEPATOLOGY , cilt.34, ss.68, 2001 (SCI-Expanded)

261. Recombinant human granulocyte colony-stimulating factor (rh-G-CSF) may accelerate hematopoietic recovery after HLA-identical sibling allogeneic peripheral blood stem cell transplantation

Ozcan M., Ustun C., Akcaglayan E., Akan H., Arslan O., Ilhan O., et al.

BONE MARROW TRANSPLANTATION , cilt.27, sa.5, ss.499-505, 2001 (SCI-Expanded, Scopus)

262. Treatment of steroid refractory GVHD with anti-thymocyte globulin

Ozcan M., Arat M., GÜRMAN G., Arslan O., Topcuoolu P., BEKSAÇ M., et al.

BONE MARROW TRANSPLANTATION , cilt.27, 2001 (SCI-Expanded)

263. Th1/Th2 cytokines and soluble adhesion molecules after allogeneic hematopoietic stem cell transplantation: influence of stem cell source and use of Dalteparin

Celebi H., Ozcan M., Arat M., Dalva K.

BONE MARROW TRANSPLANTATION , cilt.27, 2001 (SCI-Expanded)

264. High-dose Thiotepa, Melphalan and Carboplatin (TMCB) with autologous Peripheral Blood Stem Cell (PBSC) support in patients with hematologic malignancies and solid tumors

Demirer T., Ilhan O., Ayli M., Arat M., Fen T., Ozcan M., et al.

BONE MARROW TRANSPLANTATION , cilt.27, 2001 (SCI-Expanded)

265. Value of combined Ga-67 and Tc-99(m)-human immunoglobulin G whole-body scanning in malignant lymphoma

KÜÇÜK N. Ö., Aras G., Soylu A., Ozcan M., İBİŞ E., Dincol D.

NUCLEAR MEDICINE COMMUNICATIONS , cilt.22, sa.3, ss.325-329, 2001 (SCI-Expanded, Scopus)

266. The long term follow-up of lymphoma patients conditioned with CBV regimen and autologous stem cell rescue: Ibni Sina experience

Arat M., Soydan E., Arslan O., Ozcan M., GÜRMAN G., Konuk N., et al.

BONE MARROW TRANSPLANTATION , cilt.27, 2001 (SCI-Expanded)

267. The effect of G-CSF on lymphocyte subsets and CD34+cells in allogeneic stem cell transplantation

GÜRMAN G., Dilek I., Arslan O., Arat M., BEKSAÇ M., Ilhan O., et al.

TRANSFUSION AND APHERESIS SCIENCE , cilt.24, sa.1, ss.23-28, 2001 (SCI-Expanded, Scopus)

268. Whole blood tissue factor procoagulant activity remains detectable during severe aplasia following bone marrow and peripheral blood stem cell transplantation

Ozcan M., Morton C., Solovey A., Dandelet L., Bach R., Hebbel R., et al.

THROMBOSIS AND HAEMOSTASIS , cilt.85, sa.2, ss.250-255, 2001 (SCI-Expanded, Scopus)

269. Allogeneic peripheral blood stem cell transplantation for severe aplastic anemia

GÜRMAN G., Celebi H., Ustun C., Arat M., Ilhan O., Ozcan M., et al.

THERAPEUTIC APHERESIS , cilt.5, sa.1, ss.54-57, 2001 (SCI-Expanded) Sürdürülebilir Kalkınma

270. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies

GÜRMAN G., Arat M., Ilhan O., Konuk N., BEKSAÇ M., Celebi H., et al.

CYTOTHERAPY , cilt.3, sa.4, ss.253-260, 2001 (SCI-Expanded, Scopus)

271. CD41+and CD42+hematopoietic progenitor cells may predict platelet engraftment after allogeneic peripheral blood stem cell transplantation

Demirer T., Ilhan O., Arat M., Genc Y., Ozcan M., Dalva K., et al.

JOURNAL OF CLINICAL APHERESIS , cilt.16, sa.2, ss.67-73, 2001 (SCI-Expanded, Scopus)

272. Collection of donor lymphocytes for cellular immunotherapy.

Arat M., Ilhan O., Arslan O., GÜRMAN G., Ozcan M., Ciftci A., et al.

BLOOD , cilt.96, sa.11, 2000 (SCI-Expanded)

273. The influences of stem cell source and G-CSF administration on changes in naturally occurring anticoagulants after allogeneic hematopoietic stem cell transplantation.

Ozcan M.

BLOOD , cilt.96, sa.11, 2000 (SCI-Expanded)

274. Phase-II study of high-dose thiotepa, melphalan and carboplatin (TMCb) with autologous peripheral blood stem cell (PBSC) support in patients with hematologic malignancies and solid tumors.

Demirer T., Ilhan O., Ayli M., Arat M., Fen T., Haznedar R., et al.

BLOOD , cilt.96, sa.11, 2000 (SCI-Expanded)

275. The use of rhG-CSF for peripheral blood progenitor cell collection in healthy donors may induce the tissue factor dependent pathway.

Topcuoglu P., Ozcan M., Dalva K., Arat M.

BLOOD , cilt.96, sa.11, 2000 (SCI-Expanded, Scopus)

276. The value of peripheral blood CD34(+) cell quantification in autologous hematopoietic stem cell apheresis.

Ilhan O., Arslan O., Arat M., Ozcan M., GÜRMAN G., Dalva K., et al.

BLOOD , cilt.96, sa.11, 2000 (SCI-Expanded)

277. Circulating CD44 and intercellular adhesion molecule-1 levels in low grade non-Hodgkin lymphoma and B-cell chronic lymphocytic leukemia patients during interferon-alpha-2a treatment

BEKSAÇ M., Arat M., Akan H., Koc H., Ilhan O., Ozcan M.

CANCER , cilt.89, sa.7, ss.1474-1481, 2000 (SCI-Expanded, Scopus)

278. Hepatitis B virus vaccination of recipients and donors of allogeneic peripheral blood stem cell transplantation: Risk and benefit ratio of HBV vaccination in recipients.

Idilman R., Ustun C., Akan H., Karayalcin S., Ozcan M., Arslan O., et al.

HEPATOLOGY , cilt.32, sa.4, 2000 (SCI-Expanded) Sürdürülebilir Kalkınma

279. Allogeneic peripheral blood stem cell transplantation for standard risk leukemia: experience of Ibni Sina Hospital

Arslan O., COŞKUN H. Ş., Arat M., Celebi H., Ozcan M., GÜRMAN G., et al.

BONE MARROW TRANSPLANTATION , cilt.25, sa.12, ss.1229-1232, 2000 (SCI-Expanded, Scopus)

280. Uptake of Tc-99m human, immunoglobulin in malignant abdominal lymphoma

KÜÇÜK N. Ö., Aras G., Soylu A., Ozcan M., İBİŞ E., Akin A., et al.

CLINICAL NUCLEAR MEDICINE , cilt.25, sa.3, ss.227-228, 2000 (SCI-Expanded)

281. Soluble adhesion molecules (sICAM-1, sL-Selectin, sE-Selectin, sCD44) in healthy allogenic peripheral stem-cell donors primed with recombinant C-CSF

Arslan O., Akan H., Arat M., Dalva K., Ozcan M., GÜRMAN G., et al.

CYTOTHERAPY , cilt.2, sa.4, ss.259-265, 2000 (SCI-Expanded, Scopus)

282. Treatment of acute and chronic graft versus host disease with mycophenolate mofetil.

Ilhan O., Celebi H., Arat M., Arslan O., Akcaglayan E., Ustun C., et al.

BLOOD , cilt.94, sa.10, 1999 (SCI-Expanded, Scopus)

283. Adoptive immunity transfer in hepatitis B virus carriers with hematological malignancy who undergoing allogeneic hematopoietic stem cell transplantation

Idilman R., Ustun C., Turkyilmaz A., GÜRMAN G., Ozcan M., Karayalcin S., et al.

HEPATOLOGY , cilt.30, sa.4, 1999 (SCI-Expanded) Sürdürülebilir Kalkınma

284. The value of Tc-99m HIG scan in malignant lymphoma

KÜÇÜK N. Ö., Aras G., Soylu A., Ozcan M., İBİŞ E., Dincol D., et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE , cilt.26, sa.9, ss.1149, 1999 (SCI-Expanded)

285. Treatment of aregeneratoric anemia following an ABO-incompatible allogeneic peripheral blood stem cell transplantation: A case report

Üstün C., Çelebi H., Arat M., ÖZCAN M., Dilek I., GÜRMAN G., et al.

Therapeutic Apheresis , cilt.3, sa.3, ss.275-277, 1999 (SCI-Expanded)

286. Analysis of tissue factor (TF) expression on leukemic cells by flow cytometry: Correlation with tissue factor activity and clinical parameters

Kilic S., Ozcan M., Dalva K., BEKSAÇ M., Koc H.

THROMBOSIS AND HAEMOSTASIS , ss.763, 1999 (SCI-Expanded)

287. Autoimmune thrombocytopenia in a patient with small cell lung cancer developing after chemotherapy and resolving following autologous peripheral blood stem cell transplantation

Demirer T., Celebi H., Arat M., Ustun C., Demirer S., Dilek I., et al.

BONE MARROW TRANSPLANTATION , cilt.24, sa.3, ss.335-337, 1999 (SCI-Expanded, Scopus)

288. Hematopoietic stem cell transplantation from non-replicative hepatitis B virus carriers is safe

Ustun C., Idilman R., GÜRMAN G., Ozcan M., Akyol G., Akan H., et al.

JOURNAL OF HEPATOLOGY , cilt.31, sa.2, ss.202-209, 1999 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

289. The influence of CD41+ and CD42+ peripheral blood stem cells on platelet engraftment after allo PBSCT.

Ilhan O., Demirer T., Arat M., Dalva K., COŞKUN H. Ş., BEKSAÇ M., et al.

BONE MARROW TRANSPLANTATION , cilt.23, 1999 (SCI-Expanded)

290. Clinical effects of intravenous immune globulin (IVIG) treatment in patients with allogeneic peripheral stem cell transplantation.

Ustun C., Ozcan M., Beksac M., Ilhan O., Cakir M., GÜRMAN G., et al.

BONE MARROW TRANSPLANTATION , cilt.23, 1999 (SCI-Expanded)

291. The effect of G-CSF in the first 100 days of allogeneic peripheral blood stem cell transplantation.

Ozcan M., Ustun C., Ilhan O., Beksac M., Akcaglayan E., GÜRMAN G., et al.

BONE MARROW TRANSPLANTATION , cilt.23, 1999 (SCI-Expanded)

292. A protocol proposal comparing conventional approach with high-dose chemotherapy (HDC) and peripheral blood stem cell transplantation (PBSCT) in patients with small cell lung cancer limited to thorax.

Demirer T., Arat M., Koc H., Ilhan O., Celebi H., Ozcan M., et al.

BONE MARROW TRANSPLANTATION , cilt.23, 1999 (SCI-Expanded) Sürdürülebilir Kalkınma

293. Allogeneic peripheral blood stem cell transplantation in patients with severe aplastic anemia.

Gurman G., Celebi H., Ustun C., Arat M., Ilhan O., Ozcan M., et al.

BONE MARROW TRANSPLANTATION , cilt.23, 1999 (SCI-Expanded)

294. Allogeneic hematopoietic cell transplantation in patients with advanced hematological malignancies by using nonmyeloablative conditioning regimen.

GÜRMAN G., Ustun C., Arslan O., BEKSAÇ M., Konuk N., Arat M., et al.

BONE MARROW TRANSPLANTATION , cilt.23, 1999 (SCI-Expanded)

295. Peripheral blood stem cell (PBSC) collection with cyclophosphamide (CY) - Paclitaxel and recombinant human granulocyte-colony stimulating factor (rhG-CSF) in patients with breast cancer: Ibni Sina experience

Arat M., Demirer T., Ilhan O., Koc H., Ustun C., Celebi H., et al.

BONE MARROW TRANSPLANTATION , cilt.23, 1999 (SCI-Expanded) Sürdürülebilir Kalkınma

296. The impact of the CD34+ cell dose on engraftment in allogeneic peripheral blood stem cell transplantation

Ilhan O., Arslan O., Arat M., BEKSAÇ M., Akan H., Ozcan M., et al.

TRANSFUSION SCIENCE , cilt.20, sa.1, ss.69-71, 1999 (SCI-Expanded, Scopus)

297. A retrospective comparison of allogeneic peripheral blood stem cell and bone marrow transplantation results from a single center: A focus on the incidence of graft-vs.-host disease and relapse

Üstün C., ARSLAN Ö., BEKSAÇ M., Koç H., GÜRMAN G., Özçelik T., et al.

Biology of Blood and Marrow Transplantation , cilt.5, sa.1, ss.28-35, 1999 (SCI-Expanded) Sürdürülebilir Kalkınma

298. Differences in liver pathology and clinical outcome between two patients with Hepatitis B virus and graft versus host disease

Üstün C., ÖZCAN M., GÜRMAN G., Çakir M., Erekul S., AKYOL G., et al.

Pathology and Oncology Research , cilt.5, sa.3, ss.229-232, 1999 (SCI-Expanded) Sürdürülebilir Kalkınma

299. Allogeneic peripheral blood stem cell transplantation in acute non-lymphoblastic leukemia

Arslan O., Ustun C., Arat M., Celebi H., Akan H., BEKSAÇ M., et al.

HEMATOLOGICAL ONCOLOGY , cilt.16, sa.4, ss.155-162, 1998 (SCI-Expanded, Scopus)

300. Allogeneic peripheral blood stem cell transplantation in patients with severe aplastic anemia.

GÜRMAN G., Celebi H., Ustun C., Arat M., Ilhan O., Ozcan M., et al.

BLOOD , cilt.92, sa.10, 1998 (SCI-Expanded)

301. Clinical effects of intravenous immune globulin (IVIG) treatment in patients with allogeneic peripheral stem cell transplantation.

Ustun C., Ozcan M., BEKSAÇ M., Ilhan O., Cakir M., GÜRMAN G., et al.

BLOOD , cilt.92, sa.10, 1998 (SCI-Expanded, Scopus)

302. Enhanced expression of tissue factor (TF) by circulating endothelial cells (CECs) following bone marrow transplantation (BMT).

Morton C., Solovey A., Dandelet L., Ozcan M., Slungaard A., Hebbel R., et al.

BLOOD , cilt.92, sa.10, 1998 (SCI-Expanded, Scopus)

303. Serum transforming growth factor beta 1 levels in multiple myeloma.

COŞKUN H. Ş., Ilhan O., Ozcan M., Ayaz S., Dalva K., Ustun C., et al.

BLOOD , cilt.92, sa.10, 1998 (SCI-Expanded)

304. T-cell subsets in multiple myeloma: Relation to clinical phase and stage of disease and prognosis.

Ates A., Ilhan O., Ozcan M., Dalva K., Ugur N., BEKSAÇ M., et al.

BLOOD , cilt.92, sa.10, 1998 (SCI-Expanded, Scopus)

305. The effect of G-CSF in the first 100 days of allogeneic peripheral blood stem cell transplantation.

Ozcan M., Ustun C., Ilhan O., BEKSAÇ M., Akcaglayan E., GÜRMAN G., et al.

BLOOD , cilt.92, sa.10, 1998 (SCI-Expanded)

306. Allogeneic hematopoietic stem cell transplantation in patients with advanced hematological malignancies by using nonmyeloablative conditioning regimen.

GÜRMAN G., Ustun C., Arslan O., BEKSAÇ M., Konuk N., Arat M., et al.

BLOOD , cilt.92, sa.10, 1998 (SCI-Expanded)

307. Interferon alpha 2a and low dose cytarabine in chronic myeloid leukemia: Second interim analysis of multicenter study.

Ilhan O., Ozcan M., Yalcin A., Koc H., BEKSAÇ M., Unal A., et al.

BLOOD , cilt.92, sa.10, 1998 (SCI-Expanded)

308. Increased CD38 expression on peripheral blood lymphocytes associate with more advanced disease and poor survival in multiple myeloma patients.

Ates A., Ilhan O., Ozcan M., Dalva K., Ugur N., BEKSAÇ M., et al.

BLOOD , cilt.92, sa.10, 1998 (SCI-Expanded)

309. Circulating CD44 and ICAM-1 levels in low grade non-Hodgkin's lymphoma and B-CLL patients during interferon alpha-2A treatment.

BEKSAÇ M., Arat M., Akan H., Koc H., Ilhan O., Ozcan M.

BLOOD , cilt.92, sa.10, 1998 (SCI-Expanded)

310. Which hematopoietic stem cell transplantation type is safe for patients with hepatitis B virus carriers.

Ustun C., Idilman R., Ozcan M., Akan H., Karayalcin S., GÜRMAN G., et al.

HEPATOLOGY , cilt.28, sa.4, 1998 (SCI-Expanded) Sürdürülebilir Kalkınma

311. Randomised unicenter trial for comparison of three regimens in de novo adult acute nonlymphoblastic leukaemia

BEKSAÇ M., Arslan O., Koc H., Akan H., Ilhan O., Arat M., et al.

MEDICAL ONCOLOGY , cilt.15, sa.3, ss.183-190, 1998 (SCI-Expanded, Scopus)

312. Acute myeloblastic leukemia associated with hyperleukocytosis and diabetes insipidus

Dilek I., Uysal A., Demirer T., Koc H., Ozcan M., Keles H., et al.

LEUKEMIA & LYMPHOMA , cilt.30, sa.5-6, ss.657-660, 1998 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

313. Cladribine therapy in chronic lymphoproliferative disorders: Single center experience

BEKSAÇ M., Ilhan O., Uysal A., Koc H., Idilman R., Arat M., et al.

BRITISH JOURNAL OF HAEMATOLOGY , cilt.102, sa.1, ss.244, 1998 (SCI-Expanded)

314. Randomized unicenter trial for comparison of three regimens in de novo adult acute nonlymphoblastic leukemia

BEKSAÇ M., Arslap O., Koc H., Akan H., Ilhan O., Arat M., et al.

BRITISH JOURNAL OF HAEMATOLOGY , cilt.102, sa.1, ss.220, 1998 (SCI-Expanded)

315. Flow cytometric G-CSF receptor expression in acute myeloid leukemia and role in G-CSF use at induction chemotherapy

Kutlay S., BEKSAÇ M., Dalva K., Ilhan O., Koc H., Akan H., et al.

BRITISH JOURNAL OF HAEMATOLOGY , cilt.102, sa.1, ss.87, 1998 (SCI-Expanded)

316. Allogeneic peripheral blood stem cell transplantation in leukemias: A single center results

Koc H., GÜRMAN G., Arslan O., Ustun C., Ozcan M., Dilek I., et al.

BONE MARROW TRANSPLANTATION , cilt.21, 1998 (SCI-Expanded)

317. Acquired ichthyosis associated with chronic graft-versus-host disease following allogeneic peripheral blood stem cell transplantation in a patient with chronic myelogenous leukemia

Dilek I., Demirer T., Ustun C., Arat M., Koc H., BEKSAÇ M., et al.

BONE MARROW TRANSPLANTATION , cilt.21, sa.11, ss.1159-1161, 1998 (SCI-Expanded, Scopus)

318. Intravesical tranexamic acid instillations for the treatment of hemorrhagic cystitis

Ozcan M., Ustun C., Turan M., GÜRMAN G., BEKSAÇ M.

BONE MARROW TRANSPLANTATION , cilt.21, 1998 (SCI-Expanded)

319. Is there a relationship between G-CSF response to conditioning regimen and engraftment after bone marrow transplantation?

Ozcan M., BEKSAÇ M.

BONE MARROW TRANSPLANTATION , cilt.21, sa.5, ss.533-534, 1998 (SCI-Expanded, Scopus)

320. Allogeneic peripheral blood stem cell transplants cause more chronic graft versus host disease and less relapse compared to bone marrow transplants

BEKSAÇ M., Ustun C., Ozcan M., Koc H., Ilhan O., Ozcelik T., et al.

BONE MARROW TRANSPLANTATION , cilt.21, 1998 (SCI-Expanded)

321. Incidence of Tuberculosis after bone marrow transplantation in a single center from Turkey

Arslan O., GÜRMAN G., Dilek I., Ozcan M., Koc H., Ilhan O., et al.

HAEMATOLOGIA , cilt.29, sa.1, ss.59-62, 1998 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

322. Serial change in circulating tissue factor procoagulant activity in bone marrow transplantation (BMT).

Ozcan M., Slungaard A., Dandelet L., Bach R., Key N.

BLOOD , cilt.90, sa.10, ss.1883, 1997 (SCI-Expanded)

323. Donor leukocyte infusions for the treatment of leukemia relapse after allogeneic hematopoietic progenitor cell transplantation.

GÜRMAN G., Arslan O., Koc H., Dilek I., Ustun C., Ozcan M., et al.

BLOOD , cilt.90, sa.10, ss.4452, 1997 (SCI-Expanded)

324. Hematological and cytogenetic efficiency of interferon alpha 2a plus low dose cytarabine in chronic myelogenous leukemia: An interim analysis of multicenter study.

Ilhan O., Ozcan M., Yalcin A., Koc H., BEKSAÇ M., Unal A., et al.

BLOOD , cilt.90, sa.10, ss.3999, 1997 (SCI-Expanded)

325. Clinical relevance of flow cytometric BCL-2 and CD95 expression in acute myeloid leukemia.

Kutlay S., BEKSAÇ M., Dalva K., Ilhan O., Akan H., Koc H., et al.

BLOOD , cilt.90, sa.10, ss.3709, 1997 (SCI-Expanded)

326. A phase III, randomized multicenter study of induction with or without granulocyte colony stimulating factor (G-CSF) followed by intensive consolidation versus stem cell transplantation (PBSCT) in AML (preliminary results of Turkish Leukemia Study Group TLG95-002).

BEKSAÇ M., Tunali A., Akoglu T., Dundar S., Paydas S., Ilhan O., et al.

BLOOD , cilt.90, sa.10, ss.3805, 1997 (SCI-Expanded)

327. Surface adhesion molecules in peripheral stem cells of healthy donors primed with G-CSF.

Akan H., Dalva K., Ustun C., Koc H., Ilhan O., Uysal A., et al.

BLOOD , cilt.90, sa.10, ss.3487, 1997 (SCI-Expanded)

328. A randomized single institutional study on comparison of idarubicin (I) versus daunorubicin (D) versus mitoxantrone (M) containing induction and consolidation regimens in acute myeloblastic leukemia (AML).

BEKSAÇ M., Arslan O., Koc H., Akan H., Ilhan O., Arat M., et al.

BLOOD , cilt.90, sa.10, ss.3806, 1997 (SCI-Expanded)

329. Serial change in circulating tissue factor procoagulant activity (TF PCA) in bone marrow transplantation.

Ozcan M., Slungaard A., Dandelet L., Bach R., Key N.

BLOOD , cilt.90, sa.10, ss.3157, 1997 (SCI-Expanded)

330. HLA DR2: A predictive marker in response to cyclosporine therapy in aplastic anemia

Ihan O., BEKSAÇ M., Arslan O., Ozcan M., Koc H., Akan H., et al.

INTERNATIONAL JOURNAL OF HEMATOLOGY , cilt.66, sa.3, ss.291-295, 1997 (SCI-Expanded, Scopus)

331. Allogeneic peripheral blood stem cell transplantation: Is there an increased risk of graft vs host disease in leukemia patients?

Koc H., GÜRMAN G., Arslan O., Ozcan M., Dilek I., Akan H., et al.

JOURNAL OF CHEMOTHERAPY , cilt.9, sa.5, ss.371-376, 1997 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

332. Hepatitis B virus infection in allogeneic bone marrow transplantation

Ustun C., Koc H., Karayalcin S., Akyol G., GÜRMAN G., Ilhan O., et al.

BONE MARROW TRANSPLANTATION , cilt.20, sa.4, ss.289-296, 1997 (SCI-Expanded, Scopus)

333. Protein-C, protein-S, antithrombin-III levels after hematopoietic stem cell transplantation

Akar H., Ozcan M., Arslan O., Ilhan O., Koc H., Akan H., et al.

THROMBOSIS AND HAEMOSTASIS , 1997 (SCI-Expanded)

334. Incidence of graft vs host disease in allogeneic bone marrow transplantation in a single center study from Turkey

Ilhan O., Akan H., Koc H., GÜRMAN G., Arslan O., Ozcan M., et al.

HEMATOLOGY AND CELL THERAPY , cilt.39, sa.3, ss.133-136, 1997 (SCI-Expanded, SSCI, Scopus)

335. Hemorrhagic cystitis as a complication of bone marrow transplantation

Ilhan O., Koc H., Akan H., GÜRMAN G., Arslan O., Ozcan M., et al.

JOURNAL OF CHEMOTHERAPY , cilt.9, sa.1, ss.56-61, 1997 (SCI-Expanded, Scopus)

336. Use of high-dose chemotherapy plus granulocyte colony-stimulating factor for the salvage of refractory or resistant-relapse lymphoma patients without stem cell support

Koc H., Arslan O., Akan H., Ozcan M., Ilhan O., Aydogdu I., et al.

ACTA HAEMATOLOGICA , cilt.98, sa.3, ss.136-139, 1997 (SCI-Expanded) Sürdürülebilir Kalkınma

337. Comparison of peripheral blood, lymph node and bone marrow lymphocyte surface antigens, adhesion molecules in B-cll and low grade non-Hodgkin's lymphoma (NHL).

BEKSAÇ M., Arat M., Ozcan M., Arslan O., Koc H., Akan H., et al.

BLOOD , cilt.88, sa.10, ss.958, 1996 (SCI-Expanded)

338. Hepatic complications of allogeneic bone marrow transplantation.

Ustun C., Koc H., Karayalcin S., Akyol G., GÜRMAN G., Ilhan O., et al.

BLOOD , cilt.88, sa.10, ss.3815, 1996 (SCI-Expanded)

339. CD34 cell dose influences hematological recovery after peripheral blood stem cell transplantation.

Ilhan O., BEKSAÇ M., Arslan O., Akan H., Koc H., Dilek I., et al.

BLOOD , cilt.88, sa.10, ss.3751, 1996 (SCI-Expanded)

340. Donor mononuclear cells infusion and alfa interferon administration in relapsed chronic myeloid leukemia patients after allogeneic bone marrow transplantation

GÜRMAN G., Koc H., Akan H., Ilhan O., Ozcan M., Arslan O., et al.

BLOOD , cilt.88, sa.10, ss.3800, 1996 (SCI-Expanded)

341. Hemorrhagic cystitis after bone marrow transplantation: The role of electron microscopy in differential diagnosis.

GÜRMAN G., Sencer H., Uysal A., Cinar K., Arslan O., Ozcan M., et al.

BLOOD , cilt.88, sa.10, ss.3747, 1996 (SCI-Expanded)

342. The prognostic relevance of HLA phenotype in allogeneic bone marrow transplantation in Turkish patients with chronic myelogenous leukemia (CML).

Ilhan O., Ozcan M., BEKSAÇ M., Koc H., Akan H., Kutlay S., et al.

BLOOD , cilt.88, sa.10, ss.3825, 1996 (SCI-Expanded)

343. Lack of prognostic value of CD34 in adult AML

Arslan O., Akan H., BEKSAÇ M., Ozcan M., Koc H., Ilhan O., et al.

LEUKEMIA & LYMPHOMA , cilt.23, sa.1-2, ss.185-186, 1996 (SCI-Expanded, Scopus)

344. Is there an increased risk of graft-versus-host disease after allogeneic peripheral blood stem cell transplantation?

Koc H., GÜRMAN G., Arslan O., Ozcan M., Akan H., Ilhan O., et al.

BLOOD , cilt.88, sa.6, ss.2362-2364, 1996 (SCI-Expanded, Scopus)

345. Eosinophilia after allogeneic bone marrow transplantation using busulfan and cyclophosphamide conditioning regimen

Arslan O., Akan H., Koc H., BEKSAÇ M., Ilhan O., Ozcan M., et al.

BONE MARROW TRANSPLANTATION , cilt.18, sa.1, ss.261, 1996 (SCI-Expanded, Scopus)

346. Febrile neutropenia in a bone marrow transplantation unit

Akan H., Koc H., Arslan O., BEKSAÇ M., Ilhan O., GÜRMAN G., et al.

BRITISH JOURNAL OF HAEMATOLOGY , cilt.93, ss.982, 1996 (SCI-Expanded)

347. HLA DR2; A prognostic factor in response to immunosuppressive therapy in aplastic anemia

Ilhan O., BEKSAÇ M., Koc H., Akan H., Arslan O., GÜRMAN G., et al.

BRITISH JOURNAL OF HAEMATOLOGY , cilt.93, ss.473, 1996 (SCI-Expanded)

348. Soluble adhesion molecules during progenitor cell engraftment

Akan H., Senqul S., BEKSAÇ M., Koc H., Ilhan O., GÜRMAN G., et al.

BLOOD , cilt.86, sa.10, ss.3887, 1995 (SCI-Expanded)

349. Relationship between serum cytokine levels and aplasia period following high dose chemotherapy supported by granulocyte-colony stimulating factor as a salvage chemotherapy without stem cell rescue in malignant lymphomas.

Koc H., Akan H., Ilhan O., GÜRMAN G., Ozcan M., Arslan O., et al.

BLOOD , cilt.86, sa.10, ss.2779, 1995 (SCI-Expanded)

350. Multidrug resistance and p-glycoprotein analysis in Candida species obtained from patients with hematological malignancies

BEKSAÇ M., Arman D., Ozcan M., Ferhat S., Cakar N.

BLOOD , cilt.86, sa.10, ss.2986, 1995 (SCI-Expanded)

351. High dose epirubicin containing CEOP regimen in intermediate or high grade nonHodgkin's lymphoma

Ilhan O., Arslan O., Koc H., BEKSAÇ M., Akan H., GÜRMAN G., et al.

BLOOD , cilt.86, sa.10, ss.3245, 1995 (SCI-Expanded)

352. CORRELATION OF STEM-CELL FACTOR AND SOLUBLE ADHESION MOLECULES WITH BLAST COUNTS IN PATIENTS UNDERGOING CHEMOTHERAPY

AKAN H., BEKSAÇ M., ILHAN O., KOC H., GÜRMAN G., OZCAN M.

BLOOD , cilt.84, sa.10, 1994 (SCI-Expanded)

353. CIRCULATING SOLUBLE CD44 AND ICAM-1 LEVELS IN LOW-GRADE NON-HODGKINS-LYMPHOMA PATIENTS DURING INTERFERON-ALPHA TREATMENT

BEKSAÇ M., AKAN H., KOC H., LIHAN O., OZCAN M.

BLOOD , cilt.84, sa.10, 1994 (SCI-Expanded, Scopus)

354. PERIPHERAL T-CELL RECEPTORS ALPHA-BETA AND GAMMA-DELTA IN PATIENTS WITH HODGKINS LYMPHOMA

AKAN H., BEKSAÇ M., AYDOGDU I., KOC H., ILHAN O., OZCAN M.

BRITISH JOURNAL OF HAEMATOLOGY , cilt.87, sa.3, ss.544-547, 1994 (SCI-Expanded)

355. RELEVANCE OF SERUM G-CSF LEVELS IN BONE-MARROW TRANSPLANTATION PATIENTS

BEKSAÇ M., OZCAN M., KOC H., AKAN H., ILHAN O.

EXPERIMENTAL HEMATOLOGY , cilt.22, sa.6, ss.480-481, 1994 (SCI-Expanded, Scopus)

356. CIRCULATING ENDOGENOUS GRANULOCYTE COLONY-STIMULATING FACTOR LEVELS AFTER BONE-MARROW TRANSPLANTATION

BEKSAÇ M., OZCAN M., KOC H., AKAN H., ILHAN O., SARDAS O.

BLOOD , cilt.80, sa.11, ss.2946-2947, 1992 (SCI-Expanded, Scopus)

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 417

1. MANTLE HÜCRELİ LENFOMA TANILI HASTALARDA İBRUTİNİB KULLANIMI: TEK MERKEZ DENEYİMİ

Yüksel M., Toprak S. K., Cengiz Seval G., Arslan Ö., Özcan M., Topçuoğlu P.

50.Ulusal Hematoloji Kongresi, Antalya, Türkiye, 29 Ekim - 02 Kasım 2024, ss.113, (Tam Metin Bildiri)

2. PERİFERİK T HÜCRELİ LENFOMA TANILI HASTALARIN ANALİZİ: TEK MERKEZ DENEYİMİ

Yüksel M., Cengiz Seval G., Topçuoğlu P., Arslan Ö., Özcan M., Demirer T.

50.Ulusal Hematoloji Kongresi, Antalya, Türkiye, 29 Ekim - 02 Kasım 2024, ss.136-137, (Tam Metin Bildiri)

3. PAROKSİSMAL NOKTURNAL HEMOGLOBİNÜRİ TANILI HASTALARIN DEĞERLENDİRMESİ, TEK MERKEZLİ ÇALIŞMA

Bektaş M., Cengiz Seval G., Toprak S. K., Topçuoğlu P., Özcan M., Arslan Ö., et al.

50.Ulusal Hematoloji Kongresi, Antalya, Türkiye, 29 Ekim - 02 Kasım 2024, ss.209, (Tam Metin Bildiri)

4. MİKOSİZ FUNGOİDES VE SEZARY SENDROMLU HASTALARDA BRENTUXİMAB VEDOTİN TEDAVİSİNİN UZUN DÖNEM SONUÇLARI

Yüksel M., Şanlı H., Dalva K., Cengiz Seval G., Topçuoğlu P., Arslan Ö., et al.

50.Ulusal Hematoloji Kongresi, Antalya, Türkiye, 29 Ekim - 02 Kasım 2024, ss.111, (Tam Metin Bildiri)

5. NÜKS DİRENÇLİ T HÜCRELİ LENFOMALARDA PRALATREKSAT KULLANIMI: TEK MERKEZ DENEYİMİ

Sönmez G. M., Cengiz Seval G., Yüksel M., Topçuoğlu P., Arslan Ö., Özcan M., et al.

50.Ulusal Hematoloji Kongresi, Antalya, Türkiye, 29 Ekim - 02 Kasım 2024, ss.152-153, (Tam Metin Bildiri)

6. HODGKİN LENFOMALI HASTALARDA TEDAVİ SONRASINDA GÖZLENEN ISRARCI ERİTROSİTOZUN PATOGENEZİNDE ROL ALAN MOLEKÜLER MEKANİZMALAR

Koyun D., Yüksel S., Civriz Bozdağ S., Tuncalı T., Kuzu I., Özcan M.

50. Ulusal Hematoloji Kongresi , Antalya, Türkiye, 29 Ekim - 03 Kasım 2024, ss.138-139, (Tam Metin Bildiri)

7. PERİFERİK T HÜCRELİ LENFOMA TANILI HASTALARIN ANALİZİ: TEK MERKEZ DENEYİMİ

YÜKSEL M., DEMİR C. K., CENGİZ SEVAL G., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.

50.Ulusal Hematoloji Kongresi, 29 Ekim 2024, (Tam Metin Bildiri)

8. GÜNCEL KLAVUZLAR EŞLİĞİNDE KLİNİKTE MASTOSİTOZ: TEK MERKEZ DENEYİMİ

AYDOĞAN M., CENGİZ SEVAL G., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., et al.

50.Ulusal Hematoloji Kongresi, 29 Ekim - 02 Kasım 2024, (Tam Metin Bildiri)

9. MİKOSİZ FUNGOİDES VE SEZARY SENDROMLU HASTALARDA BRENTUXİMAB VEDOTİN TEDAVİSİNİN UZUN DÖNEM SONUÇLARI

SÖNMEZ G. M., ÖZSAN İ., DÜZ B., ŞANLI H., CENGİZ SEVAL G., DALVA K., et al.

50.Ulusal Hematoloji Kongresi, 29 Ekim - 02 Kasım 2024, (Tam Metin Bildiri)

10. Prognostic evaluation of PET/CT in residual post-chemotherapy +/- RT masses in patients with Hodgkin Lymphoma and its impact on survival

BEKTAŞ M., KAR İ., CENGİZ SEVAL G., TOPRAK S. K., TOPÇUOĞLU P., ÖZCAN M., et al.

11TH AEGEAN HEMATOLOGY ONCOLOGY SYMPOSIUM, 19 - 22 Eylül 2024, (Tam Metin Bildiri)

11. Allogeneic Stem Cell Transplantation for Relapsed and/or Refractory Hodgkin Lymphoma: A Multicenter Real World Experience

Koyun D., Şahin U., Cengiz Seval G., Gören D., Gökmen A., Civriz Bozdağ S., et al.

65th ASH® Annual Meeting and Exposition, California, Amerika Birleşik Devletleri, 9 - 12 Aralık 2023, ss.3617-3619, (Tam Metin Bildiri)

12. ALPHA-1-ANTITRYPSIN EXPERIENCE FOR STEROID-RESISTANT ACUTE GRAFT-VERSUS-HOST DISEASE

Koyun D., Cengiz Seval G., Bozdag S. C., Toprak S. K., Topçuoğlu P., Özcan M., et al.

49th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, ELECTR NETWORK, 23 - 26 Nisan 2023, ss.301-302, (Özet Bildiri)

13. KRONİK LENFOSİTİK LÖSEMİLERDE İMMUNGLOBULİN GENLERİ VARYANT ALT TİPLERİ, ALT KLONLAR İLE SOMATİK HİPERMUTASYON İLE HASTALIK BİYOLOJİSİNİN İLİŞKİSİ

Aygün R. Ş., Yüksel S., Örüncü M. B., Yüksel M., Cengiz Seval G., Arslan Ö., et al.

49. Ulusal Hematoloji Kongresi , Antalya, Türkiye, 1 - 05 Kasım 2023, ss.148-149, (Tam Metin Bildiri)

14. İdiopatik multisentrik Castleman hastalığının nadir bir varyantı : Tafro sendromu olgu sunumu

Yılmaz H., Yüksel S., Kuzu I., Özcan M.

49. Ulusal Hematoloji Kongresi , Antalya, Türkiye, 1 - 04 Kasım 2023, ss.309, (Özet Bildiri)

15. ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN RELAPS/REFRACTORY LYMPHOMA PATIENTS: A SINGLE CENTER EXPERIENCE

Karakaya B., Yilmaz H., Ermis G. Y., Cengiz Seval G., Bozdag S. C., Toprak S. K., et al.

49th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, ELECTR NETWORK, 23 - 26 Nisan 2023, ss.457-458, (Özet Bildiri)

16. EXTERNAL VALIDATION OF THREE EXISTING EARLY MYELOMA RELAPSE SCORES (BY EBMT, CIBMTR, AND GIMEMA) IN A SINGLE CENTER SHOWS MAJOR DIFFERENCES

Beksaç M., Cengiz Seval G., Civriz Bozdağ S., Toprak S. K., Yüksel M., Topçuoğlu P., et al.

The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians, Paris, Fransa, 23 Nisan 2023, cilt.58, ss.107, (Tam Metin Bildiri)

17. Akut B Lenfoblastik Lösemi Tanılı Bir Olguda Merkaptopürin Tedavisi Sırasında Kazanılmış Faktör V Eksikliği

Koyun D., Özcan M.

3. Lösemi Lenfoma Miyelom Kongresi, Ankara, Türkiye, 25 - 27 Mayıs 2023, ss.25, (Tam Metin Bildiri)

18. EVALUATION OF THE EFFICACY AND SAFETY RITUXIMAB, LENALIDOMIDE,AND IBRUTINIB IN RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA

Koyun D., Şahin U., Gökmen A., Özcan M.

9th International Congress on Leukemia Lymphoma Myeloma, Antalya, Türkiye, 12 - 13 Mayıs 2023, ss.47-48, (Tam Metin Bildiri)

19. ALLOGENEIC STEM CELL TRANSPLANTATION FOR RELAPSED AND/OR REFRACTORY HODGKIN LYMPHOMA:A MULTICENTER REAL WORLD EXPERIENCE

Koyun D., Şahin U., Cengiz Seval G., Gören Şahin D., Civriz Bozdağ S., Koçak Toprak S., et al.

9th International Congress on Leukemia Lymphoma Myeloma, Antalya, Türkiye, 12 - 13 Mayıs 2023, ss.40-41, (Tam Metin Bildiri)

20. COVID-19 ENFEKSİYONUNUN OTOLOG KÖK HÜCRE NAKLİ UYGULANAN MULTİPLE MYELOM TANILI BİR OLGUDA ETKİSİ

Koyun D., Cengiz Seval G., Civriz Bozdağ S., Özcan M., Beksaç M., Koçak Toprak S.

15. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi , Antalya, Türkiye, 16 - 19 Mart 2023, ss.101, (Tam Metin Bildiri)

21. NÜKS VEYA DİRENÇLİ PRİMER MEDİASTİNAL BÜYÜK B HÜCRELİ LENFOMA TANILI HASTALARDA KÖK HÜCRE NAKİL DENEYİMİ

Koyun D., Özcan M.

15. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Türkiye, 16 - 19 Mart 2023, ss.91-92, (Tam Metin Bildiri)

22. INFECTION FREQUENCY AND DISTRIBUTION IN CASES USING KINASE INHIBITORS IN HEMATOLOGY: RETROSPECTIVE REAL-LIFE EXPERIENCE

YİLMAZ H., İLKEM ŞAHİN Y., MAMMADLİ H., YILDIZ B., DURAN O. F., AYDIN R. F., et al.

9th International Congress on Leukemia Lymphoma Myeloma, 12 Mayıs 2023, (Tam Metin Bildiri)

23. INFECTION FREQUENCY AND DISTRIBUTION IN CASES USING KINASE INHIBITORS IN HEMATOLOGY: RETROSPECTIVE REAL-LIFE EXPERIENCE

YILMAZ H., Şahin Y. I., Mammadli H., YILDIZ B., Duran O. F., AYDIN R. F., et al.

9th International Congress on Leukemia Lymphoma Myeloma, Türkiye, 12 Mayıs 2023, (Tam Metin Bildiri)

24. EVALUATION OF THE EFFICACY AND SAFETY IMMUNOSUPPRESSIVE THERAPY IN PATIENTS WITH ACQUIRED FACTOR VIII AND IX INHIBITOR

Koyun D., Cengiz Seval G., Civriz Bozdağ S., Özcan M., Topçuoğlu P.

2023 Highlights of ASH, İstanbul, Türkiye, 17 - 18 Şubat 2023, ss.24-26, (Tam Metin Bildiri)

25. Single Center Real World Data That Compares Autologous Stem Cell Transplant in the Era of Anti- CD38 Monoclonal Antibody Based Treatments for AL Amyloidosis

Yılmaz H., Cengiz Seval G., Karakaya B., Yavuz G., Aydoğan M., Civriz Bozdağ S., et al.

64th ASH Annual Meeting & Exposition, Louisiana, Amerika Birleşik Devletleri, 09 Aralık 2022, (Tam Metin Bildiri)

26. NÜKS VE DİRENÇLİ HODGKİN LENFOMA HASTALARINDA ALLOJENİK HEMATOPOETİK KÖK HÜCRE NAKLİ: ÇOK MERKEZLİ GERÇEK YAŞAM VERİSİ

Koyun D., Şahin U., Cengiz Seval G., Gören Şahin D., Gökmen A., Civriz Bozdağ S., et al.

48. ULUSAL HEMATOLOJİ KONGRESİ, Antalya, Türkiye, 1 - 05 Kasım 2022, ss.130-132, (Tam Metin Bildiri)

27. LENFOPLAZMASİTİK LENFOMADA YENİ NESİL DİZİLEME YÖNTEMİYLE MUTASYON İNCELEMESİNİN TANI VE TEDAVİ PLANINDA YERİ

Koyun D., Kıvrak H., Cengiz Seval G., Yüksel S., Civriz Bozdağ S., Koçak Toprak S., et al.

48. Ulusal Hematoloji Kongresi, Antalya, Türkiye, 1 - 05 Kasım 2022, ss.165-166, (Tam Metin Bildiri)

28. AKUT MİYELOİD LÖSEMİ HASTALARINDA FLT3 VE NPM1 MUTASYONLARININ KÜTLE SPEKTROMETRİSİYLE BELİRLENMİŞ METABOLİT ŞABLONLARLA İLİŞKİSİ

Gerekçi Yeşilyurt S., Koyun D., Özcan M., Koçak Toprak S., Özen C.

48. ULUSAL HEMATOLOJİ KONGRESİ, Antalya, Türkiye, 1 - 05 Kasım 2022, ss.167-168, (Tam Metin Bildiri)

29. Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Final Results of a Phase Ib/II Randomized Study and Single-Arm Extension (Ext) Study

Sehn L. H., Hertzberg M., Opat S., Herrera A. F., Assouline S., Flowers C. R., et al.

64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Louisiana, Amerika Birleşik Devletleri, 10 - 13 Aralık 2022, ss.9464-9467, (Özet Bildiri)

30. Pooled Safety Analysis from Phase I-III Studies for Patients with Hematological Malignancies Treated with the PI3K Inhibitor Copanlisib

Zinzani P. L., ÖZCAN M., Capra M., Santoro A., Panayiotidis P., Bouabdallah K., et al.

64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Louisiana, Amerika Birleşik Devletleri, 10 - 13 Aralık 2022, ss.6470-6473, (Özet Bildiri)

31. Pembrolizumab and Chemotherapy in Newly-Diagnosed, Early Unfavorable or Advanced Stage Classic Hodgkin Lymphoma: The Phase 2 Keynote-C11 Study

Advani R. H., Avigdor A., Sureda A., Lavie D., Hohaus S., Zaucha J. M., et al.

64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Louisiana, Amerika Birleşik Devletleri, 10 - 13 Aralık 2022, ss.1759-1760, (Özet Bildiri)

32. Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma: Real World Data

Ferhanoglu B., Gulbas Z., Uzay A., ÖZCAN M., ÖZKALEMKAŞ F., Dal M. S., et al.

64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Louisiana, Amerika Birleşik Devletleri, 10 - 13 Aralık 2022, cilt.140, ss.6704-6705, (Özet Bildiri)

33. The Impact of CD34+Cell and Immunefector Cell Dose on Transplant Outcomes

Koyun D., Cengiz Seval G., Bozdag S. C., Toprak S. K., Topçuoğlu P., Özcan M., et al.

64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Louisiana, Amerika Birleşik Devletleri, 10 - 13 Aralık 2022, cilt.140, ss.12673-12674, (Özet Bildiri)

34. Single Center Real World Data That Compares Autologous Stem Cell Transplant in the Era of Anti-CD38 Monoclonal Antibody Based Treatments for AL Amyloidosis

Yilmaz H., Cengiz Seval G., Karakaya B., Yavuz G., Aydogan M., Bozdag S. C., et al.

64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Louisiana, Amerika Birleşik Devletleri, 10 - 13 Aralık 2022, cilt.140, ss.4369-4370, (Özet Bildiri)

35. MUTATION PROFILING BY TARGETTED NGS PANELS ARE USEFUL FOR EITHER DIFFERENTIAL DIAGNOSIS OF IG SECRETING B CELL LYMPHOMAS BUT ALSO HELPFUL FOR GUIDING THE TREATMENT

Gahramanlı Z., Kıvrak H., Yüksel S., Koyun D., Toprak S. K., Özcan M., et al.

21st Meeting of the European association for Haematopathology, Florence, İtalya, 17 - 22 Eylül 2022, ss.159, (Tam Metin Bildiri)

36. Relaps/Refrakter Mikozis Fungoides ve Sezary Sendromu Vakalarında Brentiksumab Vedotinin Etkinliği: Tek Merkez Deneyimi

CENGİZ SEVAL G., ŞANLI H., GÜNDÜZ K., CİVRİZ BOZDAĞ S., AKAY B. N., YILDIZHAN İ., et al.

30. Ulusal Dermatoloji Kongresi, Girne, Kıbrıs (Kktc), 18 - 22 Ekim 2022, (Özet Bildiri)

37. Novel targets detected by next generation sequencing among triple refractory patients can be clinically targetable

CENGİZ SEVAL G., KUZU I., Yüksel S., YILMAZ H., Yavuz G., KAYGUSUZ G., et al.

19th International Myeloma Society Annual Meeting, 25 Ağustos 2022, (Tam Metin Bildiri)

38. Ibrutınıb As A Promısıng Treatment For Waldenström Macroglobulınemıa

İLHAN O., CENGİZ SEVAL G., AVCU F., Ferhanoglu B., ÖZCAN M., ÇETİN G., et al.

HemaSphere 2022, Amerika Birleşik Devletleri, 05 Haziran 2022, (Tam Metin Bildiri)

39. The efficacy and safety of second allogeneic hematopoietic stem cell transplantation

TOPRAK S. K., KIRCALİ E., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., et al.

2022 ASCO Annual Meeting, Amerika Birleşik Devletleri, 01 Haziran 2022, (Tam Metin Bildiri)

40. Primary results from the double-blind, placebo-controlled, phase III SHINE study of ibrutinib in combination with bendamustine-rituximab (BR) and R maintenance as a first-line treatment for older patients with mantle cell lymphoma (MCL).

Wang M., Jurczak W., Jerkeman M., Trotman J., Zinzani P. L., Walewski J. A., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 3 - 07 Haziran 2022, (Özet Bildiri)

41. The Effects of Plerixafor on Hemostatic System in Patients Undergoing Stem Cell Mobilization

KOÇ Ö., DOĞAN Ö., ŞAHİN U., KIRCALI E., KOYUN D., ÖZCAN M.

Tandem Meetings ASTCT and CIBMTR, Amerika Birleşik Devletleri, 23 Nisan 2022, (Tam Metin Bildiri)

42. Response And Vaccınatıon Status Or Lack Of Immunoparesıs Are Assocıated Wıth Better Outcome Followıng Covıd-19 Infectıon Among Patıents Dıagnosed Wıth Multıple Myeloma: A Sıngle Center Experıence On 110 Patıents

CENGİZ SEVAL G., KIRCALİ E., KOYUN D., KARAKAYA B., YILMAZ H., AKBULUT H., et al.

3rd European Myeloma Network Meeting Virtual, Amerika Birleşik Devletleri, 06 Nisan 2022, (Tam Metin Bildiri)

43. Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia: A single center experience

İLHAN O., YAVUZ G., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., et al.

48th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Amerika Birleşik Devletleri, 19 - 22 Mart 2022, (Tam Metin Bildiri)

44. Prophylactic defibrotide is effective for acute graft versus host disease as well as sinusoidal obstructive syndrome

KIRCALİ E., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.

48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), Amerika Birleşik Devletleri, 19 - 22 Mart 2022, (Tam Metin Bildiri)

45. OKHN SONRASI İLK 12 AYDA NÜKSÜ BELİRLEMEDE GIMEMA VE CIBMTR SKORLAMA YAKLAŞIMLARININ BAĞIMSIZ HASTA GRUBUNDA VALİDASYONU

Beksaç M., Cengiz Seval G., Koyun D., Yilmaz H., Karakaya B., Akbulut H., et al.

14. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Türkiye, 10 - 12 Mart 2022, sa.165, ss.82-83, (Tam Metin Bildiri)

46. ALLOJENEİK KÖK HÜCRE NAKLİ SONRASI NÜKS ETMİŞ AML HASTALARINDA HİPOMETİLE EDİCİ İLAÇLARLA KOMBİNE VENETOKLAX TEDAVİSİ

ÖZTÜRK C., URAL A. U., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., et al.

14. Ulusal kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 10 Mart 2022, (Tam Metin Bildiri)

47. İKİNCİ ALLOJENEİK KÖK HÜCRE NAKLİ: GERÇEK YAŞAM VERİSİ

KIRCALI E., CENGİZ SEVAL G., ÖZTÜRK C., YILMAZ H., Yavuz G., Karakaya B., et al.

14. Ulusal kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 10 Mart 2022, (Tam Metin Bildiri)

48. GRAFT VERSUS HOST HASTALIĞI PROFİLAKSİSİNDE ATG VE POST CY KULLANIMININ NAKİL SONUÇLARINA ETKİSİ: TEK MERKEZ DENEYİMİ

Karakaya B., ŞAHİN Y. İ., MAMMADLI H., Yavuz G., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., et al.

14. Ulusal kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 10 Mart 2022, (Tam Metin Bildiri)

49. THE OUTCOME OF AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION IN ELDERLY PATIENTS WITH AGGRESSIVE NON-HODGKIN LYPHOMA

İLHAN O., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., et al.

63TH ASH CONGRESS, ATLANTA, Amerika Birleşik Devletleri, 8 - 11 Aralık 2021, (Tam Metin Bildiri)

50. CHRONOS-3: randomized Phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma (iNHL)

Zinzani P. L., Capra M., ÖZCAN M., Lv F., Li W., Yañez E., et al.

EHA 2021, 12 Aralık 2021, (Tam Metin Bildiri)

51. The Outcome of Autologous Hematopoietic Cell Transplantation in Elderly Patients with Aggressive Non-Hodgkin Lymphoma

İLHAN O., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., et al.

63rd ASH Annual Meeting and Exposition, 11 Aralık 2021, (Tam Metin Bildiri)

52. Final Analysis of KEYNOTE-170: Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma

Zinzani, P. L., Thieblemont C., Melnichenko V., Bouabdallah K., Waleswski J., Majlis A., et al.

Ash Annual Meeting 2021, ATLANTA, Amerika Birleşik Devletleri, 11 Aralık 2021, (Tam Metin Bildiri)

53. HODGKİN LENFOMA TANILI HASTALARDA EKSTRANODAL TUTULUM VE YENİ TEDAVİLER

Yavuz Ermiş G., Yilmaz H., Özütemiz S., Selvi N., Öztürk C., Kırcalı E., et al.

47. Ulusal Hematoloji Kongresi , Antalya, Türkiye, 4 - 07 Kasım 2021, ss.346-347, (Tam Metin Bildiri)

54. KAZANILMIŞ FAKTÖR 8 VE 9 İNHİBİTÖRÜ OLAN HASTALARDA İMMUNSUPRESİF TEDAVİ ETKİNLİK VE GÜVENİLİRLİĞİ

Koyun D., Cengiz Seval G., Yazgan S. C., Civriz Bozdağ S., Özcan M., Topçuoğlu P.

47. Ulusal Hematoloji Kongresi, Antalya, Türkiye, 4 - 07 Kasım 2021, sa.256, ss.221-222, (Tam Metin Bildiri)

55. AKUT PROMİYELOSİTİK LÖSEMİ TANILI HASTALARIN KLİNİK ÖZELLİKLERİ VE TEDAVİ SONUÇLARI: TEK MERKEZ DENEYİMİ

Yavuz Ermiş G., Yilmaz H., Özütemiz S., Selvi N., Öztürk C., Kırcalı E., et al.

47. Ulusal Hematoloji Kongresi , Antalya, Türkiye, 4 - 07 Kasım 2021, ss.202-204, (Tam Metin Bildiri)

56. T/B LENFOBLASTİK LENFOMA TANILI HASTALARIN YENİ TEDAVİLER IŞIĞINDA RETROSPEKTİF DEĞERLENDİRİLMESİ

Karakaya B., Akbulut H., Öztürk C., Koyun D., Kırcalı E., Yilmaz H., et al.

47. Ulusal Hematoloji Kongresi , Antalya, Türkiye, 4 - 07 Kasım 2021, ss.178-179, (Tam Metin Bildiri)

57. PRİMER AMİLOİDOZ TEDAVİSİNE ANTİ-CD38 MONOKLONAL ANTİKOR İLAVESİYLE EN AZ OTOLOG NAKİLE EŞ DEĞER YANITLAR ALINABİLİR

Yilmaz H., Cengiz Seval G., Karakaya B., Kırcalı E., Koyun D., Yüksel M., et al.

47. Ulusal Hematoloji Kongresi , Antalya, Türkiye, 4 - 07 Kasım 2021, ss.224, (Tam Metin Bildiri)

58. NÜKS VEYA DİRENÇLİ HODGKİN DIŞI LENFOMADA RİTUXİMAB, LENALİDOMİD, İBRUTİNİB BİRLİKTE KULLANIM ETKİNLİK VE GÜVENİLİRLİĞİ

Koyun D., Şahin U., Gökmen A., Özcan M.

47. Ulusal Hematoloji Kongresi, Antalya, Türkiye, 4 - 07 Kasım 2021, cilt.14, sa.227, ss.170-171, (Tam Metin Bildiri)

59. PROFLAKTİK DEFİBROTİD SOS DIŞINDA AKUT GRAFT VS HOST HASTALIĞINDA DA ETKİN

KIRCALI E., CENGİZ SEVAL G., ÖZTÜRK C., YILMAZ H., Yavuz G., Karakaya B., et al.

47. Ulusal Hematoloji Kongresi, 04 Kasım 2021, (Tam Metin Bildiri)

60. Effect of Pembrolizumab Monotherapy Versus Brentuximab Vedotin on Symptoms Associated With Health-Related Quality of Life in Relapsed/Refractory Classical Hodgkin Lymphoma in the Randomized Phase 3 KEYNOTE-204 Study

Zinzani P. L., Ramchandren R., Santoro A., Paszkiewicz-Kozik E., Gasiorowski, R., Johnson N. A., et al.

2021 Blood Meeting, Adelaide, Avustralya, 19 Eylül 2021, (Tam Metin Bildiri)

61. Copanlisib plus rituximab vs placebo plus rituximab in patients (pts) with relapsed marginal zone lymphoma (MZL) treated in the Phase III CHRONOS-3 trial

ÖZCAN M., JİN J., Szomor Á., Panayiotis P., Yoon D. H., Tyczyńska A., et al.

ESMO 2021, 16 Eylül 2021, (Tam Metin Bildiri)

62. Molecular Alterations Obtained by High Throughput Methods in Multiple Myeloma Patients with Recurrent or Refractory to Heavy Treatment Regimens Could Guide Alternative Targetted Therapies

KUZU I., SEVAL G. C., YÜKSEL S., Kaygusuz G., DALVA K., ÖZCAN M., et al.

Multiple miyelom AMP kongre 2021, 30 Nisan - 01 Mayıs 2021, (Tam Metin Bildiri)

63. RELAPS/ REFRAKTER HODGKİN LENFOMA HASTALARINDA ALLOJENİK HEMATOPOETİK KÖK HÜCRE NAKLİ: TEK MERKEZ DENEYİMİ

Koyun D., Şahin U., Cengiz Seval G., Civriz Bozdağ S., Toprak S. K., Yüksel M., et al.

13. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Türkiye, 2 - 03 Nisan 2021, sa.52, ss.104-105, (Tam Metin Bildiri)

64. Relaps/Refrakter Hodgkin Lenfoma Hastalarında Allojenik Hematopoetik Kök Hücre Nakli: Tek Merkez Deneyimi

KOYUN D., ŞAHİN U., SEVAL G. C., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M. K., et al.

13. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 2 - 03 Nisan 2021, (Tam Metin Bildiri)

65. MULTİPL MİYELOMDA OTOLOG PRİFERİK KÖK HÜCRE NAKLİ SONRASI ERKEN NÜKSÜ BELİRLEMEDE CIBMTR, ISS VE R-ISS SKORLAMA SİSTEMLERİNİN KARŞILAŞTIRILMASI

CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.

13. Ulusal kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 02 Nisan 2021, (Tam Metin Bildiri)

66. ALLOJENİK KÖK HÜCRE NAKLİ HASTALARINDA PERİTRANSPLANT METRONİDAZOL KULLANIMIYLA AKUT GVHD RİSKİNİN İLİŞKİ

KIRCALI E., CENGİZ SEVAL G., ÖZTÜRK C., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., et al.

13. Ulusal kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 02 Nisan 2021, (Tam Metin Bildiri)

67. Solid Organ Nakli Ve Allojenik Kök Hücre Nakli Sonrası Gelişen Post-Transplant Lenfoproliferatif Hastalık- Tek Merkez Deneyimi

Öztürk C., KIRCALİ E., KOYUN D., YILMAZ H., YAVUZ G., KARAKAYA B., et al.

13. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 2 - 03 Nisan 2021, (Tam Metin Bildiri)

68. Allojenik Kök Hücre Nakli Hastalarında Peritransplant Metronidazol Kullanımıyla Akut GVHD Riskinin İlişkisi

KIRCALİ E., SEVAL G. C., Öztürk C., CİVRİZ BOZDAĞ S., YÜKSEL M. K., TOPÇUOĞLU P., et al.

13. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 2 - 03 Nisan 2021, (Tam Metin Bildiri)

69. KAN GRUBU UYUŞUMSUZLUĞUNUN HAPLOİDENTİK TRANSPLANT SONUÇLARINA ETKİSİ VE KAN GRUBU DÖNÜŞÜM SÜRECİ

GÖKGÖZ M., ŞAHİN U., GÖKMEN A., SOYDAN E., CENGİZ SEVAL G., ARSLAN Ö., et al.

13. Ulusal kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 02 Nisan 2021, (Tam Metin Bildiri)

70. PATIENT RELATED FACTORS OVERRIDE LENALIDOMIDE MAINTENANCE AS A FACTOR OF SEVERITY FOR COVID-19 INFECTION

KIRCALI E., CENGİZ SEVAL G., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., et al.

8th International Congress on Leukemia Lymphoma Myeloma, Ankara, Türkiye, 21 Mayıs 2021, cilt.38, ss.50, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

71. THE IMPACT OF PRETRANSPLANT IMMUNOMODULATORY DRUGS ON CMV REACTIVATION

YÜKSEL M., CENGİZ SEVAL G., USLU A., KIRCALI E., KOYUN D., Yavuz G., et al.

8 45 th International Congress on Leukemia Lymphoma Myeloma, Ankara, Türkiye, 21 Mayıs 2021, cilt.38, sa.71, ss.1-81, (Tam Metin Bildiri)

72. PRIMARY GASTRIC NK/T CELL LYMPHOMA WITH T CELL PHENOTYPE: A RARE EBV RELATED LOCALLY INVOLVED AGRESSIVE LYMPHOMA CASE.

KOYUN D., YÜKSEL S., CENGİZ SEVAL G., KUZU I., ÖZCAN M., CİVRİZ BOZDAĞ S.

8th International Congress on Leukemia Lymphoma Myeloma, Ankara, Türkiye, 21 Mayıs 2021, cilt.28, ss.60-61, (Tam Metin Bildiri)

73. Immune Checkpoint Molecule (PD-1, PD-L1, PD-L2) Expression, 9p24.1 Gene Locus Alterations and Tumor Microenvironment Status of Primary Central Nervous System Lymphoma and Their Clinical Relevance: A Quantitative Analysis

AKBULUT D., YÜKSEL S., KIRCALI E., AKTAŞ B. Y., KAYGUSUZ G., Saglam A., et al.

UNITED STATES CANADIAN ACADEMY OF PATHOLOGY 110th ANNUAL MEETING, 05 Mart 2021, cilt.34, ss.796-797, (Özet Bildiri)

74. The impact of pretransplant ımmunomodulatory drugs on cmv reactıvatıon

YÜKSEL M., CENGİZ SEVAL G., USLU A., KIRCALI E., KOYUN D., YAVUZ G., et al.

8th International congress on leukemia lymphoma myeloma, 2021, 21 Mayıs 2021, (Tam Metin Bildiri)

75. Impact of Peritransplant Metronidazole Use on Acute Graft Versus Host Disease in Allogeneic Hematopoietic Transplant Patients

KIRCALİ E., SEVAL G. C., ÖZTÜRK C., BOZDAĞ S., YÜKSEL M. K., TOPÇUOĞLU P., et al.

Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR, 8 - 12 Şubat 2021, (Tam Metin Bildiri)

76. Comparative Analysis and Validation of CIBMTR Early Relapse Risk Score with ISS and R-ISS: Single Center Experience from Ankara University

SEVAL G. C., BOZDAĞ S., TOPRAK S. K., YÜKSEL M. K., TOPÇUOĞLU P., ARSLAN Ö., et al.

Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR, 08 Şubat 2021, (Tam Metin Bildiri)

77. Comparison of Two Alkylating Agents Among Refractory Multiple Myeloma: Published and Our Retrospective Bendamustine Combination Experience with Melflufen As Single Agent

KIRCALI E., CENGİZ SEVAL G., ÇOLAK S., GÜNDÜZ M., ATACA ATİLLA P., ATİLLA E., et al.

62nd ASH Annual Meeting and Exposition, 05 Aralık 2020, (Tam Metin Bildiri)

78. Effect of Pembrolizumab Monotherapy Versus Brentuximab Vedotin (BV) on Symptoms Associated with Health-Related Quality of Life (HRQoL) in Relapsed/Refractory (R/R) Classical Hodgkin Lymphoma (cHL) in the Randomized, Phase 3, Keynote-204 Study

ÖZCAN M., Ramchandren R., Zinzani P. L., Santoro A., Paszkiewicz-Kozik E., Gasiorowski R., et al.

62th ASH Meeting, Türkiye, 5 Aralık - 08 Şubat 2020, cilt.136, ss.19-20, (Tam Metin Bildiri)

79. FOLİKÜLER LENFOMADA BAZAL PET’ TE TOPLAM METABOLİK TÜMÖR HACMİ VE TOPLAM LEZYON GLİKOLİZİNİN PROGNOSTİK ÖNEMİ

Kırcalı E., Cengiz Seval G., Araz M., Uslu A., Öztürk C., Koyun D., et al.

46. Ulusal Hematoloji Kongresi, Antalya, Türkiye, 28 - 31 Ekim 2020, sa.278, ss.105, (Tam Metin Bildiri)

80. GRAFT VS HOST HASTALIĞINDA ALFA- 1 ANTİTRİPSİN DENEYİMİMİZ

Koyun D., Cengiz Seval G., Kırcalı E., Civriz Bozdağ S., Toprak S. K., Topçuoğlu P., et al.

46. Ulusal Hematoloji Kongresi , Antalya, Türkiye, 28 - 31 Ekim 2020, sa.283, ss.117-118, (Tam Metin Bildiri)

81. MYELOPROLİFERATİF NEOPLAZİDE PEG-IFN-α-2A ETKİNLİK VE GÜVENİLİRLİĞİ: TEK MERKEZ RETROSPEKTİF GERÇEK YAŞAM ÇALIŞMASI

Koyun D., Cengiz Seval G., Civriz Bozdağ S., Toprak S. K., Topçuoğlu P., Arslan Ö., et al.

46. Ulusal Hematoloji Kongresi , Antalya, Türkiye, 28 - 31 Ekim 2020, sa.197, ss.112, (Tam Metin Bildiri)

82. R/ R MULTİPL MYELOM HASTALARINDA BENDAMUSTİN ETKİSİNİN GERİYE YÖNELİK DEĞERLENDİRİLMESİ VE MELFLUFENLE KIYASI

CENGİZ SEVAL G., ÖZCAN M., BEKSAÇ M., ATİLLA E., ATACA ATİLLA P.

42.Ulusal Hematoloji Kongresi, Türkiye, 28 - 30 Ekim 2020, (Tam Metin Bildiri)

83. AKUT MYELOBLASTİK LÖSEMİ HASTALARINDA NÜKLEOFOSMİN MUTASYONU MİNİMAL REZİDÜEL HASTALIK TAKİBİNDE YOL GÖSTERİCİMİDİR

CENGİZ SEVAL G., ÖZCAN M., TOPÇUOĞLU P., DEMİRER T., BEKSAÇ M., CİVRİZ BOZDAĞ S., et al.

42.Ulusal Hematoloji Kongresi, Türkiye, 28 - 30 Ekim 2020, (Tam Metin Bildiri)

84. Health-related quality of life (HRQoL) from KEYNOTE-204: A phase III, randomized, open-label study of pembrolizumab (pembro) vs brentuximab vedotin (BV) in relapsed or refractory classical Hodgkin lymphoma (R/R cHL)

Zinzani P. L., Ramchandren R., Santoro A., Paszkiewicz-Kozik E., Gasiorowski R., Johnson N. A., et al.

ESMO Virtual Congress, ELECTR NETWORK, 19 Eylül - 18 Ekim 2020, cilt.31, (Özet Bildiri)

85. Flamsa-Based Hıgh-Dose Sequentıal Condıtıonıng Regımen Followed By Allogeneıc Hematopoıetıc Stem Cell Transplantatıon (Allo-Hsct): Is It Effectıveın Patıents Wıth Prımary Refractory Or Relapsed Acute Leukemıa?

CENGİZ SEVAL G., EKİN K., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., ARSLAN Ö., et al.

46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), 29 Ağustos - 01 Eylül 2020, (Tam Metin Bildiri)

86. Role Of Chımerısm And Flow-Cytometrıc Monıtorıng Of Measurable Resıdualdısease (Mrd) After Allogeneıc Hematopoıetıc Stem Cell Transplantatıon (Allohsct) In Predıctıng Relapse In Acute Myeloıd Leukemıa (AML)

CENGİZ SEVAL G., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., DALVA K., et al.

46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT, 29 Ağustos - 01 Eylül 2020, (Tam Metin Bildiri)

87. Treatment Of Thrombocytopenıa After Allogeneıc Stem Cell Transplantatıonwıth Eltrombopag

KIRCALİ E., CENGİZ SEVAL G., KOYUN D., ÖZTÜRK C., CİVRİZ BOZDAĞ S., TOPRAK S. K., et al.

46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), 29 Ağustos - 01 Eylül 2020, (Tam Metin Bildiri)

88. The Influence Of Antı-Thymocyte Globulın (Atg) On The Outcomes Of Patıents Wıth Aml W/Wo Measurable Resıdual Dısease (Mrd) At The Tıme Of Unrelated Donor Transplantatıon

CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., YÜKSEL M., KIRCALİ E., BALTACI M. A., TOPÇUOĞLU P., et al.

46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), 29 Ağustos - 01 Eylül 2020, (Tam Metin Bildiri)

89. Rapid drug desensitization with rituximab in 24 cases: A single-center experience

PÜR L., SOYUER O., ÖZTÜRK A. B., BAVBEK S.

EAACI Meeting 2020, 6 - 08 Haziran 2020, cilt.75, ss.5-99, (Tam Metin Bildiri)

90. Molecular Alterations Obtained by High-Throughput Methods in Multiple Myeloma Patients with Recurrent or Refractory to Heavy Treatment Regimens Could Guide Alternative Targeted Therapies

KUZU I., CENGİZ SEVAL G., YÜKSEL S., KAYGUSUZ G., DALVA K., ÖZCAN M., et al.

2nd AMP Europe Congress on Clinical Genomics - Beyond the Somatic Mutation, Milan, İtalya, 11 Mayıs - 13 Şubat 2020, cilt.22, ss.35, (Özet Bildiri)

91. A real-world single-center retrospective study on efficacy and safety of pegylated interferon alpha-2a in patients with myeloproliferative neoplasm

Özcan M., Koyun D., Cengiz Seval G., Uslu A., Kırcali E., Öztürk C., et al.

ASCO 2020, 29 Mayıs - 02 Haziran 2020, cilt.38, sa.15, (Tam Metin Bildiri)

92. Molecular Alterations Obtained by High-Throughput Methods in Multiple Myeloma Patients with Recurrent or Refractory to Heavy Treatment Regimens Could Guide Alternative Targeted Therapies

KUZU I., CENGİZ SEVAL G., YÜKSEL M., KAYGUSUZ G., DALVA K., ÖZCAN M., et al.

2nd AMP Europe Congress on Clinical Genomics - Beyond the Somatic Mutation, 11 - 13 Mayıs 2020, (Tam Metin Bildiri)

93. Allogeneic hematopoietic stem cell transplantation for primary myelofibrosis: A single-center experience.

Demirer T., Seval G. C., Bozdag S. C., Toprak S. K., Yuksel M. K., Topcuoglu P., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 - 31 Mayıs 2020, cilt.38, (Özet Bildiri)

94. Safety and outcome of allogeneic stem cell transplantation in mycosis fungoides and Sezary syndrome: A seven-year tertiary center analysis.

Toprak S. K., Seval G. C., Atilla E., Bozdag S. C., Yuksel M., Topcuoglu P., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 - 31 Mayıs 2020, cilt.38, (Özet Bildiri)

95. A real-world single-center retrospective study on efficacy and safety of pegylated interferon alpha-2a in epatients with myeloproliferative neoplasm.

Ozcan M., Koyun D., Seval G. C., Uslu A., Kircali E., Ozturk C., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 - 31 Mayıs 2020, cilt.38, (Özet Bildiri)

96. AML TANISI İLE AKRABA DIŞI VERİCİDEN AHKHN YAPILAN HASTALARDA ATG KULLANIMININ NAKİL SONUÇLARINA ETKİSİ

CENGİZ SEVAL G., ÖZCAN M., TOPÇUOĞLU P., DEMİRER T., BEKSAÇ M., CİVRİZ BOZDAĞ S., et al.

12. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Türkiye, 5 - 07 Mart 2020, (Tam Metin Bildiri)

97. YÜKSEK DOZ MELFALAN SONRASI YANIT DERİNLİĞİ ARTIŞI NÖTROPENİ DERİNLİĞİ İLEDEĞİL AMA TROMBOSİTOPENİ DERİNLİĞİ İLE İLŞKİLİ

CENGİZ SEVAL G., ÖZCAN M., TOPÇUOĞLU P., BEKSAÇ M., CİVRİZ BOZDAĞ S., TOPRAK S. K., et al.

12. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Türkiye, 5 - 07 Mart 2020, (Tam Metin Bildiri)

98. HEMORAJİK SİSTİT İÇİN YARGILANAN SİKLOFOSFAMİD SUÇSUZ BULUNDU: TEK MERKEZ 7 YILLIK DENEYİM

CENGİZ SEVAL G., ÖZCAN M., TOPÇUOĞLU P., DEMİRER T., BEKSAÇ M., CİVRİZ BOZDAĞ S., et al.

12. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Türkiye, 5 - 07 Mart 2020, (Tam Metin Bildiri)

99. CD34 VE İMMUNEFEKTÖR HÜCRE SAYIMININ TRANSPLANTASYON SONUÇLARINA ETKİSİ

CENGİZ SEVAL G., ÖZCAN M., TOPÇUOĞLU P., DEMİRER T., BEKSAÇ M., CİVRİZ BOZDAĞ S., et al.

12. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Türkiye, 5 - 07 Mart 2020, (Tam Metin Bildiri)

100. CD34+ VE İMMUNEFEKTÖR HÜCRE SAYIMININ TRANSPLANTASYON SONUÇLARINA ETKİSİ

Koyun D., Cengiz Seval G., Dalva K., Uslu A., Öztürk C., Kırcalı E., et al.

12. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Muğla, Türkiye, 5 - 07 Mart 2020, sa.159, ss.60-61, (Tam Metin Bildiri)

101. Large Granular Lymphocytosis and Its Impact on Long Term Clinical Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: 14-Year Follow

CENGİZ SEVAL G., USLU A., KIRCALİ E., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., et al.

Transplantation and Cellular Therapy (TCT) Meetings of ASTCT and CIBMTR, 19 - 23 Şubat 2020, (Tam Metin Bildiri)

102. Effect of Cyclophosphamide on Hemorrhagic Cystitis Following Haploidentical Related Compared to Matched Related/Unrelated Donor Hematopoietic Stem Cell Transplantation: A 7-Year Tertiary Center Analysis

CENGİZ SEVAL G., ÖZTÜRK N., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.

Transplantation and Cellular Therapy (TCT) Meetings of ASTCT and CIBMTR 2020, 19 - 23 Şubat 2020, (Tam Metin Bildiri)

103. Large Granular Lymphocytosis and Its Impact on Long Term Clinical Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: 14-Year Follow-up Data

CENGİZ SEVAL G., USLU A., KİRCALİ E., CİVRİZ BOZDAĞ S., DALVA K., TOPRAK S. K., et al.

61st ASH Annual Meeting and Exposition, NY, Amerika Birleşik Devletleri, 7 - 10 Aralık 2019, cilt.26, ss.305-306, (Özet Bildiri)

104. Relaps/Refrakter Hodgkin Lenfomada Nivolumab: Çok Merkezli Türkiye Deneyimi Uzun Dönem Sonuçları

BEKÖZ H. S., ÖZBALAK M. M., KARADURMUŞ N., PAYDAŞ S., TÜRKER F. A., TOPTAŞ T., et al.

45. Ulusal Hematoloji Kongresi, Antalya, Türkiye, 30 Ekim - 02 Kasım 2019, (Tam Metin Bildiri)

105. RELAPS VE REFRAKTER HODGKİN LENFOMADA BRENTUXİMAB VEDOTİN UZUN DÖNEM SONUÇLARI: ÇOKMERKEZLİ GERÇEK YAŞAM DENEYİMİ

ÖZBALAK M. M., SALİHOĞLU A., SOYSAL T., karadoğan i., PAYDAŞ S., ÖZDEMİR E., et al.

45. Ulusal Hematoloji Kongresi, Antalya, Türkiye, 30 Ekim - 02 Kasım 2019, ss.159-160, (Tam Metin Bildiri)

106. Relaps ve Refrakter Hodgkin Lenfomada Brentuximab Vedotin Uzun Dönem Sonuçları: Çok Merkezli Gerçek Yaşam Deneyimi

ÖZBALAK M. M., Salihoğlu A., SOYSAL T., Karadogan İ., PAYDAŞ S., Özdemir E., et al.

45. Ulusal Hematoloji Kongresi, Türkiye, 30 Ekim - 02 Kasım 2019, (Tam Metin Bildiri)

107. Large Granular Lymphocytosis and Its Impact on Long Term Clinical Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: 14-Year Follow-up Data

CENGİZ SEVAL G., Uslu A., Kircali E., CİVRİZ BOZDAĞ S., DALVA K., TOPRAK S. K., et al.

61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Florida, Amerika Birleşik Devletleri, 7 - 10 Aralık 2019, cilt.134, (Özet Bildiri)

108. Long-Term Efficacy and Safety of Copanlisib in Multiply Relapsed or Refractory Patients with Marginal Zone Lymphoma

Dreyling M., Panayiotidis P., Follows G. A., Mollica L., Nagler A., ÖZCAN M., et al.

61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Florida, Amerika Birleşik Devletleri, 7 - 10 Aralık 2019, cilt.134, (Özet Bildiri)

109. Polatuzumab Vedotin Plus Bendamustine with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study

Sehn L. H., Matasar M. J., Flowers C. R., Kamdar M., McMillan A. K., Hertzberg M., et al.

61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Florida, Amerika Birleşik Devletleri, 7 - 10 Aralık 2019, cilt.134, (Özet Bildiri)

110. Next Generation Sequencing May be Helpful in Designing Novel Combinations Among Heavily Pretreated Myeloma Patients, Refractory to All Available Approved Anti-Myeloma Drugs

CENGİZ SEVAL G., KUZU I., YÜKSEL S., KAYGUSUZ G., DALVA K., ÖZCAN M., et al.

61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Florida, Amerika Birleşik Devletleri, 7 - 10 Aralık 2019, cilt.134, (Özet Bildiri)

111. Effect of Cyclophosphamide on Hemorrhagic Cystitis Following Haploidentical Related Compared to Matched Related/Unrelated Donor Hematopoietic Stem Cell Transplantation: A 7-Year Tertiary Center Analysis

CENGİZ SEVAL G., Ozturk N., CİVRİZ BOZDAĞ S., Yuksel M. K., TOPÇUOĞLU P., ARSLAN Ö., et al.

61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Florida, Amerika Birleşik Devletleri, 7 - 10 Aralık 2019, cilt.134, (Özet Bildiri)

112. Which One, Generic Vs Original Glivec Is More Effective in Patients with Chronic Myeloid Leukemia?

Kircali E., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., Yuksel M. K., ARSLAN Ö., et al.

61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Florida, Amerika Birleşik Devletleri, 7 - 10 Aralık 2019, cilt.134, (Özet Bildiri)

113. Quality of Life Was Not Negatively Impacted By the Addition of Lenalidomide to R-CHOP Chemotherapy (R-2-CHOP) Compared with Placebo Plus R-CHOP Chemotherapy in Patients with Previously Untreated Activated B-Cell (ABC)-Type Diffuse Large B-Cell Lymphoma (DLBCL): Health-Related Quality of Life (HRQoL) Analysis of the International Robust Study

Chiappella A., Witzig T. E., Cocks K., Greenwood M., Williams A., Scott D. W., et al.

61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Florida, Amerika Birleşik Devletleri, 7 - 10 Aralık 2019, cilt.134, (Özet Bildiri)

114. HANGİSİ, ORJİNAL İMATİNİB Mİ JENERİK Mİ KRONİK MYELOİD LÖSEMİDE DAHA ETKİN?

KIRCALI E., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., ARSLAN Ö., et al.

45. Ulusal Hematoloji Kongresi, 31 Ekim 2019, (Tam Metin Bildiri)

115. YENİ TANI KLL HASTALARINDA TANI SIRASINDAKİ CD49DEKSPRESYONUNUN HASTALIĞA OZGU BAŞKA PARAMETRELERLEİLİŞKİSİ

TOPRAK S. K., güven m., CENGİZ SEVAL G., DALVA K., İpek Ş., Okul N., et al.

45. ULUSAL HEMATOLOJİ KONGRESİ, Türkiye, 30 Ekim - 02 Kasım 2019, (Özet Bildiri)

116. KRONİK MİYELOİD LOSEMİ (KML) HASTALARINDA KML KOKHUCRESİ BCR- ABL’DEN BAĞIMSIZ PROGNOSTİK BİR FAKTOR OLABİLİR Mİ?

TOPRAK S. K., güven m., CENGİZ SEVAL G., DALVA K., İpek Ş., Okul N., et al.

45. ULUSAL HEMATOLOJİ KONGRESİ, Türkiye, 30 Ekim - 02 Kasım 2019, (Özet Bildiri)

117. NGS TUM SECENEKLERİ TUKETMİŞ NUKS VE DİRENCLİ MMHASTALARINDA ENDİKASYON DIŞI TEDAVİ OLUŞTURMADAREHBERLİK EDEBİLİR Mİ?

CENGİZ SEVAL G., KUZU I., YÜKSEL S., DALVA K., ÖZCAN M., BEKSAÇ M.

45. Ulusal Hematoloji Kongresi, Türkiye, 31 Ekim - 02 Kasım 2019, (Özet Bildiri)

118. Nivolumab for relapsed or refractory Hodgkin lymphoma: long term results of multi-center experience in Turkey

FERHANOĞLU A. B., BEKÖZ H. S., ÖZBALAK M. M., KARADURMUŞ N., PAYDAŞ S., TÜRKER F. A., et al.

6th Aegean Hematology Oncology Symposium, 3 - 06 Ekim 2019, (Özet Bildiri)

119. Negative Impact of High LDH at Diagnosis on OS, But Not PFS, Can Be Overcome by Autologous Stem Cell Transplantation

CENGİZ SEVAL G., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.

17th International Myeloma Workshop, 12 - 15 Eylül 2019, (Tam Metin Bildiri)

120. Is mobilization with chemotherapy effect response in the multiple myeloma?

CENGİZ SEVAL G., Uslu A., CİVRİZ BOZDAĞ S., YÜKSEL M., ARSLAN Ö., ÖZCAN M., et al.

45th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Frankfurt, Almanya, 24 - 27 Mart 2019, cilt.54, ss.500, (Özet Bildiri)

121. Can the drugs used before autologous hematopoietic stem cell transplantation have impact on CMV reactivation that results in decreased os in myeloma patients after ASCT?

YÜKSEL M., CENGİZ SEVAL G., Uslu A., Kircili E., KOYUN D., Ozturk C., et al.

45th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Frankfurt, Almanya, 24 - 27 Mart 2019, cilt.54, ss.505-506, (Özet Bildiri)

122. Results of a single center experience: An attempt to augment conditioning regimen in first autologous stem cell transplantation

CENGİZ SEVAL G., KOYUN D., Kircali E., TOPRAK S. K., ÖZCAN M., BEKSAÇ M.

45th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Frankfurt, Almanya, 24 - 27 Mart 2019, cilt.54, ss.500-501, (Özet Bildiri)

123. Phase 1/2a LYM1002 study of ibrutinib (ibr) plus nivolumab (nivo): Exome and gene expression profiling (GEP) analyses by histology and responder status

Hodkinson B., Schaffer M., Brody J., Jurczak W., Carpio C., Ben-Yehuda D., et al.

Annual Meeting of the American-Association-for-Cancer-Research (AACR), Georgia, Amerika Birleşik Devletleri, 29 Mart - 03 Nisan 2019, cilt.79, (Özet Bildiri)

124. Haploidentical stem cell transplantation may be an option for hematological malignancies in urgent conditions

İLHAN O., CENGİZ SEVAL G., Uslu A., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., et al.

45th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Frankfurt, Almanya, 24 - 27 Mart 2019, cilt.54, ss.382, (Özet Bildiri)

125. Can Nelarabıne Rescue The Graft After Allogeneıc Hematopoıetıc Stem Cell Transplantatıon In T-All ?

YÜKSEL M., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., et al.

24 Congress of the European Hematology Association, 13 - 16 Haziran 2019, (Özet Bildiri)

126. Nivolumab for Relapsed or Refractory Hodgkin Lymphoma: Long-Term Results of Multi-Center Experience in Turkey.

FERHANOĞLU A. B., ÖZBALAK M. M., BEKÖZ H. S., KARADURMUŞ N., PAYDAŞ S., TÜRKER F. A., et al.

The 24th Congress of European Hematology Association, Amsterdam, Hollanda, 13 - 16 Haziran 2019, (Özet Bildiri)

127. Nivolumab for Relapsed or Refractory Hodgkin Lymphoma: Real-Life Experience.

FERHANOĞLU A. B., ÖZBALAK M. M., BEKÖZ H. S., KARADURMUŞ N., PAYDAŞ S., TÜRKER F. A., et al.

EHA24, 24th International Congress of European Hematology Association, Amsterdam, Hollanda, 13 - 16 Haziran 2019, (Özet Bildiri)

128. CAN AUTOLOGOUS STEM CELL TRANSPLANTATION ABROGATE THE POOR PROGNOSIS ASSOCIATED WITH HIGH LDH?

Cengiz Seval G., Civriz Bozdağ S., Yüksel M., Topçuoğlu P., Arslan Ö., Özcan M., et al.

7th International Congress on Leukemia Lymphoma Myeloma, İstanbul, Türkiye, 2 - 04 Mayıs 2019, ss.45, (Tam Metin Bildiri)

129. LEUKAPHERESIS REDUCES 4-WEEK MORTALITY IN ACUTE MYELOID LEUKEMIA PATIENTS WITH HYPERLEUKOCYTOSIS - A RETROSPECTIVE STUDY FROM A TERTIARY CENTER

Cengiz Seval G., Uslu A., Civriz Bozdağ S., Toprak S. K., Yüksel M., Topçuoğlu P., et al.

7th International Congress on Leukemia Lymphoma Myeloma, İstanbul, Türkiye, 2 - 04 Mayıs 2019, ss.37, (Tam Metin Bildiri)

130. HAPLOIDENTICAL STEM CELL TRANSPLANTATION MAY BE A GOOD ALTERNATIVE AS SALVAGE TREATMENT FOR HEAVILY PRETREATED PATIENTS WITH LEUKEMIA

Cengiz Seval G., Uslu A., Civriz Bozdağ S., Toprak S. K., Yüksel M., Topçuoğlu P., et al.

7th International Congress on Leukemia Lymphoma Myeloma, İstanbul, Türkiye, 2 - 04 Mayıs 2019, ss.56-57, (Tam Metin Bildiri)

131. COMPARISION OF AUTOLOGOUS CONDITIONING REGIMENS AMONG LYMPHOMA PATIENTS

Gokgöz Z., Uğur Bilgin A., Arslan Ö., Özcan M., İlhan O.

7th International Congress on Leukemia Lymphoma Myeloma, İstanbul, Türkiye, 2 - 04 Mayıs 2019, ss.52, (Tam Metin Bildiri)

132. CAN THE DRUGS USED BEFORE AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (ASCT) HAVE IMPACT ON CMV REACTIVATION THAT RESULTS IN DECREASED OS IN MYELOMA PATIENTS AFTER ASCT?

Yüksel M., Cengiz Seval G., Uslu A., Kırcalı E., Koyun D., Öztürk C., et al.

7th International Congress on Leukemia Lymphoma Myeloma, İstanbul, Türkiye, 2 - 04 Mayıs 2019, ss.59, (Tam Metin Bildiri)

133. IS AGE AN IMPORTANT FACTOR FOR AUTOLOGOUS PERIPHERAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ELDERLY PATIENTS WITH NONHODGKIN LYMPHOMA?

Cengiz Seval G., Uslu A., Civriz Bozdağ S., Toprak S. K., Yüksel M., Topçuoğlu P., et al.

7th International Congress on Leukemia Lymphoma Myeloma, İstanbul, Türkiye, 2 - 04 Mayıs 2019, ss.47-48, (Tam Metin Bildiri)

134. SUCCESSFUL TREATMENT OF GRAFT FAILURE WITH SECOND ALLOGENEIC STEM CELL TRANSPLANTATION WITHOUT CONDITIONING REGIMEN

Cengiz Seval G., Uslu A., Öztürk C., Civriz Bozdağ S., Yüksel M., Topçuoğlu P., et al.

8th International Congress on Leukemia Lymphoma Myeloma, İstanbul, Türkiye, 2 - 04 Mayıs 2019, ss.75, (Tam Metin Bildiri)

135. Pretransplant hemoglobin and serum creatinine levels correlate with progression free survival in myeloma patients undergoing autologous stem cell transplantation.

DEMİRER T., CENGİZ SEVAL G., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2019, cilt.37, (Özet Bildiri)

136. Can autologous stem cell transplantation abrogate the poor prognosis associated with high LDH in myeloma patients?

Ilhan O., CENGİZ SEVAL G., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., Topcuoglu P., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2019, cilt.37, (Özet Bildiri)

137. retrospective analysis of 149 unselected patıents wıth mantle cell lymphoma confırms prognostic relevance of mıpı: sıngle center ecperıence

CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., et al.

ICLLM 2019, 02 Mayıs 2019, (Tam Metin Bildiri)

138. CAN AUTOLOGOUS STEM CELL TRANSPLANTATIONABROGATE THE POOR PROGNOSIS ASSOCIATED WITH HIGHLDH?

SEVAL G. C., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., et al.

7th International Congress on Leukemia Lymphoma Myeloma, 2 - 04 Mayıs 2019, (Tam Metin Bildiri)

139. RETROSPECTIVE ANALYSIS OF 149 UNSELECTED PATIENTSWITH MANTLE CELL LYMPHOMA CONFIRMS PROGNOSTICRELEVANCE OF MIPI: SINGLE CENTER EXPERIENCE

SEVAL G. C., ULAŞ B. B., bolat b., Taşçı O., karatepe f., KUZU I., et al.

7th International Congress on Leukemia Lymphoma Myeloma, 2 - 04 Mayıs 2019, (Tam Metin Bildiri)

140. Nodüler Lenfosit Baskın Hodgkin Lymphoma (NLBHL)’da Kombine İnflamasyon İndeksinin Prognostik Önemi

PAYDAŞ S., ÇAKAR M. K., BARIŞTA İ., SEYDAOĞLU G., PEHLİVAN M., DOĞAN M., et al.

23. Ulusal Kanser Kongresi, Antalya, Türkiye, 17 - 21 Nisan 2019, (Özet Bildiri)

141. CAN ELTROMBOPAG TREAT THE THROMBCYTOPENIA AFTER STEM CELL TRANSPLANTATION

Yüksel M., Kırcalı E., Cengiz Seval G., Koyun D., Uslu A., Öztürk C., et al.

7th International Congress on Leukemia Lymphoma, İstanbul, Türkiye, 2 - 04 Mayıs 2019, (Tam Metin Bildiri)

142. MULTİPLE MYELOM HASTALARINDA OTOLOG PERİFERİK KÖK HÜCRE NAKLİ ESNASINDA GELİŞEN NÖTROPENİK ATEŞ

Uslu A., Cengiz Seval G., Öztürk C., Narlı Özdemir Z., Kırcalı E., Koyun D., et al.

11. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Türkiye, 1 - 02 Mart 2019, sa.142, ss.130, (Tam Metin Bildiri)

143. Refrakter Akut Lösemili Hastalarda Ardışık Kurtarma Tedavisi İle Birlikte Ahkhn Yeterli Kür Sağlayabilir mi?

CENGİZ SEVAL G., KIRCALİ E., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., ARSLAN Ö., et al.

11. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Türkiye, 1 - 03 Mart 2019, (Özet Bildiri)

144. Transplant Sonrası Trombositopenide Eltrombopag: Tek Merkez Deneyimimiz

Kırcali E., Cengiz Seval G., Koyun D., Civriz Bozdağ S., Topçuoğlu P., Özcan M., et al.

11. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Türkiye, 1 - 03 Mart 2019, (Tam Metin Bildiri)

145. T-All Hastalarında Allojeneik Hematopoetik Kök Hücre Nakli Sonrasında Nelarabin Tedavisi Graftı Kurtarabilir mi?

CENGİZ SEVAL G., USLU A., NARLI ÖZDEMİR Z., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., et al.

11. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Türkiye, 1 - 03 Mart 2019, (Özet Bildiri)

146. Posttransplant Lenfositoz Önemli Bir Parametre midir?

CENGİZ SEVAL G., USLU A., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.

11. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Türkiye, 1 - 03 Mart 2019, (Özet Bildiri)

147. Akut Miyeloid Lösemide Nakil Öncesi Minimal Kalıntı Hastalık Diğer Risk Faktörlerinden Daha Önemli midir

NARLI ÖZDEMİR Z., ŞAHİN U., BALTACI M. A., USLU A., ÖZTÜRK C., CENGİZ SEVAL G., et al.

11. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Türkiye, 1 - 03 Mart 2019, (Özet Bildiri)

148. Miyelom Hastalarında Ohkhn Öncesi Kullanılan İlaçların Cmv Reaktivasyonu Üzerine Sağkalımı Azaltıcı Etkisi Olabilir mi?

YÜKSEL M., CENGİZ SEVAL G., USLU A., KIRCALİ E., KOYUN D., ÖZTÜRK C., et al.

11. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Türkiye, 1 - 03 Mart 2019, (Özet Bildiri)

149. Allojeneik Kök Hücre Nakli Sonrası Akut Lösemi Hastalarında Nüksü Öngörmede Kimerizm İle Mrd Karşılaştırılması

CENGİZ SEVAL G., ULAŞ B. B., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.

11. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Türkiye, 1 - 03 Mart 2019, (Özet Bildiri)

150. Multipl Miyelom Olgularında Otolog Kök Hücre Naklinde Yüksek Doz Melfelana Bortezomib Eklenmesinin Tek Merkez Sonuçları

Cengiz Seval G., Koyun D., Kırcali E., Şahin U., Toprak S. K., Özcan M., et al.

11. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Türkiye, 1 - 03 Mart 2019, (Tam Metin Bildiri)

151. İyi Riskli Aml’de İkinci Tam Remisyonda Allojeneik Hematopoietik Kök Hücre Nakli Tek Merkez Deneyimi

PEKCAN G., NARLI ÖZDEMİR Z., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., et al.

11. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Türkiye, 1 - 03 Mart 2019, (Özet Bildiri)

152. CAN AUTOLOGOUS STEM CELL TRANSPLANTATIONABROGATE THE POOR PROGNOSIS ASSOCIATED WITH HIGH LDH?

CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., et al.

7th International Congress on Leukemia Lymphoma Myeloma, 3 - 04 Mayıs 2019, (Tam Metin Bildiri)

153. MİYELOM HASTALARINDA OHKHN ÖNCESİ KULLANILANİLAÇLARIN CMV REAKTİVASYONU ÜZERİNE SAĞKALIMIAZALTICI ETKİSİ OLABİLİR Mİ?

YÜKSEL M., CENGİZ SEVAL G., USLU A., KIRCALI E., KOYUN D., ÖZTÜRK C., et al.

11. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Türkiye, 1 - 03 Mart 2019, (Özet Bildiri)

154. Does Level of Vitamin D Prior to Allogeneic Stem Cell Transplantation Affect the Transplant Outcomes?

Soydan E., Gokmen A., Gokgoz Z., Sen S., Ozkumur K. O., Okcu M. K., et al.

Transplant and Cell Therapy Meeting / Combined Annual Meetings of the American-Society-for-Blood-and-Marrow-Transplantation (ASBMT) and the Center-for-International-Blood-and-Marrow-Transplant-Research (CIBMTR), Texas, Amerika Birleşik Devletleri, 13 - 24 Şubat 2019, cilt.25, (Özet Bildiri)

155. LEUKAPHERESIS REDUCES 4-WEEK MORTALITY IN ACUTEMYELOID LEUKEMIA PATIENTS WITH HYPERLEUKOCYTOSIS - A RETROSPECTIVE STUDY FROM A TERTIARY CENTER

CENGİZ SEVAL G., USLU A., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., et al.

7th International Congress on Leukemia Lymphoma Myeloma, 3 - 04 Mayıs 2019, (Tam Metin Bildiri)

156. Influence of Conditioning Regimens with Total Body Irradiation (TBI) on Graft Versus Host Disease and Graft Versus Leukemia Effect Following Donor Lymphocyte Infusions (DLI)

CENGİZ SEVAL G., Atilla E., Ulas B., CİVRİZ BOZDAĞ S., TOPRAK S. K., Yuksel M. K., et al.

157. İmmun Trombositopeni (İTP) hastalarında ABO kan gruplarının birinci basamak tedavi yanıtına etkisi

AKKUŞ E., FİDAN Ç., KUŞTAŞ A. A., NARLI ÖZDEMİR Z., CİVRİZ BOZDAĞ S., TOPRAK S. K., et al.

TKBD Uluslararası Katılımlı Hematolojik Hastalıkların Tanı Ve İzleminde Laboratuvar Sempozyumu, Türkiye, 5 - 07 Nisan 2018, cilt.16, ss.44, (Özet Bildiri)

158. PEMBROLIZUMAB İN PATIENTS WITH RELAPSED OR REFRACTORY PMBCL DATA FROM THE KEYNOTE-013 AND KEYTONE-170 STUDIES

ÖZCAN M.

ASH 2018, 4 - 08 Aralık 2018, (Tam Metin Bildiri)

159. Comparision of Outcomes According to HLA Disparity in Acute Leukemia Patients: A Single Center Institution Experience

TOPÇUOĞLU P., SEVAL G. C., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., DALVA K., et al.

60th ASH Annual Meeting, san diego, Amerika Birleşik Devletleri, 29 Kasım - 05 Aralık 2018, cilt.132, ss.4673, (Tam Metin Bildiri)

160. Impact of ABO Mismatch on Outcomes of Allogeneic Hematopoietic Stem Cell Recipients: 30 Years of Experience with 1016 Patients

Atilla E., TOPÇUOĞLU P., AKKUŞ E., Atilla P. A., CİVRİZ BOZDAĞ S., YÜKSEL M., et al.

60th Annual Meeting of the American-Society-of-Hematology (ASH), California, Amerika Birleşik Devletleri, 1 - 04 Aralık 2018, cilt.132, (Özet Bildiri)

161. Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 Studies

Armand P., Rodig S. J., Melnichenko V., Thieblemont C., Bouabdallah K., Tumyan G., et al.

60th Annual Meeting of the American-Society-of-Hematology (ASH), California, Amerika Birleşik Devletleri, 1 - 04 Aralık 2018, cilt.132, (Özet Bildiri)

162. Retrospective Analysis of 149 Unselected Patients with Mantle Cell Lymphoma Confirms Prognostic Relevance of Mantle Cell Lymphoma International Prognostic Index: Single Center Experience

CENGİZ SEVAL G., Ulas B., TAŞCI O., Ozel F., Bulat B., KUZU I., et al.

60th Annual Meeting of the American-Society-of-Hematology (ASH), California, Amerika Birleşik Devletleri, 1 - 04 Aralık 2018, cilt.132, (Özet Bildiri)

163. Donor Lymphocyte Infusions for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience

GÜRMAN G., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., et al.

60th Annual Meeting of the American-Society-of-Hematology (ASH), California, Amerika Birleşik Devletleri, 1 - 04 Aralık 2018, cilt.132, (Özet Bildiri)

164. Is the End Close for the Graft-Versus-Host Disease That Is a Big Problem Following Allogeneic Hematopoetic Stem Cell Transplantation?

İLHAN O., CENGİZ SEVAL G., ÖZKURT Z. N., Ural A. U., Ayli M., Sevindik O. G., et al.

60th Annual Meeting of the American-Society-of-Hematology (ASH), California, Amerika Birleşik Devletleri, 1 - 04 Aralık 2018, cilt.132, (Özet Bildiri)

165. Polatuzumab Vedotin (Pola) Plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase (Ph) Ib/II Study

Sehn L. H., Herrera A. F., Matasar M. J., Kamdar M., Assouline S., Hertzberg M., et al.

60th Annual Meeting of the American-Society-of-Hematology (ASH), California, Amerika Birleşik Devletleri, 1 - 04 Aralık 2018, cilt.132, (Özet Bildiri)

166. Evaluation of Elderly Patients with Hematological Malignancies By Two Different Geriatric Risk Scoring Systems: G8 and Flemish Version of the Triage Risk Screening Tool (fTRST)

Atilla E., Yalciner M., Kilic O., Muftuoglu N., Atilla P. A., CİVRİZ BOZDAĞ S., et al.

60th Annual Meeting of the American-Society-of-Hematology (ASH), California, Amerika Birleşik Devletleri, 1 - 04 Aralık 2018, cilt.132, (Özet Bildiri)

167. Long-Term Efficacy and Safety from the Copanlisib CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma

Dreyling M., Santoro A., Mollica L., Leppa S., Follows G. A., Lenz G., et al.

60th Annual Meeting of the American-Society-of-Hematology (ASH), California, Amerika Birleşik Devletleri, 1 - 04 Aralık 2018, cilt.132, (Özet Bildiri)

168. ALLOJENİK HEMATOPOİETİK KÖK HÜCRE NAKLİ YAPILAN ALL HASTALARINDA CMV ENFEKSİYONUNUN NAKİL SONUÇLARINA ETKİLERİ

KALACI E., ŞAHİN EROĞLU D., CENGİZ SEVAL G., NARLI ÖZDEMİR Z., BEKSAÇ M., ÖZCAN M., et al.

44. Ulusal Hematoloji Kongresi, Türkiye, 31 Ekim - 03 Kasım 2018, (Tam Metin Bildiri)

169. Akut Miyeloid Lösemide Nakil Öncesi ve Nakil Sonrası +28. Gün Değerlendirilen Minimal Kalıntı Hastalığın Hastalık Seyrine Etkisi

DALVA K., NARLI ÖZDEMİR Z., ŞAHİN U., USLU A., MURADOVA B., CENGİZ SEVAL G., et al.

44. Ulusal Hematoloji Kongresi, Antalya, Türkiye, 31 Ekim - 03 Kasım 2018, ss.245-246, (Özet Bildiri)

170. BLASTİK PLAZMASİTOİD DENDRİTİK HÜCRELİ NEOPLAZİ: NADİR GÖRÜLEN BİR HEMATOLOJİK MALİGNİTEDE TEK MERKEZ DENEYİMİ

NARLI ÖZDEMİR Z., CENGİZ SEVAL G., USLU A., GÜNDÜZ M., CİVRİZ BOZDAĞ S., TOPRAK S. K., et al.

44. Ulusal Hematoloji Kongresi, Antalya, Türkiye, 31 Ekim 2018, (Özet Bildiri)

171. ALLOJENİK HEMATOPOİETİK KÖK HÜCRE NAKLİ YAPILANALL HASTALARINDA CMV ENFEKSİYONUNUN NAKİLSONUÇLARINA ETKİLERİ

KALACI E., ŞAHİN EROĞLU D., CENGİZ SEVAL G., NARLI ÖZDEMİR Z., BEKSAÇ M., ÖZCAN M., et al.

44. Ulusal Hematoloji Kongresi, Türkiye, 31 Ekim - 03 Kasım 2018, (Özet Bildiri)

172. AKUT LÖSEMİ HASTALARINDA HLA UYUŞUMSUZLUĞUNUNNAKİL SONUÇLARINA ETKİSİ: TEK MERKEZ DENEYİMİ

CENGİZ SEVAL G., NARLI ÖZDEMİR Z., TATAR L., SÖKMEN M., CİVRİZ BOZDAĞ S., TOPRAK S. K., et al.

44. Ulusal Hematoloji Kongresi, Türkiye, 31 Ekim - 03 Kasım 2018, (Özet Bildiri)

173. Comparing Conditioning Regimens for Autologous Stem Cell Transplantation in Lymphoma Patients

CENGİZ SEVAL G., GÖREN ŞAHİN D., SOYDAN E., ÖZÇELİK E. T., GÖKMEN A., GÖKGÖZ Z., et al.

2018 Society of Hematologic Oncology (SOHO) Annual Conference, 12 - 15 Eylül 2018, (Tam Metin Bildiri)

174. Impact of Hepatitis B Core Antibody Seopositivity on the Liver Function Tests after Autologous Hematopoietic Stem Cell Transplantation For Multiple Myeloma

CENGİZ SEVAL G., Sertesen E., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., Aslan O., et al.

44th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Lisbon, Portekiz, 18 - 21 Mart 2018, cilt.53, ss.338, (Özet Bildiri) Sürdürülebilir Kalkınma

175. Donor lymphocyte infusion after salvage chemotherapy in relapsed acute myeloblastic leukemia patients after allogeneic stem cell transplantation

Uslu A., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., GÜRMAN G., Demirer T., Arslan O., et al.

44th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Lisbon, Portekiz, 18 - 21 Mart 2018, cilt.53, ss.161-162, (Özet Bildiri)

176. Is post-transplant albumin a predictor of early transplant complications?

TOPÇUOĞLU P., CENGİZ SEVAL G., AKKUŞ E., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., et al.

44th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Lisbon, Portekiz, 18 - 21 Mart 2018, cilt.53, ss.344-345, (Özet Bildiri)

177. Haploidentical transplantation does not have survival advantage over unrelated donor transplantation in haematological diseases

Soydan E., Gokmen A., Gokgoz Z., İLHAN O., ARSLAN Ö., ÖZCAN M.

44th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Lisbon, Portekiz, 18 - 21 Mart 2018, cilt.53, ss.747, (Özet Bildiri)

178. The Outcome of Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation for Isolated CD4 (+) T-cell Deficiency with Interleukin-2 Inducible T-cell Kinase (ITK) Gene Defect

YÜKSEL M., Ozdemir Z. N., Sahin U., ÇAĞDAŞ AYVAZ D. N., Atikcan D. T., Sertesen E., et al.

44th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Lisbon, Portekiz, 18 - 21 Mart 2018, cilt.53, ss.533-534, (Özet Bildiri)

179. BCNU-EAM vs non-BCNU alternative alkylator -EAM conditioning regimens for autologous stem cell transplantation in lymphoma patients

Sahin D. G., Cengiz G. S., Soydan E., Ozcelik E. T., Gokmen A., Gokgoz Z., et al.

44th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Lisbon, Portekiz, 18 - 21 Mart 2018, cilt.53, ss.256-257, (Özet Bildiri)

180. Fit Elderly Patients with aggressive lymphoma do not need dose reduction of conditioning regimen

Ilhan O., CENGİZ SEVAL G., Uslu A., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., et al.

44th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Lisbon, Portekiz, 18 - 21 Mart 2018, cilt.53, ss.272-273, (Özet Bildiri)

181. Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation with Different Doses of Antithymocyte Globulin Containing Conditioning in Hematological Malignancies

Gokgoz Z., Soydan E., Gokmen A., ARSLAN Ö., İLHAN O., ÖZCAN M.

44th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Lisbon, Portekiz, 18 - 21 Mart 2018, cilt.53, ss.284-285, (Özet Bildiri)

182. adding polatuzumab vedotin (pola) to bendamustine and rituximab (br) treatment improves survival in patients with relapsed/refractory dlbcl result of a phase 2 clinical trial

ÖZCAN M.

23TH EHA, 11 - 15 Haziran 2018, (Tam Metin Bildiri)

183. Retrospective analysis of 115 unselected patients with mantle cell lymphoma: Single center experience

Cengiz Seval G., BULAT B., Ozel F., Tasci O., Kuzu I., CİVRİZ BOZDAĞ S., et al.

ASCO Annual Meeting 2018, 1 - 05 Haziran 2018, cilt.36, ss.19525, (Tam Metin Bildiri)

184. BlastIc Plasmacyto Id DendrItIc Cell Neoplasm: SIngle CenterExperIence on a Rare Hematological Malignancy

NARLI ÖZDEMİR Z., SEVAL G. C., USLU A., GÜNDÜZ M., CİVRİZ BOZDAĞ S., TOPRAK S. K., et al.

5th Aegean Hematology Oncology Symphosium, Yunanistan, 20 - 23 Mart 2018, (Özet Bildiri)

185. Akciğer Yerleşimli Ekstranodal Marjinal Zon LenfomaOlgusu

yıldız c., eroğlu z., özcan a., CANBAKAN S., DEMİRAĞ F., ÖZCAN M.

ASYOD UASK 2018, Antalya, Türkiye, 14 - 18 Mart 2018, (Özet Bildiri)

186. ALLOJENEİK KÖK HÜCRE NAKLİ SONRASI GELİŞENKARACİĞER SİNÜZOİDAL TIKANIKLIK SENDROM İNSİDANSIVE KLİNİK BULGULAR

GÜNDÜZ M., ATİLLA E., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., ARSLAN Ö., et al.

10. ULUSAL KEMİK İLİĞİTRANSPLANTASYONU VEHÜCRESEL TEDAVİLER KONGRESİ, Antalya, Türkiye, 1 - 03 Mart 2018, (Özet Bildiri)

187. Allojeneik Hematopoetik Kök Hücre Nakli Sonrası Akut Myeloid Lösemi Nüksünün Yönetimi ve Prognozu

ŞAHİN U., GÜNDÜZ M., MERTER M., NARLI ÖZDEMİR Z., ÖZEN M., CİVRİZ BOZDAĞ S., et al.

10. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Türkiye, 1 - 03 Mart 2018, ss.126-127, (Özet Bildiri)

188. KEMOTERAPİ İLE MOBİLİZASYON MULTİPL MİYELOMDA YANITLARI ETKİLİYOR MU?

CENGİZ SEVAL G., USLU A., CİVRİZ BOZDAĞ S., YÜKSEL M., ARSLAN Ö., ÖZCAN M., et al.

10. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 01 Mart 2018, (Tam Metin Bildiri)

189. Age is Not an Important Factor for Autologous Peripheral Hematopoietic Stem Cell Mobilization and Collection in Patients with Multiple Myeloma

İLHAN O., CENGİZ SEVAL G., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., et al.

Blood and Marrow Transplantion Tandem Meetings of the Center-for-International-Blood-and-Marrow-Transplant-Research (CIBMTR) / American-Society-for-Blood-and-Marrow-Transplantation (ASBMT), Utah, Amerika Birleşik Devletleri, 21 - 25 Şubat 2018, cilt.24, (Özet Bildiri)

190. Ph Negatif ALL’de 1. Tam Remisyonda Yapılan Pekiştirme Tedavileri Nakil Sonrası Başarıyı Arttırır

NARLI ÖZDEMİR Z., ŞAHİN U., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., et al.

10. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Türkiye, 1 - 03 Mart 2018, (Özet Bildiri)

191. ITK Gen Defektine Bağlı CD4+ T Hücre Yetmezliği Olan Erişkinde Allojeneik Hematopoietik Kök Hücre Naklinin Sonuçları

YÜKSEL M., NARLI ÖZDEMİR Z., ŞAHİN U., CENGİZ SEVAL G., ÇAĞDAŞ AYVAZ D., ATİKCAN D. T., et al.

10. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Türkiye, 01 Mart 2018, ss.138, (Özet Bildiri)

192. Retrospective Analysis Learn Conditioning for Autologous Stem Cell Transplantation

Soydan E., Gokmen A., Gokgoz Z., İLHAN O., ARSLAN Ö., ÖZCAN M.

193. AKUT GRAFT VERSUS HOST HASTALIĞI KLİNİK SONUÇLARI: TEK MERKEZ DENEYİMİ

NARLI ÖZDEMİR Z., CENGİZ SEVAL G., USLU A., ÖZTÜRK C., CİVRİZ BOZDAĞ S., TOPRAK S. K., et al.

10. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Türkiye, 01 Mart 2018, (Özet Bildiri)

194. MYELOFİBROZİSTE ALLOJENEİK HEMATOPOETİK KÖK HÜCRE NAKLİ SONUÇLARI: TEK MERKEZ DENEYİMİ

CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.

10. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 01 Mart 2018, (Tam Metin Bildiri)

195. Real-world data in relapsed refractory myelopma patients treated with carfilzomib, a multicenter Turkish experience

SEVİNDİK Ö. G., PEHLİVAN M., TUĞLULAR A. T., solmaz ş. m., DOĞU M. H., YALNIZ F. F., et al.

AMERİKAN HEMATOLOJİ DERNEĞİ KONGRESİ, Amerika Birleşik Devletleri, 9 - 12 Aralık 2017, cilt.130, ss.5405, (Tam Metin Bildiri)

196. REAL WORLD DATA IN RELAPSED REFRACTORY MYELOMA PATIENTS TREATED WITH CARFILZOMIB, A MULTICENTER TURKISH EXPERİENCE

SEVİNDİK Ö. G., PEHLİVAN M., TUĞLULAR A. T., SOLMAZ Ş. M., DOĞU M. H., YALNIZ F. F., et al.

American Society of Hematology Congress, Atlanta, Amerika Birleşik Devletleri, 9 - 12 Aralık 2017, cilt.130, ss.5405, (Tam Metin Bildiri)

197. PhD20 Updated Safety and Efficacy from the Copanlisib CHRONOS-1 Trial in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma: Low Incidence of Late-Onset Severe Toxicities

dreyling m., santoro a., mollica l., leppa s., fallows g., lenz g., et al.

ASH, 6 - 14 Aralık 2017, (Tam Metin Bildiri)

198. Safety and Efficacy of the Combination of Ibrutinib and Nivolumab in Patients with Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

YOUNES A., BRODY J., CECİLİA C., LOPEZ A., YEHUDA D. B., FERHANOĞLU A. B., et al.

ASH 2017, 6 - 14 Aralık 2017, (Özet Bildiri)

199. MS12 Addition of Polatuzumab Vedotin to Bendamustine and Rituximab (BR) Improves Outcomes in Transplant-Ineligible Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Versus BR Alone: Results from a Randomized Phase 2 Study

SEHN L., HERRERA A. F., MATASAR M. J., KAMDAR M., MCMİLLAN A., KİM T. M., et al.

ASH 2017, 6 - 14 Aralık 2017, (Özet Bildiri)

200. Efficacy of Copanlisib Monotherapy in Patients with Relapsed or Refractory Marginal Zone Lymphoma: Subset Analysis from the CHRONOS-1

DREYLİNG M., PANAYİOTİDİS P., MİKLOS E., GEORGE F., MİLLOCA L., NAGLER A., et al.

ASH 2017, 6 - 14 Aralık 2017, (Özet Bildiri)

201. Long-Term Results of Brentuximab Vedotin in Relapsed and Refractory Hodgkin Lymphoma: Multi-Center Real-Life Experience

Ferhanoglu A. B., ÖZBALAK M. M., SALİHOĞLU A., Soysal T., Karadogan I., Paydas S., et al.

59th Annual Meeting of the American-Society-of-Hematology (ASH), Georgia, Amerika Birleşik Devletleri, 9 - 12 Aralık 2017, cilt.130, (Özet Bildiri)

202. Dilemma-High Response Rates Vs High Toxicity: Autologous Stem Cell Transplantation for Lymphoma

Atilla E., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., Topcuoglu P., Akan H., et al.

59th Annual Meeting of the American-Society-of-Hematology (ASH), Georgia, Amerika Birleşik Devletleri, 9 - 12 Aralık 2017, cilt.130, (Özet Bildiri)

203. Age Is Not Important for Autologous Peripheral Hematopoietic Stem Cell Transplantation in Multiple Myeloma

Ilhan O., CENGİZ SEVAL G., TOPRAK S. K., Topcuoglu P., Ozel F., CİVRİZ BOZDAĞ S., et al.

59th Annual Meeting of the American-Society-of-Hematology (ASH), Georgia, Amerika Birleşik Devletleri, 9 - 12 Aralık 2017, cilt.130, (Özet Bildiri)

204. NÜKS VEYA REFRAKTER HODGKİN LENFOMAHASTALARINDA NİVOLUMAB KULLANIMI TÜRKİYE VERİLERİ

FERHANOĞLU A. B., BEKÖZ H. S., KARADURMUŞ N., PAYDAŞ S., TÜRKER F. A., TOPTAŞ T., et al.

43. Ulusal Hematoloji Kongresi, Antalya, Türkiye, 1 - 04 Kasım 2017, (Özet Bildiri)

205. NÜKS/REFRAKTER HODGKİN LENFOMA VAKALARINDABRENTUXİMAB VEDOTİN’İN UZUN DÖNEM SONUÇLARI:ÇOK MERKEZLİ TÜRKİYE DENEYİMİ

FERHANOĞLU A. B., salihoğlu a., ÖZBALAK M., SOYSAL T., KARADOĞAN İ., PAYDAŞ S., et al.

43. ULUSAL HEMATOLOJİ KONGRESİ, Türkiye, 1 - 04 Kasım 2017, (Tam Metin Bildiri)

206. Engrafmanın Erken Belirteci: Büyük Boyanmamış Hücreler

Aydın T., MERTER M., ŞAHİN U., Pekcan G., NARLI ÖZDEMİR Z., CİVRİZ BOZDAĞ S., et al.

43. Ulusal Hematoloji Kongresi, Antalya, Türkiye, 1 - 04 Kasım 2017, ss.53, (Özet Bildiri)

207. İmmun Trombositopenide (İTP) Yenilikler Işığında Klinik Retrospektif Değerlendirme: Tek Merkez Deneyimi

AKKUŞ E., KUŞTAŞ A. A., Pekcan G., MERTER M., ŞAHİN U., CİVRİZ BOZDAĞ S., et al.

43. Ulusal Hematoloji Kongresi, Antalya, Türkiye, 1 - 04 Kasım 2017, ss.98-99, (Özet Bildiri)

208. Kronik Myeloproliferatif Neoplazilerde Kalretikulin (CALR) mutasyonu

Öztekin Ş., ÖCAL E., Boyacıgil Ş., ÖZCAN M., BEKSAÇ M., ARSLAN Ö., et al.

Ulusal Hematoloji Kongresi, Türkiye, 31 Ekim - 04 Kasım 2017, (Özet Bildiri)

209. OTOLOG PERİFERİK KÖK HÜCRE NAKLİNDE KÖK HÜCRESAKLANMA SÜRESİ ENGRAFMAN SÜRESİNİ ETKİLER Mİ?

MERTER M., Güleç B., Özcan G., Zehra Özdemir Z., CİVRİZ BOZDAĞ S., YÜKSEL M., et al.

43. Ulusal Hematoloji Kongresi, Antalya, Türkiye, 1 - 04 Kasım 2017, ss.220, (Özet Bildiri)

210. Nüks veya Refrakter Hodgkin Lenfoma Hastalarında Nivolumab Kullanımı Türkiye Verileri

FERHANOĞLU B., BEKÖZ H. S., KARADURMUŞ N., PAYDAŞ S., TÜRKER A., TOPTAŞ T., et al.

43. Ulusal Hematoloji Kongresi, Antalya, Türkiye, 1 - 04 Kasım 2017, (Özet Bildiri)

211. The outcome of haploidentical stem cell transplantation

ATİLLA E., bilgiç e., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., TOPÇUOĞLU P., et al.

ebmt 2017, 22 - 25 Haziran 2017, (Özet Bildiri)

212. peripheral blood stem cell mobilization and collection from elderly patients with multiple myeloma:A single center experience

seval G., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.

ebmt 2017, 26 - 29 Mart 2017, (Özet Bildiri)

213. ALLOEGENEİC HEMATOPOİETİC STEM CELL TRANSPLANTATİON İN ADVANCED AGE ADULTS:İS İT POSSİBLE TO TRANSPLANT SAFELY?

ATİLLA E., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., AKAN H., et al.

ebmt2017, 26 - 29 Mart 2017, (Özet Bildiri)

214. Nivolumab for Relapsed or refractory Hodgkin Lymphoma: Exprience in Turkey

FERHANOĞLU A. B., BEKÖZ H. S., KARADURMUŞ N., PAYDAŞ S., GÜLBAŞ Z., TÜRKER A., et al.

22nd Congress of the European Hematolgy Association, 22 - 25 Haziran 2017, (Özet Bildiri)

215. Autologous Stem Cell Trnasplantation for Mantle Cell Lymphoma: A Single Center Exprience

TOPRAK S. K., ATİLLA E., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., et al.

Exprience22nd Congress of the European Hematolgy Association, 22 Haziran - 25 Mayıs 2017, (Özet Bildiri)

216. Allojeneik stem cell transplantation results in our myelodysplastic sydrome (MDS) patientes

GÜRMAN G., ATACA ATİLLA P., AYDIN T., ATİLLA E., CİVRİZ BOZDAĞ S., TOPRAK S. K., et al.

patientes53rd Annual Meeting Jun 2-6, 2017, 2 - 06 Haziran 2017, (Özet Bildiri)

217. Comparison of myeloablative vs reduced intensity conditioning regimens in stem cell transplantationd for acute myeloid leukemia

GÜRMAN G., AYDEMİR GULOKSUZ G., ATİLLA E., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., et al.

leukemia53rd Annual Meeting, 2 - 06 Haziran 2017, (Özet Bildiri)

218. REAL WORLD DATA IN RELAPSED REFRACTORY MYELOMA PATIENTS TREATED WITH CARFILZOMIB, A MULTICENTER EXPERİENCE

SEVİNDİK Ö. G., SOLMAZ Ş. M., PEHLİVAN M., KABUKLU S. H., YALNIZ F. F., ÖZKOCAMAN V., et al.

6.INTERNATIONAL CONGRESS OF LEUKEMIA LYMPHOMA MYELOMA, Antalya, Türkiye, 11 - 13 Mayıs 2017, (Tam Metin Bildiri)

219. REAL-WORLD DATA IN RELAPSED REFRACTORYMYELOMA PATIENTS TREATED WITH CARFILZOMIB,A MULTICENTER TURKISH EXPERIENCE

SEVİNDİK Ö. G., SOLMAZ Ş., PEHLİVAN M., KAVUKÇU S., YALNIZ F. F., ÖZKOCAMAN V., et al.

6th International Congress on Leukemia Lymphoma Myeloma, 11 - 13 Mayıs 2017, (Özet Bildiri)

220. A biosimilar G-CSF filgrastim is as effective as a reference drug, however, it is not as cost effective as it supposed to be

PEKCAN G., YÜKSEL M., ŞAHİN U., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., et al.

6th International Congress on Leukemia Lymphoma Myeloma, Antalya, Türkiye, 11 - 13 Mayıs 2017, ss.112, (Özet Bildiri)

221. Real-world data in relapsed refractory myeloma patients with carfilzomib, a multicenter turkish experience

SEVİNDİK Ö. G., medeni solmaz ş., PEHLİVAN M., HACIOĞLU S., YALNIZ F. F., ÖZKOCAMAN V., et al.

6th International Congress on Leukemia-Lymphoma-Myeloma, 11 - 13 Mayıs 2017, (Özet Bildiri)

222. Large Unstained Cell Percentage as a Predictor of Efficacious Peripheral Stem Cell Mobilization

MERTER M., KÖKEN K., YÜKSEL M., NURDAN DEMİR E., ŞAHİN U., CİVRİZ BOZDAĞ S., et al.

6th International Congress on Leukemia Lymphoma Myeloma, 11 - 13 Mayıs 2017, (Özet Bildiri)

223. Comparison of myeloablative vs reduced intensity conditioning regimens in stem cell transplantations for acute myeloid leukemia.

GÜRMAN G., Guloksuz G. A., Atilla E., Atilla P. A., CİVRİZ BOZDAĞ S., YÜKSEL M., et al.

53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, Illinois, Amerika Birleşik Devletleri, 2 - 07 Haziran 2017, cilt.35, (Özet Bildiri)

224. Intensive sequential chemoterapy with etoposide, mitoxantrone and cytarabine (EMA) as salvage in patients with AML relapsing after hematopoietic stem cell transplantation.

Gokmen A., Soydan E., Gokgoz Z., Ozkumur K. O., Arslan O., Ilhan O., et al.

225. A single center experience with two decades of follow-up on patients with hairy cell leukemia.

İLHAN O., Atilla E., Atilla P. A., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., et al.

226. Allegeneic Hematopoetic Stem Cell Trnasplantation (Allo-HSCT) in advanced age adults:Is it possible to transplant safely?

ATİLLA E., BAŞ Ö., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., et al.

43rd Annual Meeting Of EBMT, 26 - 29 Mart 2017, (Özet Bildiri)

227. Large Unsatained Cell (LUC) percentage as a predictor of efficacious peripheral stem cell mobilization in autologous stem cell transplantation

MERTER M., KÖKEN K., YÜKSEL M., DEMİR N., ŞAHİN U., CİVRİZ BOZDAĞ S., et al.

43rd Annual Meeting of the European Society for Blood and Marrow Transplantation, 26 - 29 Mart 2017, (Özet Bildiri)

228. Acute GVHD and unreated/haploidentical Trnasplants incrreses the incidence of hemorrhagic cystitis in Allo- HSCT Recipients

TOPÇUOĞLU P., ATİLLA E., ATACA ATİLLA P., USLU A., CİVRİZ BOZDAĞ S., YÜKSEL M., et al.

43rd Annual Meeting Of EBMT, 26 - 29 Mart 2017, (Özet Bildiri)

229. Peripheral blood stem cell mobilization and collection from elderly patients (265 years) with multiple myeloma: A single center experience

CENGİZ SEVAL G., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.

43rd Annual Meeting of the European Society for Blood and Marrow Transplantation, 26 Mart 2017, (Tam Metin Bildiri)

230. The outcome of Haploidentical Hematopoietic Celll Trnasplantations (Haplo HSCT)

ATİLLA E., ECE B., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., TOPÇUOĞLU P., et al.

43rd Annual Meeting Of EBMT, 26 - 29 Mart 2017, (Özet Bildiri)

231. Evalauting peritransplant albümin decline as a predictor os acute graft versus host disease

MERTER M., YÜKSEL M., NURDAN DEMİR E., ŞAHİN U., CİVRİZ BOZDAĞ S., TOPÇUOĞLU P., et al.

43rdAnnual Meeting of the European Society for Blood and Marrow Transplantation, 26 - 29 Mart 2017, (Özet Bildiri)

232. Peripheral Blood Stem Cell Mobilization and collection from elderly patients 65 years with multipl myeloma: A , single center exprience

CENGİZ SEVAL G., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.

43rd Annual Meeting Of EBMT, 26 - 29 Mart 2017, (Özet Bildiri)

233. Herpes SimplexVirus infection in patients after allogeneic hematopoetic stem cell transplantation

ATİLLA E., ÖZEL F., YILMAZ V., ATACA ATİLLA P., ATEŞAĞAOĞLU B., CİVRİZ BOZDAĞ S., et al.

43rd Annual Meeting Of EBMT, 26 - 29 Mart 2017, (Özet Bildiri)

234. Allogeneic stem cell transplantation for chonic lymphocytic Leukemai

ATİLLA E., ATACA ATİLLA P., pekcan g., İLHAN O., GÜRMAN G., ÖZCAN M., et al.

BMT TANDEM MEETINGS, 22 - 26 Şubat 2017, (Özet Bildiri)

235. Management and Outcome of Central Nervous System (CNS) Involvement in Acute Lymphoblastic Leukemia (ALL)

ATİLLA E., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., et al.

BMT Tandem Meetings, 22 - 26 Şubat 2017, (Özet Bildiri)

236. Catheter Thrombosis in Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) Recipients

GÜRMAN G., ATİLLA E., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., et al.

BMT Tandem Meetings, 22 - 26 Şubat 2017, (Özet Bildiri)

237. Comparison of Reduced Intensity Conditioning (RIC) Regimen and Myeloablative Conditioning (MAC) Regimen in Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) for Adult Patients with Acute Leukemia

GÜRMAN G., Guloksuz G. A., Atilla E., Atilla P. A., CİVRİZ BOZDAĞ S., YÜKSEL M., et al.

58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), California, Amerika Birleşik Devletleri, 3 - 06 Aralık 2016, cilt.128, (Özet Bildiri)

238. Does Hypogammaglobulinemia at Diagosis Effects Survival and Infection Risk in Chronic Lymphocytic Leukemia (CLL)?

Atilla E., Atilla P. A., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., İLHAN O., et al.

58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), California, Amerika Birleşik Devletleri, 3 - 06 Aralık 2016, cilt.128, (Özet Bildiri)

239. AKUT MYELOİD LÖSEMİDE FLOW SİTOMETRİ İLEİNDÜKSİYON SONRASI TESPİT EDİLEN CD34 HÜCRESAYISI SAĞKALIM VE RELAPSI ETKİLER

ATİLLA E., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., TOPRAK S. K., et al.

42. Ulusal Hematoloji Kongresi, Türkiye, 19 - 22 Ekim 2016

240. PRİMER MYELOFİBROZİS TE ALLOJENEİK KÖKHÜCRE NAKLİ TEK MERKEZ DENEYİMİ

CENGİZ G. S., GÜNDÜZ M., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., İLHAN O., et al.

42. Ulusal Hematoloji Kongresi, Türkiye, 19 - 22 Ekim 2016

241. AkutLenfositikLösemide ALL SantralSinirSistemi SSS TutulumunaYaklaşım

ATACA ATİLLA P., ATİLLA E., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., et al.

ULUSAL HEMATOLOJİ 2016, Türkiye, 18 - 22 Ekim 2016, (Özet Bildiri)

242. ALLOJENEİK KÖK HÜCRE NAKİL ÖNCESİ FAZLAKİLOLU OBEZ OLMANIN SAĞKALIM VE NÜKS İLEİLİŞKİSİ

ATİLLA E., ATACA ATİLLA P., CEYLAN A., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., et al.

42.ULUSAL HEMATOLOJİ KONGRESİ, Türkiye, 19 - 22 Ekim 2016

243. AllojeneikKökHücreNakliHastalarımızdaGelişenKataterTrombozları

ATİLLA E., YALÇINER M., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., et al.

ULUSAL HEMATOLOJİ 2016, Türkiye, 18 - 22 Ekim 2016, (Özet Bildiri)

244. TROMBOTİK MİKROANJİOPATİDE TERAPÖTİKPLAZMA DEĞİŞİMİ

ATİLLA E., ATACA ATİLLA P., TOPRAK S. K., TOPÇUOĞLU P., YÜKSEL M., CİVRİZ BOZDAĞ S., et al.

42. Ulusal Hematoloji, Türkiye, 19 - 22 Ekim 2016

245. ALLOJENEİK KÖK HÜCRE NAKLİ OLAN AKUTLÖSEMİLERDE HAZIRLIK REJİMLERİNİNKARŞILAŞTIRILMASI

GÜLÖKSÜZ G. A., ATİLLA E., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., et al.

42. Ulusal Hematoloji Kongresi, Türkiye, 19 - 22 Ekim 2016

246. KRONİK LENFOSİTİK LÖSEMİ DE TANI ANINDAHİPOGAMAGLOBULİNEMİ SAĞKALIM VE ENFEKSİYONRİSKİ ÜZERİNDE ETKİLİ MİDİR

ATACA ATİLLA P., ATİLLA E., PEKCAN G., TOPRAK S. K., TOPÇUOĞLU P., AKAN H., et al.

42. Ulusal Hematoloji Kongresi, Türkiye, 19 - 22 Ekim 2016

247. AllojeneikKökHücreNakli Olan AkutLösemilerdeHazırlıkRejimlerininKarşılaştırılması

ATİLLA E., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., TOPÇUOĞLU P., et al.

ULUSAL HEMATOLOJİ 2016, Türkiye, 18 - 22 Ekim 2016, (Özet Bildiri)

248. ALLOJENEİK KÖK HÜCRE NAKLİ HASTALARIMIZDAGELİŞEN KATATER TROMBOZLARI

ATİLLA E., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., TOPÇUOĞLU P., TOPRAK S. K., YÜKSEL M., et al.

42. Ulusal Hematoloji Kongresi, Türkiye, 19 - 22 Ekim 2016

249. Akut Myeloid Lösemide Flow SitometriileİndüksiyonSonrasıTespitEdilen CD34 HücreSayısıSağkalımveRelapsıEtkiler

ATİLLA E., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.

ULUSAL HEMATOLOJİ 2016, Türkiye, 18 - 22 Ekim 2016

250. MYELODİSPLASTİK SENDROM HASTALARININOGATA SKORLAMASI İLE FLOW SİTOMETRİKOLARAK DEĞERLENDİRİLMESİ

ATİLLA E., ATACA ATİLLA P., TÜREDİ Ö., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., et al.

42.Ulusal Hematoloji Kongresi, Türkiye, 19 - 22 Ekim 2016

251. AKUT LENFOSİTİK LÖSEMİDE ALL SANTRAL SİNİRSİSTEMİ SSS TUTULUMUNA YAKLAŞIM

ATİLLA E., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., et al.

42.Ulusal Hematoloji Kongresi, Türkiye, 19 - 22 Ekim 2016

252. ALLOJENEİK KÖK HÜCRE NAKLİ YAPILANHASTALARDA PERİTRANSPLANT ALBUMİN DÜŞÜŞÜİLE GVHD İLİŞKİSİ

MERTER M., Şah F. T., ŞAHİN U., YALÇINER M., Kocabay H. E., CİVRİZ BOZDAĞ S., et al.

42. Ulusal Hematoloji Kongresi, Türkiye, 19 - 22 Ekim 2016

253. ANTİ HLA ANTİKOR VARLIĞININ ALLOJENEİK KÖKHÜCRE NAKLİ YAPILAN HASTALARDA ENGRAFMANÜZERİNE ETKİSİ TEK MERKEZ DENEYİMİ

MERTER M., AYDOĞAN M., TEKEŞ M. A., ŞAHİN U., AYYILDIZ Ö. M., KOCABAY H. E., et al.

42. Ulusal Hematoloji Kongresi, Türkiye, 19 - 22 Ekim 2016

254. SeyrekbirMalignite Primer Mediastinal Büyük B

ATACA ATİLLA P., ATİLLA E., CENGİZ SEVAL G., PEKCAN G., İLHAN O., ARSLAN Ö., et al.

ULUSAL HEMATOLOJİ 2016, Türkiye, 18 - 22 Ekim 2016

255. PERİFERİK T HÜCRELİ LENFOMALARDA OTOLOGHEMATOPOETİK KÖK HÜCRE TRANSPLANTASYONU TEK MERKEZ DENEYİMİ

ŞAHİN U., MERTER M., NARLI ÖZDEMİR Z., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., et al.

42. Ulusal Hematoloji Kongresi, Türkiye, 19 - 22 Ekim 2016

256. Myelodisplastik Sendrom Hastalarının OgataSkorlaması ile FlowSitometrik Olarak Değerlendirilmesi

ATİLLA E., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., TOPRAK S. K., AKAN H., BEKSAÇ M., et al.

ULUSAL HEMATOLOJİ 2016, Türkiye, 18 - 22 Ekim 2016, (Özet Bildiri)

257. Kronik LenfositikLösemi de Tanı Anında HipogamaglobulinemiSağkalım ve Enfeksiyon Riski Üzerinde Etkili Midir

ATİLLA E., ATACA ATİLLA P., TOPRAK S. K., AKAN H., BEKSAÇ M., İLHAN O., et al.

ULUSAL HEMATOLOJİ 2016, Türkiye, 18 - 22 Ekim 2016, (Özet Bildiri)

258. SEYREK BİR MALİGNİTE: PRİMER MEDİASTİNALBÜYÜK B HÜCRELİ LENFOMA

ATACA ATİLLA P., ATİLLA E., CENGİZ SEVAL G., PEKCAN G., İLHAN O., ARSLAN Ö., et al.

42.Ulusal Hematoloji Kongresi, Türkiye, 18 - 22 Ekim 2016, (Özet Bildiri)

259. BEING OVERWEIGHT PRIOR TO ALLOGENEIC STEM CELL TRANSPLANTATION IS RELATED TO BETTER SURVIVAL

ATİLLA E., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., AKAN H., et al.

JSH 2016, 13 - 15 Ekim 2016, (Özet Bildiri)

260. MANAGEMENT AND OUTCOME OF CENTRAL NERVOUS SYSTEM CNS INVOLVEMENT IN ACUTE LYMPHOBLASTIC LEUKEMIA ALL PRE AND POST TRANSPLANT Conference 21st Congress of the European Hematology AssociationLocation Copenhagen DENMARK

ATACA ATİLLA P., ATİLLA E., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., et al.

21st Congress of the European-Hematology-AssociationLocation: Copenhagen, DENMARK, 9 - 12 Haziran 2016, cilt.101

261. Approach to Hairy Cell Leukemia HCL 31 years of Experience

KIRCALI E., ATACA ATİLLA P., ATİLLA E., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., et al.

EHA 2016, 9 - 12 Haziran 2016, (Özet Bildiri)

262. Extracorporeal Photopheresis Safe and Effective for the Treatment of Mycosis Fungoides

ATİLLA E., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., AKAY B. N., et al.

EHA 2016, 9 - 12 Haziran 2016, (Özet Bildiri)

263. MANAGEMENT AND OUTCOME OF CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT IN ACUTE LYMPHOBLASTIC LEUKEMİA (ALL): PRE AND POST TRANSPLANT

ATACA ATİLLA P., ATİLLA E., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., et al.

EHA 2016, 9 - 12 Haziran 2016, (Özet Bildiri)

264. Age as a dicision factor for doing autuologous stem cell transplantation in fit patients with myeloma and lymphoma ASCO Annual Meeting J Clin Oncol 34 2016 suppl abstr e 19001

İLHAN O., ATİLLA E., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., et al.

ASCO, 3 - 07 Haziran 2016

265. Age as a decision factor for doing autologous stem cell transplantation in fit patients with myeloma and lymphoma Subcategory

İLHAN O., ATİLLA E., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., et al.

ASCO 2016, ABD, 3 - 07 Haziran 2016, (Özet Bildiri)

266. THE EFFICACY OF TYROSINE KINASE INHIBITORS WITH STEROID IN Ph ACUTE LYMPHOBLASTIC LEUKEMIA

GÜRMAN G., MERTER M., ATİLLA E., ŞAHİN U., TOPÇUOĞLU P., ARSLAN Ö., et al.

ASCO 2016, ABD, 3 - 07 Haziran 2016, (Özet Bildiri)

267. Age is not a Significant Factor in Decision of Doing Autologous Stem Cell Transplantation in Fit Patients with Myeloma and Lymphoma!

ATİLLA E., ATACA ATİLLA P., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ÖZCAN M., et al.

ASCO 2016, 3 - 07 Haziran 2016, (Özet Bildiri)

268. 9 THROMBOSIS IN PAROXYSMAL NOCTURNAL HEMOGLOBULINURIA PATIENTS SINGLE CENTER EXPERIENCE

MERTER M., ŞAHİN U., gündüz m., NARLI ÖZDEMİR Z., CİVRİZ BOZDAĞ S., TOPRAK S. K., et al.

24th Biennial International Congress on Thrombosis / EMLTD Congress Location: Istanbul, 4 - 07 Mayıs 2016

269. Are Age and JAK2V617F Mutation Related to Trombosis in Chronic Myeloproliferative Diseases

ATİLLA E., ATACA ATİLLA P., TOPRAK S. K., KAYGUSUZ G., KUZU I., CİVRİZ BOZDAĞ S., et al.

24th Biennial International Congress on Thrombosis, 4 - 07 Mayıs 2016, (Özet Bildiri)

270. Successful treatment in primary central nervous system lymphoma.

Atilla E., Ataca P., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., İLHAN O., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 3 - 07 Haziran 2016, cilt.34, (Özet Bildiri)

271. The efficacy of tyrosine kinase inhibitors with steroid in phi- acute lymphoblastic leukemia.

GÜRMAN G., Merter M., Atilla E., Sahin U., TOPÇUOĞLU P., ARSLAN Ö., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 3 - 07 Haziran 2016, cilt.34, (Özet Bildiri)

272. Age as a decision factor for doing autologous stem cell transplantation in fit patients with myeloma and lymphoma.

Ilhan O., Atilla E., Ataca P., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 3 - 07 Haziran 2016, cilt.34, (Özet Bildiri)

273. Thrombosis in Paroxysmal Nocturnal Hemoglobinuria Patients: Single Center Experience

MERTER M., ŞAHİN U., GÜNDÜZ M., NARLI ÖZDEMİR Z., CİVRİZ BOZDAĞ S., TOPRAK S. K., et al.

24th Biennial International Congress on Thrombosis, İstanbul, Türkiye, 1 - 07 Mayıs 2016, cilt.141, ss.72, (Özet Bildiri)

274. A rare manifestation: Primary mediastinal large-b cell lymphoma.

Atilla E., Ataca P., İLHAN O., ARSLAN Ö., GÜRMAN G., ÖZCAN M.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 3 - 07 Haziran 2016, cilt.34, (Özet Bildiri)

275. PRACTICAL APPROACH IN DIFFERENTIAL DIAGNOSIS WITH INTERACTIVE DISCUSSION OF REPRESENTATIVE CASES

ÖZCAN M.

UPTADES IN WHO LYMPHOMA CLASSIFICATION:2008-2016 PRACTICAL DIAGNOSTIC APPROACH WITH CLINICAL ASPECTS, 16 - 17 Nisan 2016, (Tam Metin Bildiri)

276. Age as a dicision factor for doing autuologous stem cell transplantation in fit patients with myeloma and lymphoma

İLHAN O., ATİLLA E., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., et al.

ASCO, 3 - 07 Haziran 2016, (Özet Bildiri)

277. 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation

TOPÇUOĞLU P., ATİLLA E., CİVRİZ BOZDAĞ S., YÜKSEL M., ARSLAN Ö., BEKSAÇ M., et al.

42nd Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, 3 - 06 Nisan 2016, (Özet Bildiri)

278. Succesfull treatment in primary central nervous system lymphoma

ATİLLA E., ATACA ATİLLA P., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., İLHAN O., et al.

ASCO, 3 - 07 Haziran 2016, (Özet Bildiri)

279. prognosis of acute leukemia patients in active disease undergoing allogeneic hematopoietic stem cell transplantation

ŞAHİN U., MERTER M., ateşağoğlu b., erdal h., CİVRİZ BOZDAĞ S., TOPRAK S. K., et al.

41.ebmt meeting, 22 - 25 Mart 2015

280. AKTİF HASTALIKLI AKUT LÖSEMİDE ATG VEHAZIRLIK REJİMİ İLE ALLOJENİK NAKİL SONRASICMV REAKTİVASYONUNUN PROGNOZA ETKİSİ

GÜNDÜZ M., ŞAHİN U., MERTER M., NARLI ÖZDEMİR Z., CİVRİZ BOZDAĞ S., TOPRAK S. K., et al.

9.Ulusal Kemik İliği Transplantasyonu ve Kök Hücre Tedavileri Kongresi, Türkiye, 3 - 05 Mart 2016

281. PAROKSİSMAL NOKTÜRNAL HEMOGLOBİNÜRİHASTALARINDA ALLOJENEİK HEMATOPOETİK KÖKHÜCRE NAKLİ TEK MERKEZ DENEYİMİ

NARLI ÖZDEMİR Z., TOPRAK S. K., TOPÇUOĞLU P., ŞAHİN U., GÜNDÜZ M., ATİLLA E., et al.

9.Ulusal Kemik İliği Transplantasyonu ve Kök Hücre Tedavileri Kongresi, Türkiye, 3 - 05 Mart 2016

282. HAİRY CELL LÖSEMİ HCL VAKALARIMIZ TEKMERKEZ DENEYİMİ

Kırcalı E., ATACA P., ATİLLA E., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., et al.

41.Ulusal Hematoloji Kongresi, Türkiye, 21 - 24 Ekim 2015

283. The Efficacy of Tyrosine Kinase Inhibitors with Steroid As First Line Induction Therapy in Ph Acute Lymphoblastic Leukemia

GÜRMAN G., MERTER M., ATACA P., TOPRAK S. K., TOPÇUOĞLU P., ÖZCAN M., et al.

The Efficacy of Tyrosine Kinase Inhibitors with Steroid As First Line Induction Therapy in Ph+ Acute Lymphoblastic Leukemia, 5 - 07 Aralık 2014, (Özet Bildiri)

284. Clinical Allogeneic Transplantation Acute and Chronic GVHD Immune Reconstitution

GÜRMAN G., ATACA P., ATİLLA E., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., et al.

57th ASH Annual Meeting & Exposition, 5 - 08 Aralık 2015

285. Extracorporeal Photopheresis for the Treatment of Mycosis Fungoides 5 8 December 2015 ASH Annual Meeting Abstracts Blood 2015 126 5062 published ahead of print December 5 2015

ATİLLA E., ATACA P., CİVRİZ BOZDAĞ S., TOPRAK S. K., KURT YÜKSEL M., AKAY B. N., et al.

57th American Society of Hematology Annual Meeting and Exposition, Orlando, FL, USA, 5 - 08 Aralık 2015, (Tam Metin Bildiri)

286. Extracorporeal Photopheresis for the Treatment of Mycosis Fungoides

Atilla E., Ataca P., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., AKAY B. N., et al.

57th Annual Meeting of the American-Society-of-Hematology, Florida, Amerika Birleşik Devletleri, 5 - 08 Aralık 2015, cilt.126, (Özet Bildiri)

287. Comparison of Two Different Doses of Corticosteroid Premedication for Antithymocyte Globulin in Allogeneic Hematopoietic Stem Cell Transplantation

Merter M., Atilla E., Sahin U., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., et al.

57th Annual Meeting of the American-Society-of-Hematology, Florida, Amerika Birleşik Devletleri, 5 - 08 Aralık 2015, cilt.126, (Özet Bildiri)

288. Upper and Lower Respiratory Tract Infections By Respiratory Viruses in Adult Recipients of Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)

Atilla E., Ataca P., ŞAHİN EROĞLU D., TOPÇUOĞLU P., DOLAPÇI G. İ., TEKELİ F. A., et al.

57th Annual Meeting of the American-Society-of-Hematology, Florida, Amerika Birleşik Devletleri, 5 - 08 Aralık 2015, cilt.126, (Özet Bildiri)

289. Seroprevalence for Toxoplasma Gondii in Allogeneic Hematopoietic Stem Cell Transplantation Recipients

Atilla E., Ataca P., BALLI S., Isikoglu B., TOPÇUOĞLU P., ÖZCAN M., et al.

57th Annual Meeting of the American-Society-of-Hematology, Florida, Amerika Birleşik Devletleri, 5 - 08 Aralık 2015, cilt.126, (Özet Bildiri)

290. Positive Impact of Chronic Graft-Versus Host Disease on Survival in 928 Allogeneic Hematopoietic Stem Cell Transplant Recipients

GÜRMAN G., Ataca P., Atilla E., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., et al.

57th Annual Meeting of the American-Society-of-Hematology, Florida, Amerika Birleşik Devletleri, 5 - 08 Aralık 2015, cilt.126, (Özet Bildiri)

291. Is Initial CD3+T Cell Dose in Donor Lymphocyte Infusion for Relapsed Hematological Malignancies a Prognostic Determinant?

Atilla E., Ataca P., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.

57th Annual Meeting of the American-Society-of-Hematology, Florida, Amerika Birleşik Devletleri, 5 - 08 Aralık 2015, cilt.126, (Özet Bildiri)

292. First Multicenter, Randomized Phase 3 Study in Patients (Pts) with Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator's Choice (Lumiere trial; NCT01482962)

O'Connor O. A., ÖZCAN M., Jacobsen E. D., Vidal J. M. R., Trotman J., Demeter J., et al.

57th Annual Meeting of the American-Society-of-Hematology, Florida, Amerika Birleşik Devletleri, 5 - 08 Aralık 2015, cilt.126, (Özet Bildiri)

293. Allojeneik Hematopoietik Kök Hücre Nakli AHKHN Hastalarında Gelişen Üst ve Alt Solunum Yolları Viral Enfeksiyonları

ATİLLA E., ATACA P., ŞAHİN D., DOLAPÇI G. İ., TEKELİ F. A., CİVRİZ BOZDAĞ S., et al.

Febril Nötropeni Simpozyumu, Türkiye, 28 - 30 Kasım 2015, (Özet Bildiri)

294. Hairy Cell Lösemi HCL vakalarımız Tek Merkez Deneyimi

KIRCALI E., ATACA P., ATİLLA E., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., et al.

41. Ulusal Hematoloji Kongresi, Türkiye, 21 - 24 Ekim 2015

295. Ph Negatif ALL Hastalarında Allojenik Kök Hücre Nakli Öncesi Tedavilerin Klinik Seyir ile İlişkisi

NARLI ÖZDEMİR Z., EKİN K., ATACA P., ATİLLA E., TOPÇUOĞLU P., CİVRİZ BOZDAĞ S., et al.

41. Ulusal Hematoloji Kongresi, Türkiye, 21 - 24 Ekim 2015

296. MYELODİSPLASTİK SENDROMDA MDS ALLOJENEİKHEMATOPOİETİK KÖK HÜCRE NAKLİ

ATİLLA E., ATACA P., BEKSAÇ M., ÖZCAN M., ARSLAN Ö., İLHAN O., et al.

41.Ulusal Hematoloji Kongresi, Türkiye, 21 - 24 Ekim 2015

297. ALLOJENEİK HEMATOPOİETİK KÖK HÜCRENAKLİNDE İKİ FARKLI ANTİTİMOSİTGLOBULİN PREMEDİKASYON PROTOKOLÜNÜNKARŞILAŞTIRILMASI

MERTER M., ŞAHİN U., Ateşağaoğlu B., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., et al.

41.Ulusal Hematoloji Kongresi, Türkiye, 21 - 24 Ekim 2015

298. MİKOZİS FUNGOİDES TEDAVİSİNDEEKSTRAKORPOREAL FOTOFEREZ ECP

ATİLLA E., ATACA P., ŞAHİN D., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., et al.

41.Ulusal Hematoloji Kongresi, Türkiye, 21 - 24 Ekim 2015

299. ALLOJENEİK HEMATOPOİETİK KÖK HÜCRE NAKLİ YAPILAN HASTALARDA ANTİ HLA ANTİKORLARI İLE ENGRAFMAN YETMEZLİĞİ İLİŞKİSİ TEK MERKEZ

ATACA P., ATİLLA E., CİVRİZ BOZDAĞ S., YÜKSEL M., KAYGUSUZ G., KUZU I., et al.

41.Ulusal Hematoloji Kongresi, Türkiye, 21 - 23 Ekim 2015, (Özet Bildiri)

300. Allojeneik Hematopoietik Kök Hücre Nakli Yapılan Hastalarda Anti HLA Antikorları ile Engrafman Yetmezliği İlişkisi: Tek Merkez Deneyimi

MERTER M., ŞAHİN U., ATEŞAĞAOĞLU B., TUTKAK H., TOPRAK S. K., YÜKSEL M., et al.

41. Ulusal Hematoloji Kongresi, Antalya, Türkiye, 21 - 24 Ekim 2015, (Özet Bildiri)

301. ALLOJENEİK KÖK HÜCRE TRANSPLANTASYONHASTASINDA KRONİK GRAFT VERSUS HOSTHASTALIĞININ GENEL SAĞKALIM ÜZERİNE ETKİSİ

ATİLLA E., ATACA P., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., DEMİRER T., et al.

41. Ulusal Hematoloji Kongresi, Türkiye, 21 - 24 Ekim 2015

302. WALDENSTRÖM MAKROGLOBULİNEMİSİNDE TEKMERKEZ DENEYİMİ

ŞAHİN U., MERTER M., ATİLLA E., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., et al.

41.Ulusal Hematoloji Kongresi, Türkiye, 21 - 24 Ekim 2015

303. MİKOZİS FUNGOİDES TEDAVİSİNDE EKSTRAKORPOREAL FOTOFEREZ ECP

ATİLLA E., ATACA P., ŞAHİN D., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., et al.

). 41.Ulusal Hematoloji Kongresi, Türkiye, 21 - 23 Ekim 2015, (Özet Bildiri)

304. PH NEGATİF ALL HASTALARINDA ALLOJENİK KÖKHÜCRE NAKLİ ÖNCESİ TEDAVİLERİN KLİNİK SEYİRİLE İLİŞKİSİ

Özdemir Z. N., Kırcalı E., ATACA P., ATİLLA E., TOPÇUOĞLU P., CİVRİZ BOZDAĞ S., et al.

41.Ulusal Hematoloji Kongresi, Türkiye, 21 - 24 Ekim 2015

305. Waldenström Makroglobulinemisinde Tek Merkez Deneyimi

ŞAHİN U., MERTER M., ATİLLA E., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., et al.

41. Ulusal Hematoloji Kongresi, Antalya, Türkiye, 21 - 24 Ekim 2015, ss.106-107, (Özet Bildiri)

306. ALLOJENEİK HEMATOPOİETİK KÖK HÜCRE NAKLİ YAPILAN HASTALARDA ANTİ HLA ANTİKORLARI İLE ENGRAFMAN YETMEZLİĞİ İLİŞKİSİ TEK MERKEZ DENEYİMİ

MERTER M., ŞAHİN U., ateşağaoğlu b., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., et al.

41.Ulusal Hematoloji Kongresi, Türkiye, 21 - 23 Ekim 2015, (Özet Bildiri)

307. Allojeneik Hematopoietik Kök Hücre Naklinde İki Farklı Antitimosit Globulin Premedikasyon Protokolünün Karşılaştırılması

MERTER M., ATİLLA E., ŞAHİN U., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., et al.

41. Ulusal Hematoloji Kongresi, Antalya, Türkiye, 21 - 24 Ekim 2015, ss.71-72, (Özet Bildiri)

308. HODGKİN HL VE HODGKİNDIŞI LENFOMALI HDL HASTALARDA TEDAVİ SONRASI GEÇ DÖNEMDEYÜKSEK HEMATOKRİT DEĞERLERİ HL İLEERİTROSİTOZ ARASINDA İLİŞKİ Mİ VAR

Ateşağaoğlu B., ATACA P., Tuncay G., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., et al.

41. Ulusal Hematoloji Kongresi, Türkiye, 21 - 24 Ekim 2015

309. Chronic Myeloproliferative Disease in Geriatric Patients Single Center Experience

TOPRAK S. K., ATİLLA E., ATACA P., BEKSAÇ M., konuk n., TOPÇUOĞLU P., et al.

77th Annual Meeting of the Japanese Society of Hematology, 16 - 18 Ekim 2015

310. Is Allogeneic Stem Cell Transplantation Safe in MDS

TOPÇUOĞLU P., ATİLLA E., ATACA P., BEKSAÇ M., ÖZCAN M., ARSLAN Ö., et al.

77th Annual Meeting of Japanese Society of Hematology, 16 - 18 Ekim 2015

311. Allogeneic Stem Cell Transplant Safe in MDS

TOPÇUOĞLU P., ATİLLA E., ATACA P., BEKSAÇ M., ÖZCAN M., ARSLAN Ö., et al.

77th Annual Meeting of the Japanese Society of Hematology, October 16-18, 2015, Kanazawa, Japan., 1 - 03 Ekim 2015, (Özet Bildiri)

312. Myeloproliferative Disease in Geriatric Patients Single Center Experience

TOPRAK S. K., ATİLLA E., ATACA P., BEKSAÇ M., Konuk N., TOPÇUOĞLU P., et al.

77th Annual Meeting of the Japanese Society of Hematology, 16 - 19 Ekim 2015

313. Is Allogeneic Stem Cell Transplant Safe in MDS

TOPÇUOĞLU P., ATİLLA E., ATACA P., BEKSAÇ M., ÖZCAN M., ARSLAN Ö., et al.

77th Annual Meeting of the Japanese Society of Hematology, Oral Presentation, 16 - 18 Ekim 2015

314. Autologous Stem Cell Transplantation and Primary Systemic Light Chain AL Amyloidosis

TOPRAK S. K., ATACA P., ATİLLA E., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., et al.

15th International Myeloma Workshop, Auditorium Parco della Musica, Rome, Italy, September 23-26, 2015., 23 - 26 Eylül 2015, (Özet Bildiri)

315. Follow up of del 5 q MDS patients with or without other chromosomal abnormalities

TÜREDİ Ö., ATACA P., TUNCALI T., ATİLLA E., VİCDAN N. A., DURMAZ C. D., et al.

10th European Cytogenetics Conference, 4 - 07 Temmuz 2015, ss.102, (Özet Bildiri)

316. posttransplant erytrocytosisin eleven cases

TOPRAK S. K., pekcan g., ATACA P., ATİLLA E., CİVRİZ BOZDAĞ S., YÜKSEL M., et al.

ehameeting 2015, 11 - 14 Haziran 2015

317. allogeneic stem cell transplantation for advanced mycosıs fungoides seary syndrome

ATİLLA E., ATACA P., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., et al.

EHA MEETING 2015, 11 - 14 Haziran 2015

318. CML leukemic stem cell CML LCS Its existence in patients who achieved cytogenetic molecular response under treatment of TKI

İLHAN O., USLU A., TOPRAK S. K., TOPÇUOĞLU P., ATİLLA E., ATACA P., et al.

ASCO 2015, 29 - 02 Mayıs 2015

319. Does chronic lymphoctic leukemia occur in younger adults in Turkey

PEKCAN G., ATİLLA E., CİVRİZ BOZDAĞ S., TOPRAK S. K., KURT YÜKSEL M., AKAN H., et al.

ASCO 2015, 29 Mayıs - 02 Haziran 2015

320. Azatitidine in combination with ATRA valproic acid in elderly AML patient

ÖZCAN M., CİVRİZ BOZDAĞ S., BERNA A., ATİLLA E., ATACA P., TOPRAK S. K., et al.

ASCO 2015, 29 Mayıs - 02 Haziran 2015

321. Allagenic stemcell transplantation results in our myelodysplastic syndrome MDS patient

GÜRMAN G., ATACA P., AYDIN T., ATİLLA E., CİVRİZ BOZDAĞ S., TOPRAK S. K., et al.

ASCO -2015, 29 - 02 Mayıs 2015

322. Extramedullary Relapse of Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation Allo HSCT A Single Center Experience 41st Annual Meeting of the European Society for Blood and

MERTER M., uğur ş., gündüz m., ATİLLA E., CİVRİZ BOZDAĞ S., TOPRAK S. K., et al.

(Allo-HSCT): A Single Center Experience. 41st Annual Meeting of the European Society for Blood and Marrow Transplantation, Istanbul, 22-25 Mayıs 2015., 22 - 25 Mayıs 2015, (Tam Metin Bildiri)

323. AUTOLOGOUS STEM CELL TRANSPLANTATION IN ELDERLY PATIENTS 60 YEARS WITH MYELOMA OR LYMPHOMA

ATİLLA E., GÜNDÜZ M., ATACA P., CİVRİZ BOZDAĞ S., TOPRAK S. K., MELTEM K. Y., et al.

5th International Congress on Lymphoma Leukemia Myeloma, İstanbul, Turkey, 21 - 23 Mayıs 2015, (Özet Bildiri)

324. Allogeneic Stem Cell Transplantation for Hodgkin and non Hodgkin Lymphoma

ATACA P., ATİLLA E., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., et al.

5th International Congress on Lymphoma Leukemia Myeloma, İstanbul, Turkey, 21-23 May 2015. Turkish Society of Hematology, Proceedings & Abstract Book, abstract # 0109, poster # PS-101 pp 175., 21 - 23 Mayıs 2015

325. Allogeneic stem cell transplantation results in our myelodysplastic syndrome (MDS) patients.

GÜRMAN G., Ataca P., Aydin T., Atilla E., CİVRİZ BOZDAĞ S., TOPRAK S. K., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri)

326. Does chronic lymphocytic leukemia occur in younger adults in Turkey?

Pekcan G., Atilla E., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., et al.

327. CML leukemic stem cell (CML LSC): Its existence in patients who achieved cytogenetic/molecular response under treatment of TKI.

Ilhan O., Uslu A., TOPRAK S. K., Topcuoglu P., Atilla E., Ataca P., et al.

328. Azacitidine in combination with ATRA, valproic acid in elderly AML patients.

ÖZCAN M., CİVRİZ BOZDAĞ S., Atesagaoglu B., Atilla E., Ataca P., TOPRAK S. K., et al.

329. allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Single Centre Experienc

ŞAHİN U., MERTER M., ATİLLA E., TOPÇUOĞLU P., TOPRAK S. K., İLHAN O., et al.

BONE MARROW TRANSPLANTATION, 22 - 25 Mart 2015

330. Autologous Stem Cell Transplantation in Elderly Patients with Myeloma or Lymphoma

ATİLLA E., MEHMET G., ATACA P., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., et al.

Best of ASBMT Tandem Meetings, Poster Presentation, Türkiye, 27 - 28 Mart 2015

331. DIFFERENT DOSES OF ATG IN THE CONDITIONING REGIMEN FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

PEKCAN G., ATEŞAĞAOĞLU B., MERTER M., TOPÇUOĞLU P., CİVRİZ BOZDAĞ S., TOPRAK S. K., et al.

41.EBMT MEETING, 24 - 26 Mart 2015

332. ALOGENEİC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITHPAROXYSMAL NOCTURNAL HEMOGLOBINURIA SINGLE CENTER EXPERIENCE

MERTER M., ŞAHİN U., ATİLLA E., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., et al.

41.EBMT MEETING, 24 - 26 Mart 2015

333. EXTRAMEDULLARY RELAPSE OF ACUTE LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION A SINGLE CENTER EXPERIENCE

MERTER M., ŞAHİN U., GÜNDÜZ M., ATİLLA E., CİVRİZ BOZDAĞ S., TOPRAK S. K., et al.

41.EBMT MEETING, 24 - 26 Mart 2015

334. Autologus stem cell transplantation in elderly patients with myeloma and lymphoma single center experience

GÜNDÜZ M., ATİLLA E., ATACA P., PEKCAN G., CİVRİZ BOZDAĞ S., TOPRAK S. K., et al.

41.EBMT KONGRESİ, 24 - 26 Mart 2015

335. ımpact pf pretransplant serum ferritinon outcomes of allogeenic hematopoeitic stem cell transplantationfor acute leukemia

ŞAHİN U., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.

41.ebmt meeting, 22 - 25 Mart 2015

336. THE RELAPSE IN ACUTE LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION NO APPROACHES HAVE BEEN SUPERIOR YET

TOPÇUOĞLU P., GÜNDÜZ M., ÖZEN M., ATİLLA E., ATACA P., CİVRİZ BOZDAĞ S., et al.

41.EBMT MEETING, 24 - 26 Mart 2015

337. Prognosis of Acute Leukemia Patients with Active Disease Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Allo HSCT 22 25 March 2015 Bone Marrow Transplant 2015 50 S1 S483

UĞUR Ş., MERTER M., ATAŞAĞAOĞLU B., ERDAL H., CİVRİZ BOZDAĞ S., TOPRAK S. K., et al.

41st Annual Meeting of the European Society for Blood and Marrow Transplantation Istanbul, Turkey, 22 - 25 Mart 2015, (Özet Bildiri)

338. s it possible to overcome the catastrophic complications of Hematopoietic Stem Cell Transplantation HSCT using Plasma Exchange PE A Single Center s Experience

YÜKSEL M., Gultekin G., Edipoglu E., Bay M., CİVRİZ BOZDAĞ S., TOPRAK S. K., et al.

41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, 22 - 25 Mart 2015, (Özet Bildiri)

339. Upper and Lower Respiratory Tract Infections by Respiratory Viruses by Respiratory Viruses in Adult Recipients of Allogeneic Hematopoietic Stem Cell Transplantation Single Center Experience

ŞAHİN D., ATİLLA E., CİVRİZ BOZDAĞ S., ATACA P., TOPRAK S. K., TOPÇUOĞLU P., et al.

41th EBMT Meeting, 22 - 25 Mart 2015, (Özet Bildiri)

340. Different Doses of Anti Thymocyte Globulin ATG in the Conditioning Regimen for Allogeneic Hematopoetic Stem Cell Transplantation 22 25 March 2015 Bone Marrow Transplant 2015 50 S1 S228

GÜLTEKİN P., ATEŞAĞAOĞLU B., MERTER M., TOPÇUOĞLU P., CİVRİZ BOZDAĞ S., TOPRAK S. K., et al.

41st Annual Meeting of the European Society for Blood and Marrow Transplantation Istanbul, Turkey, 22 - 25 Mart 2015, (Özet Bildiri)

341. Chronic Myeloproliferative Disease in Geriatric Patients

TOPRAK S. K., ATİLLA E., ATACA P., BEKSAÇ M., konuk n., TOPÇUOĞLU P., et al.

77th Annual Meeting of the Japanese Society of Hematolog, 16 - 18 Ekim 2015, (Tam Metin Bildiri)